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Abstract  
 
Antibodies play a prominent role in chemical and biological research and the largest 
application  of  chemical  bioconjugation  reagents  is  in  the  production  of  antibody 
conjugates. These conjugates provide a means of highly sensitive detection, for example 
in  enzyme-linked  immunosorbent  assay  (ELISA)  systems.  In  therapeutics,  such 
conjugates have enabled the development of bispecifics and antibody-enzyme directed 
prodrug therapy (ADEPT).  
 
Long-established chemical modification techniques for the conjugation of antibodies 
yield highly heterogeneous products. This heterogeneity is far from optimal and for 
therapeutic use antibody conjugates must be of a defined composition.  Recently the 
site-specific introduction of chemical linkers has been reported through unnatural amino 
acid insertion. In this approach however, each protein must undergo successful mutation 
and expression prior to conjugation. To avoid this, an ideal site-directed conjugation 
technique would use residues natural to the protein.  
 
A new class of chemical bioconjugation reagents, the 3,4-substituted maleimides, allow 
the selective modification and bridging of naturally occurring protein disulfide bonds. 
In this thesis, the generation of homogeneous antibody-protein conjugates using 3,4-
substituted maleimide based cross-linkers is investigated, with a focus on producing 
conjugates  for  ADEPT  and  bispecific  therapeutics.  A  range  of  direct  and  indirect 
chemical  cross-linking  strategies  via  disulfide  bridging  are  explored  and  the 
consequences of each approach examined.  
 
Ultimately, a new chemical platform to generate site-specific, homogeneous, antibody-
antibody  conjugates  by  targeting  and  bridging  disulfide  bonds  was  developed.  A 
bispecific antibody construct was produced in good yield using a readily synthesised 
bis-dibromomaleimide cross-linker. Binding activity of antibodies was maintained, and 
in  vitro  binding  of  target  antigens  was  observed.  This  technology  is  demonstrated 
through  linking  scFv  and  Fab  antibody  fragments,  showing  its  potential  for  the 
construction of a diverse range of bispecifics.  
 
Finally,  the  ability  of  3,4-substituted  maleimide  based  reagents  to  functionalise 
antibodies for diagnostic applications is investigated. A strategy for the modification of 
a  scFv-Fc  construct  with  commercially  available  fluorophores  is  achieved  and  a 
synthetic route towards reagents suitable for immuno-PET applications determined.   
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1  Introduction 
1.1  Antibodies 
 
Antibodies are an integral part of the body’s defence system, identifying and attacking 
foreign  substances  such  as  bacteria  and  viruses.  Identification  is  achieved  through 
antibody  recognition  of  a  specific,  unique  structure  on  the  surface  of  the  foreign 
substance, termed an antigen. In order to successfully defend, numerous antibodies with 
different specificities are required. This diverse range of antibodies is generated through 
the variation of a relatively limited set of antibody genes in the B-cells of our lymphatic 
system. The variability and high targeting specificity of antibodies has given them a 
prominent role in chemical and biological research. Subsequently, this has led to the 
development  of  numerous  antibody-based  research  techniques,  for  example, 
immunoassays, immunohistochemistry and flow cytometry.  
 
In recent years, there has been an increasing interest in the use of monoclonal antibodies 
(mAbs) and antibody fragments as therapeutic entities. The first antibody to be used as a 
therapeutic in humans was Muromonab, which was approved in 1986 for use in acute 
transplant rejection. Since then, antibody therapeutic development has continued, with 
more than 30 antibodies approved for clinical use and over 150 in clinical development 
(1,2). Monoclonal antibodies represent the highest-earning category of all biological 
drugs and have been applied to a variety of diseases including immunological disorders 
and viral infections (3,4). Oncology though is the major focus of this growing class of 
therapeutics owing to the identification of numerous antigens over-expressed in cancer 
cells.  
1.2  Antibody Structure 
 
Antibodies  (or  immunoglobulins,  Ig)  are  macromolecular  glycoproteins,  with  each 
monomer consisting of four polypeptide chains; two identical heavy chains and two 
identical  light  chains  (Figure  1.1).  The  amino  terminal  ends  of  these  chains  are 
responsible for antigen binding, and as such these show great variation in amino acid 
composition. These are referred to as the variable regions, distinguishing them from the 
more conserved constant regions. Each heavy chain is composed of one variable (VH) 
and three constant domains (CH1, CH2, CH3), whereas each light chain contains only a 
single variable (VL) and constant (CL) domain. The heavy and light chains are held  
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together by both non-covalent interactions and a series of covalent interchain disulfide 
bonds. Together these chains form a bilateral symmetric structure.  
Figure 1.1 Human IgG antibody; it is composed of light (L) and heavy (H) polypeptide 
chains, and within these chains there are variable (V) and constant (C) domains. The 
heavy  (H)  and  light  (L)  chains  are  linked  through  disulfide  bonds.  Green  spheres 
indicate glycosylation sites of the CH2 domain. 
 
Antibodies can be divided into two distinct functional entities: the fragment of antigen 
binding (Fab) and the constant fragment (Fc, for “fragment crystallisable”) (Figure 1.1). 
The Fab contains the regions VL and VH, together forming the variable fragment (Fv). 
In each Ig monomer there are two antigen-binding sites embedded within the Fv region, 
generated by three hypervariable complementarity-determining regions (CDRs) in each 
of the VL and VH chains.  It is the CDRs that confer antigen specificity. Between the 
CH1 and CH2 domains exists an exposed proline-rich hinge region, which confers some 
flexibility to this large glycoprotein structure. Together with interchain disulfides, this 
region links the two Fab fragments to the Fc fragment. The immunological effector 
function-mediating  region  is  located  in  the  Fc  fragment,  and  this  is  capable  of 
prompting targeted cell killing via  antibody-dependent  cellular cytotoxicity  (ADCC) 
and complement-dependent cytotoxicity (CDC). The Fc region is also responsible for 
regulating antibody serum half-life through interaction with the neonatal Fc receptor 
(FcRn) of the reticuloendothelial system.  
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Five classes of antibodies have been identified in vertebrates based on the sequence of 
their heavy chain constant regions: IgM, IgD, IgG, IgE and IgA. These antibody classes 
differ in valency depending on the number of antibody monomers that link to form the 
complete protein. For example, human IgM antibodies consist of five monomers, thus 
giving this class a valency of 10, since each monomer is bivalent.  In contrast,  IgG 
antibodies exist as the monomer and this bivalent species constitutes the predominant Ig 
class in human serum. For this reason, combined with their high targeting specificity, 
IgG antibodies are the most frequently used class in research tools, and for therapeutic 
and diagnostic applications. Within the IgG class, there are four subclasses: IgG1, IgG2, 
IgG3, and IgG4. These are defined by the structural differences in their Fc domains, and 
their consequent altered ability to initiate immune effector functions. The IgG1 class are 
the most abundant in human serum and are highly active in initiating ADCC and CDC 
mechanisms.  Consequently,  IgG1  is  the  main  class  of  monoclonal  antibodies  in 
therapeutic and diagnostic use.  
1.3  Engineering Therapeutic Antibodies 
 
The  modern  era  of  antibody  therapeutics  was  truly  launched  by  the  invention  of 
hybridoma technology in 1975 (5). Through the fusion of B-cells with myeloma cells 
from the same species, an immortalised cell line can be prepared. Such hybridoma cell 
lines can be frozen for long periods of time, and simply cultured when required to 
produce  the  desired  specific  monoclonal  antibody.  Although  this  facilitated  the 
generation of mouse monoclonal antibodies on a large scale, early clinical success using 
murine antibodies was limited. Key issues included high immunogenicity, short serum 
half-life, and poor ability to induce an immune effector response. Over the past two 
decades considerable developments in antibody technologies have led to the dawn of 
antibody  chimerisation  and  subsequently,  complete  humanisation  (Figure  1.2). 
Chimerisation  attempts  to  overcome  many  of  the  problems  associated  with  murine 
antibodies by replacing the constant regions with those from a human antibody (6). The 
first FDA approved chimeric antibody was Rituximab in 1997 for the treatment of B-
cell non-Hodgkin’s lymphoma. Humanised antibodies go a step further; apart from the 
murine CDRs, the sequence of the antibody is identical to the human variant (7).   
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Figure 1.2 The development of monoclonal antibodies from murine to human IgG. 
 
Attempts to generate human monoclonal antibodies using hybridoma technology have 
been hampered by the lack of a suitable human myeloma cell line. In recent years, 
significant progress has been made on new technologies to produce human antibodies 
directly from human germline sequences. These technologies can be broadly classified 
into two methods; acquisition of antigen-specific B cells via phage display (8,9) and in 
vivo production from transgenic mice (10-12).  These recombinant approaches have also 
enabled  improvement  of  antibody  features  for  better  tumour  targeting  e.g.  affinity, 
avidity and specificity.  
 
To date, 36 monoclonal antibodies have been approved for therapeutic use in the EU 
and USA. Although full antibodies have made an impact as cancer therapeutics, their 
effectiveness  is  often  limited  and  most  must  be  used  in  combination  with  other 
treatments (13). The large size of these proteins results in poor tumour penetration (14) 
and long in vivo half-lives, which can in turn result in toxicity due to the inappropriate 
activation of Fc receptor expressing cells.  However, inadequate cell-killing activity is 
the main reason for the failure of monoclonal antibodies in clinical trials (15).  
1.4  Antibody fragments 
The segmental structure of antibodies allows their cleavage into fragments with distinct 
properties. Originally, this was achieved using proteolytic digestion; the hinge region is 
particularly susceptible to proteases, and two principal digested forms of IgG antibodies 
are useful for preparing immunological reagents (Figure 1.3). Digestion with pepsin 
removes  the  Fc  domain,  degrading  it  into  many  smaller  fragments,  leaving  a  large 
F(ab’)2 fragment held together by the disulfide bonds in the hinge region (16). This 
retains the bivalent antigen-binding properties of the parent IgG antibody, but without 
the  Fc  effector  region.  Alternatively,  digestion  with  papain  releases  two  identical 
monovalent  antigen-binding  Fab  fragments,  each  containing  the  VH-CH1  and  VL-CL 
segments  linked  by  a  disulfide  bond,  and  one  larger  Fc  fragment  containing  the 
remaining heavy chains (17). Through removal of the Fc domain, the Fab and F(ab’)2  
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fragments  confer  many  advantages  over  full  antibodies.  The  reduced  size  of  these 
fragments improves their diffusion through solid tumour mass (14), decreases their in 
vivo  half-life, a key  advantage in imaging  applications,  and  negates off-target  toxic 
effects  caused  by  the  Fc  region.  Advances  in  recombinant  DNA  technology  and 
antibody engineering have since enabled the generation of antibody fragments without 
the  requirement  for  proteolytic  digestion  (18,19).  Many  recombinant  antibody 
fragments  can  now  be  readily  expressed  in  microbial  systems  on  a  large  and  cost-
effective scale (20). 
 
 
Figure 1.3 F(ab’)2 and Fab fragments obtained by digestion with pepsin and papain 
respectively. 
 
1.4.1  scFv  
The variable fragment (Fv) consists only of the variable domains of the heavy and light 
chains (VH and VL), and as such is the smallest antibody fragment (~25 kDa) that retains 
full  specificity  and  antigen binding activity (Figure 1.4). The Fv  is  only associated 
through non-covalent interactions between the VH and VL domains, and is too unstable 
for  clinical  and  research  applications  (21).  A  common  practice  to  overcome  this 
instability is to incorporate a short peptide linker between the two domains, yielding a 
single-chain Fv (scFv) (Figure 1.4) (22,23). Generally a 15 residue (Gly4Ser)3 linker is 
used which provides flexibility, hydrophilicity and protease resistance.  An alternative 
stabilisation strategy is the incorporation of a single interchain disulfide bond between 
the VH and VL domains, giving a disulfide-stabilised Fv (dsFv) (Figure 1.4) (24-26). 
Many  groups  have  now  combined  these  two  stabilisation  strategies,  generating  a 
disulfide-stabilised  single-chain  Fv  (ds-scFv)  (Figure  1.4)  (27-29).  Uniting  the  two  
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approaches  creates  fragments  that  are  readily  expressed  in  high  yields  in  microbial 
systems, possess good thermal stability, and are less prone to aggregation.  
 
 
Figure  1.4  The  smallest  antibody  fragment  that  retains  full  specificity  and  binding 
activity, the Fv, and the three common stabilised variants, scFv, dsFv, and ds-scFv. 
 
A significant  advantage offered by these fragments is their small size; studies have 
demonstrated  that  tumour  penetration  is  inversely  proportional  to  the  size  of  the 
antibody  (30).  In  comparison  to  full  IgG  antibody  molecules,  scFvs  penetrate  and 
distribute homogeneously in tumours much more efficiently, a key advantage in both 
imaging and therapeutic applications (31-33). Antibody fragments below 65 kDa, such 
as Fabs and scFvs, undergo rapid, first-pass renal clearance (34), and so have much 
reduced in vivo half-lives compared to full antibodies. This can be advantageous for 
imaging applications as this limits non-specific binding and thus achieves better contrast 
(15). Furthermore, the monovalent nature of these fragments leads to lower retention 
times on the antigen compared to full antibodies (15,35). Although these features of 
scFvs  are  beneficial  in  terms  of  toxicity,  they  can  also  prove  a  disadvantage 
therapeutically, since the concentration of antibody at the tumour is low.  
 
1.4.2  Extending fragment half-life 
In order to tailor the in vivo half-lives and retention times of Fabs and scFvs, several 
strategies have been investigated including fusion with albumin (36,37), fusion with 
toxins (38) and affinity maturation (39). One of the most widely used techniques is 
PEGylation (40,41). Attaching an ethylene glycol polymer of the appropriate size via 
chemical  modification  has  been  shown  to  significantly  reduce  renal  clearance  of 
biologicals and increase protection against proteolytic degradation, as well as providing 
the additional benefit of reduced immunogenicity (42). This effect has been attributed to 
the interaction of PEG with water; each monomer of ethylene glycol binds to two water 
molecules, and so the hydrodynamic radii of PEG is 5- to 10-fold greater than would be  
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predicted by its nominal molecular weight (43). Thus the effective molecular size of the 
PEG conjugate is significantly increased.   
 
The half-lives of scFv and Fab antibody fragments can also be improved by increasing 
their valency. Through increasing the number of antigen binding sites both the size and 
also avidity of the antibody is increased, generating a construct with superior binding 
activity to the monomeric fragment.  scFv fragments can be encouraged to undergo 
spontaneous multimerisation through shortening of the peptide linker (< 12 residues) 
(44).  Alternatively, bivalent scFvs or Fabs can be generated by genetic engineering 
approaches.  For  example,  so  termed  ‘diabodies’  can  be  readily  constructed  in 
reasonable yields through the complementary pairing of the variable domains of one 
scFv with another, forming a non-covalently associated dimer (45). Fragment dimers 
can also be produced by genetic fusion and through the introduction of disulfides (46-
48).  Chemical  conjugation  approaches  have  also  been  attempted,  though  reported 
strategies generally result in heterogeneous multimers (49).   
 
1.5  Antibody conjugates for targeted therapeutics 
For many diseases, antibodies act as a therapeutic by blocking the function of their 
target molecule. In the case of cancer therapy, the antibodies must specifically recognise 
tumour cells and elicit cell death. Therapeutic antibodies have been suggested to prompt 
tumour  cell  elimination  through  several  mechanisms  including  immune  system 
recruitment  and apoptosis.  Although there has  been some success  using unmodified 
mAbs, many biological barriers must be overcome for significant accumulation in the 
target tissue, and even at this stage therapeutic efficacy is reliant upon the extent of 
antibody-induced cell death. It is the case that many antibodies simply do not have the 
cytotoxic potential to entirely destroy malignant cells.  As a consequence, antibodies 
and  antibody  fragments  are  increasingly  being  developed  as  targeting  agents  for 
administering cytotoxic substances or delivering potent effectors to selectively destroy 
cancerous  cells.  The  antibody  therefore  becomes  responsible  for  recognition  and 
binding, whilst the linked toxic component causes cellular alterations leading to cell 
death. The payload can be delivered by the antibody through two methods: direct or 
indirect targeting.  
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1.5.1  Direct targeting 
The  direct  targeting  or  “Magic-Bullet”  approach  is  the  delivery  of  a  cytotoxic 
compound such as a radioisotope or drug to only cells expressing the target antigen 
(50). This therapeutic strategy has great potential to drastically reduce the side-effects 
observed with standard chemo- or radiotherapy by concentrating the chemotherapeutic 
agent  at  the  location  of  the  tumour.  Delivery  of  the  cytotoxic  element  of 
immunoconjugates is achieved by endocytosis. Once bound to their target antigen on 
the cell surface, endocytosis can take place and the cytotoxic compound is released, 
inducing cell death (51). 
1.5.1.1 Radio-immunoconjugates 
Two  radio-immunoconjugates  have  been  approved  for  cancer  treatment, 
90Y-
Ibritumomab and 
131I-Tositumomab. These conjugates deliver lethal doses of radiation 
to the target tumour cells, resulting mainly in heavy DNA damage. Despite this, the 
level of radiation delivered is often insufficient to completely destroy solid tumours 
(52,53).  
1.5.1.2 Antibody-drug conjugates 
Over  the  last  decade,  antibody-drug  conjugates  (ADCs)  have  shown  considerable 
promise as cancer therapeutics.  Two ADCs have been approved in recent years; T-
DM1 (Kadcyla) from Genentech for the treatment of HER2-positive breast cancer and 
Brentuximab vedotin (Adcetris) from Seattle Genetics, for the treatment of relapsed 
Hodgkin and systemic anaplastic large cell lymphomas (54-56).  In fact, ADCs are now 
the main interest of immunoconjugate research since radioactive treatments are difficult 
to handle and immunotoxins are generally immunogenic (57) (see Section 1.5.1.3). For 
an ADC to be successful in the clinic, both the drug and the antibody must be validated. 
The  cytotoxic  drug  must  be  extremely  potent,  as  delivery  levels  are  low  (58). 
Furthermore, the antibody must be highly specific for its target antigen, which in turn 
must only be expressed on cancerous cells. The linker used to attach the drug to the 
antibody  must  also  be  chosen  carefully,  as  it  is  required  to  be  stable  in  blood  and 
subsequently release the cytotoxic cargo once inside the cell. In the ADC field there is 
currently extensive investigation into the chemical conjugation approach used to attach 
the drug to the antibody. Despite small molecule drug therapies requiring extensive 
investigation  to  ensure  the  synthesis  of  chemically  defined  products,  the  chemical 
conjugation strategies used to produce ADCs to date have generally been nonspecific  
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with little stoichiometric control. Thus ADCs are commonly produced as heterogeneous 
mixtures, with each conjugate possessing different pharmacokinetic, stability, affinity 
and safety profiles. An efficient chemical modification strategy to produce ADCs is key 
to future therapeutic success.  
1.5.1.3 Immunotoxins 
Immunotoxins  are conjugates  or fusion proteins of antibodies and protein toxins. A 
variety of toxins have been investigated for their use in the treatment of cancer with the 
plant-derived  toxins  ricin,  abrin  and  modeccin,  as  well  as  the  bacterial  derived 
diphtheria toxin, being the most popular. The ability of most toxins to cause cell death 
derives  from  their  enzymatic  inhibition  of  protein  synthesis.  In  order  for  the 
immunotoxin to elicit its cytotoxic effect, it must first bind and be internalised by the 
target cell. The enzymatic portion of the toxin must then undergo translocation to the 
cytosol. To date, only one immunotoxin, denileukin diftitox (Ontak), a fusion protein of 
truncated diphtheria toxin and interleukin 2, has been FDA approved, though several 
fusion proteins are currently in clinical trials (59). A major challenge in immunotoxin 
application is immunogenicity; neutralising antibodies are developed by most patients 
against the non-human toxin, limiting the number of treatment cycles.  
 
1.5.2  Indirect targeting 
Therapeutic  systems  with  a  two-step  approach  have  been  designed  whereby  the 
antibody is conjugated to an intermediate agent, which when combined with another 
non-toxic agent, can elicit cytotoxicity. One approach to generating indirect targeting 
therapeutics is to tag an antibody with a biotin label, and then a secondary avidin-toxin 
conjugate  can  be  administered  once  the  antibody  is  bound  to  the  target  cell.  This 
strategy  is  used  by  pre-targeted  radioimmunotherapy  (RIT);  a  biotin-labelled 
radionuclide is administered which possesses high affinity for a pre-targeted antibody 
fused to streptavidin (60).  
 
The most investigated method of indirect targeting is antibody-directed enzyme prodrug 
therapy  (ADEPT),  an  approach  first  described  in  the  late  1980s  (61-63).  The 
development of antibody-enzyme conjugates for use in this therapeutic system is one of 
the areas under investigation in this thesis.   
 
   
22 
 
   
1.5.2.1 ADEPT 
 
ADEPT was designed with the principal aim to restrict cytotoxic action to the site of the 
tumour. It is a two-step therapeutic; first an antibody or antibody fragment directed to 
tumour associated antigen carries the conjugated enzyme to the tumour sites, and once 
the conjugate is cleared from the blood, a non-toxic prodrug can be administered which 
is converted by the enzyme at the site of cancer, to a potent, cytotoxic drug (Figure 1.5). 
Since one enzyme can act on many prodrug molecules, a high concentration of the toxic 
drug will be produced at the site of the tumour. In addition, the small drug molecules 
can  diffuse  to  surrounding  cells,  destroying  antigen  negative  cells  and  tumour 
supportive stromal elements, referred to as a local bystander effect.  
 
 
Figure  1.5  Antibody-directed  enzyme  prodrug  therapy  (ADEPT);  a  two-stage 
therapeutic. Stage 1: The antibody-enzyme conjugate is allowed to localise in tumour 
tissue. Stage 2: Once cleared from the blood, a non-toxic prodrug can be administered, 
which is converted to a potent, cytotoxic drug by the targeted enzyme. The active drug 
diffuses through the tumour cells, causing localised cytotoxicity. Since one enzyme can 
act on many prodrug molecules, a high concentration of the toxic drug will be produced 
at the site of the tumour. 
 
ADEPT  has  many advantages  over standard chemotherapy.  Firstly, the highly toxic 
drug is delivered selectively and specifically at the site of the tumour. Secondly, through 
the use of a non-toxic prodrug, higher doses can be administered as the toxic effects will 
only be released at the site of cancer. Indeed, since ADEPT produces the cytotoxic drug 
at the tumour, it allows for the possibility of using drugs which would be deemed too  
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toxic to use as standard chemotherapeutics. Furthermore, as one enzyme can act on 
many prodrug molecules, ADEPT overcomes problems such as antigen heterogeneity, 
since  the  toxic  drug  molecules  produced  can  diffuse  to  surrounding  cells  (local 
bystander  effect).  Conversely,  antibody-drug  conjugates  require  homogeneous 
expression  of  the  target  antigen  across  the  entire  tumour  cell  population,  as  this 
approach relies on internalisation to release the cytotoxic drug.   
 
Many of the enzymes used for ADEPT are of bacterial origin and do not have a human 
equivalent. Although these non-human enzymes have an immunogenic effect, human 
enzymes are unsuitable for this system as endogenous conversion of prodrug would 
occur,  resulting  in  off-target  toxicity.  ADEPT  therapy  can  therefore  only  be 
administered before the patient experiences an immune response. The only enzyme to 
have  been  clinically  assessed  in  the  ADEPT  system  is  the  bacterial  enzyme 
carboxypeptidase  G2  (CPG2).  CPG2  is  a  dimeric  zinc-dependent  exopeptidase;  it 
hydrolyses the C-terminal glutamate moiety from folates, and has been used in ADEPT 
to facilitate the cleavage of nitrogen mustard L-glutamate prodrugs (64,65).  
 
Antibody and antibody fragment chemical conjugates to CPG2 have been constructed, 
however these conjugates are highly heterogeneous and result in a significant loss of 
both  antibody  and  enzyme  activity  (62,66-72).  Production  of  a  conjugate  of  CPG2 
linked to the F(ab’)2 fragment of an anti-carcinoembryonic antigen monoclonal antibody 
(A5B7) has undergone extensive optimisation (73). This conjugation procedure used the 
currently  available  reagents  N-succinimidyl  S-acetylthioacetate  (SATA)  and 
succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB) for lysine to lysine coupling (see 
Section 1.8.1). After optimisation, Melton et al. typically achieved yields of 30% in the 
crude reaction mixture, obtaining only 15% or less of 1:1 antibody-enzyme conjugate 
linked heterogeneously after purification (74).  
 
Developments in molecular biology have enabled antibody-enzyme recombinant fusion 
proteins to be generated for use in ADEPT (75-78). An anti-CEA scFv fusion to CPG2, 
called MFECP, has been successfully expressed as a stable homodimer in E. coli with 
maintained specificity and functional affinity (79).  Although this is currently the most 
efficient  approach  to producing  homogeneous  antibody-enzyme  conjugates,  it is  not 
without its issues. In fusion, antibodies and enzymes are linked by the direct expression 
of polypeptide chains between their N and C termini. This strategy is not suitable for all  
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proteins as many require unmodified termini for optimal activity (80-82). Furthermore, 
this fusion can complicate the folding and processing of proteins, resulting in expression 
difficulties  (83).  Certainly  in  the  case  of  MFECP,  several  problems  have  been 
encountered. In E. coli the yields of fusion protein are variable and often insufficient for 
use  in  clinical  studies  (75).  Expression  was  also  achieved  in  yeast,  however 
glycosylation of the MFECP construct resulted in rapid plasma clearance (76,77,84).  
 
1.6  Bispecific antibody therapeutics 
 
The limited ability of monoclonal antibodies to induce significant anti-tumour activity 
has also led to the development of bispecifics; fundamentally these are antibodies that 
can bind two different antigens. Presently, the concept of administering one antibody 
therapeutic to bind at least two molecular targets is one of the most exciting and highly 
investigated  areas  of  cancer  treatment.  In  recent  years,  several  clinical  successes  of 
bispecific  antibody  therapeutics  have  been  reported,  with  the  first  bispecific 
Catumaxomab (Removab), being approved for  the treatment  of malignant  ascites  in 
2009 (85). This biotherapeutic operates by guiding T-cells to epithelial cell adhesion 
molecule (EpCAM)-expressing tumour cells. Currently, bispecific therapeutics are also 
being developed to facilitate simultaneous inhibition of two cell surface receptors, or 
blocking of two ligands, cross-linking of two receptors, and T-cell recruitment to target 
tumour cells (86). Chemical construction of this therapeutic system is one of the main 
areas under investigation in this thesis. 
 
Bispecific  antibodies  can  be  produced  by  three  main  approaches:  (i)  chemical 
conjugation; (ii) fusion of two different hybridoma cell lines; (iii) recombinant DNA 
technology (87). The majority of reported chemical conjugation methods for bispecific 
production rely on modification of lysine residues, which leads to highly heterogeneous 
products (88,89). Recently the site-specific introduction of chemical linkers has been 
reported through unnatural amino acid insertion (90,91). Using this approach, Schultz et 
al. described the synthesis of a homogeneous anti-HER2/anti-CD3 bispecific in good 
yield (91). This technology and the use of lysine modification reagents will be discussed 
in detail in Section 1.8.  The earliest approach used to generate bispecifics was the 
hybrid  hybridoma  or  quadroma  approach  (92).  Through  somatic  fusion  of  two 
hybridoma cell lines, the formed quadroma cell line produces the two antibodies of 
different specificities, as well as a bispecific antibody with two distinct binding arms  
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(94). However, the bispecific is produced in very low yields, and extensive and difficult 
purification techniques are required to separate the desired antibody.  
 
The  development  of  recombinant  DNA  technology  has  allowed  for  many  of  the 
shortcomings associated with chemical conjugation and quadroma bispecific production 
to be overcome. The flexibility of this approach has enabled  a variety of bispecific 
antibody formats to be produced, from whole IgG like molecules for example Triomabs, 
to small recombinant formats, such as BiTEs (Bispecific T cell Engager) (Figure 1.6).  
These smaller bispecifics can be readily expressed at high levels in bacteria and their 
small size increases their ability to penetrate tumours. As discussed earlier, their size 
also results in a reduced serum half-life. Although sometimes an advantage, this can be 
a  major  drawback  to  therapeutic  success,  particularly  if  continuing  high  levels  of 
therapeutic are required.  
 
 
Figure 1.6 Examples of bispecific antibody formats for the recruitment of effector cells. 
Triomabs are based on rat IgG structure; one arm is specific for a tumour-associated 
antigen (blue) and the other for CD3 (red), a surface antigen expressed by cytotoxic T-
cells.  The Fc fragment  can activate the innate  immune system,  recruiting accessory 
cells. There are also several recombinant human bispecific formats, perhaps the most 
popular of which is the BiTE format. This is based on two scFv fragments joined by a 
peptide linker, one for tumour cell-binding (blue) and the other for binding effectors 
(red), such as T cells or NK cells.  
 
One of the most exciting bispecific formats currently in clinical development  is the 
Bispecific T cell Engager or BiTE. These constructs are commonly a fusion of two scFv 
fragments (~55 kDa total); one fragment with high specificity for the cancerous cell 
linked to another which engages T cells via binding to CD3, an invariant signalling  
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component of the T cell receptor (TCR) complex (90) (Figure 1.7). Through engaging a 
polyclonal population of T cells, lysis of the tumour cell is made independent of T cell 
receptor  specificity  and  MHC  (major  histocompatibility  complex)  presentation  (95). 
This  polyclonal  T  cell  engaging  approach  thus  bypasses  the  immune  escape 
mechanisms observed in many tumour cell populations.  
 
 
Figure 1.7 Construction, design and mode of action of BiTEs. 
 
Blinatumomab (anti-CD19/anti-CD3) is the most advanced BiTE in clinical trials to 
date  (95).  This  construct  has  demonstrated  clinical  activity  in  acute  lymphoblastic 
leukaemia (ALL) and non-Hodgkin’s lymphoma patients. However, its approval as a 
therapeutic has been limited by its short serum half-life, since patients require dose 
escalation and long-term exposure. Improving the half-life of homogeneous BiTEs is 
the next step in achieving a truly efficacious therapeutic.  
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1.7  Antibody conjugates for diagnostics 
 
1.7.1  Immunoassays 
Antibodies are extensively used in diagnostics, with the immunoassay being the most 
commonly  used  analytical  assay.  Immunoassays  facilitate  the  identification  of  the 
presence or concentration of a substance, the ‘analyte’, within a complex mixture. The 
chemical conjugation of antibodies to radioisotopes, dyes and enzymes enabled such 
technology  to  rapidly  expand,  particularly  in  biomedical  research.  One  of  the  most 
commonly employed immunoassays is the two antibody “sandwich” ELISA (Figure 
1.8).  This  is  used  in  diagnostics  to  determine  antigen  concentration  in  unknown 
samples, for example the blood plasma. This assay is quantified by using a secondary 
antibody conjugated to an enzyme e.g. horseradish peroxidise (HRP), through the use of 
a colorimetric substrate. This antibody-enzyme conjugate is generally produced using a 
cross-linker between two lysine residues, and is a heterogeneous mixture ranging from 
free antibody to that with several enzymes attached. 
 
Figure  1.8  Sandwich  ELISA;  termed  such  as  the  antigen  is  bound  between  two 
antibodies. 1. A known quantity of capture antibody is bound to a 96-well plate. 2. After 
a blocking step, the antigen containing sample is added. 3. After washing, the detection 
antibody  binds  to  the  antigen.  4.  After  a  second  washing  step,  an  enzyme-linked 
secondary  antibody  specific  for  the  detection  antibody’s  Fc  region  is  added.  Horse 
radish  peroxidase  (HRP)  is  generally  the  enzyme  of  choice.  5.  After  washing,  a 
chemical is added which is converted by the enzyme to a colour signal. The absorbance 
of this colorimetric substrate is used to determine presence and quantity of antigen. 
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1.7.2  Immunohistochemistry 
Immunohistochemistry (IHC) is widely used for the diagnosis of solid tumours. It can 
be used to determine the stage and grade of a tumour, whether it is benign or malignant, 
and to identify the origin of a metastasis in order to define the location of the primary 
tumour. IHC, similarly to an ELISA, uses a detection antibody that is conjugated to an 
enzyme such as HRP or a fluorophore. However, in this case the sample used is a tissue 
section, a biopsy from a patient. The simplicity of this technique means that it is readily 
available in most pathology laboratories, low-cost and yields rapid results. An example 
of IHC is the HercepTest; this determines HER2 expression levels in breast cancer to 
evaluate if treatment with the anti-HER2 monoclonal therapeutic Trastuzumab will be 
beneficial (Figure 1.9). The HercepTest is an early example of the newly evolving field 
of  theranostics,  which  is  the  merging  of  the  therapeutic  (‘thera’)  and  diagnostic 
(‘nostic’) potential of a compound. Through using a therapeutic e.g. Trastuzumab in a 
diagnostic test prior to treatment, the ability of a compound to exert a therapeutic effect 
can be ascertained. This field provides a step towards developing more personalised 
medicine, and will also enable more precise prediction and monitoring of tumours in the 
clinic.  
 
Figure 1.9 HercepTest. 1. Application of peroxidase block to tissue sample, preventing 
any endogenous peroxidase activity. 2. Application of Trastuzumab. 3. Application of  
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secondary antibody-HRP labelled polymer. Use of a polymer gives much higher assay 
sensitivity, as there are more enzyme labels per secondary antibody. 4. Application of 
3,3’-Diaminobenzidine  (DAB).  This  chromogen  is  widely  used  for 
immunohistochemical  staining;  in  the  presence  of  HRP,  DAB  produces  a  brown 
precipitate which is insoluble in alcohol and xylene.  
 
1.7.3  Flow cytometry 
Another crucial antibody-dependent diagnostic technology is flow cytometry, routinely 
used for diagnosis of haematological malignancies. This diagnostic technique provides 
not  only  immunophenotypic  data,  but  also  information  on  the  morphology  of  cells 
(96,97). In fact, the high sensitivity of flow cytometry means that it can be used to 
detect minimal levels of remaining cancerous cells, with an analytical  sensitivity of 
approximately one neoplastic cell to every 10
4 normal cells (98). Most commonly, this 
technique  measures  the  fluorescence  intensity  of  a  fluorophore-conjugated  antibody 
(Figure  1.10).  This  conjugation  may  be  on  the  diagnostic,  primary  antibody  (direct 
staining), or on a secondary antibody with high specificity for the primary (indirect 
staining). An alternative indirect approach is facilitated by avidin-biotin; the diagnostic 
antibody is chemically conjugated to avidin and in a subsequent incubation step a biotin 
labelled  fluorophore  added.  The  choice  of  conjugated  fluorophore  is  imperative  for 
precise results; antigens that are highly expressed may be resolved from background 
signal with almost any fluorophore, however low antigen expression requires a much 
higher  signal  to  background  ratio  that  can  only  be  provided  by  the  most  intense 
fluorophores e.g. PE (R-phycoerythrin).    
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Figure 1.10 Illustration of the fluidics system of a flow cytometer. 
 
1.7.4  Immuno-PET & Immuno-SPECT 
Antigen  expression  levels  can  also  be  determined  in  vivo  using  molecular  imaging 
technology.  For  both  haematological  and  solid  tumours,  immuno-positron  emission 
tomography  (PET)  and  immuno-single  photon  emission  computed  tomography 
(SPECT) can be used. Both techniques use a radioimmunoconjugate, specifically an 
antibody conjugated to a positron or γ-emitter, which is injected intravenously. Using a 
PET or SPECT scanner, the distribution of the conjugated antibody can be visualised. 
This non-invasive diagnostic technique thus provides target visualisation throughout the 
whole body.  
 
Immunoassays, immunohistochemistry, flow cytometry and molecular imaging, all rely 
on chemically conjugated antibodies. Improved antibody conjugation strategies would 
result  in  improved  specificity  and  sensitivity,  and  thus  improved  diagnosis.  The 
chemical modification of antibodies for diagnostics is an area of investigation in this 
thesis.   
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1.8  Chemical modification of antibodies 
The chemical modification of antibodies, and particularly antibody fragments, has a 
crucial role to play in the development of the next generation of immunotherapeutics 
and diagnostic tools.  Through attachment of groups such as polyethylene glycol (PEG), 
the  in  vivo  lifetimes  can  be  altered,  stability  of  antibodies  improved,  and 
immunogenicity reduced (40,41). New functions can also be conferred on antibodies 
and  antibody  fragments  through  attachment  of  radiolabels  and  fluorophores.  For 
antibody-drug conjugates (ADCs), bispecifics and antibody-directed enzyme prodrug 
therapy (ADEPT), efficient chemical modification of the antibody is key to therapeutic 
success.  
 
There  are  several  long-established  techniques  for  the  chemical  modification  of 
antibodies, particularly for the production of antibody-enzyme conjugates. Many of the 
methods  were developed to  produce conjugates for immunoassays  such as  ELISAs. 
These focus on achieving high yields of conjugate with retention of biological activity. 
However,  more  precise  techniques  are  required  for  the  generation  of  therapeutic 
antibody conjugates. Investigations into the chemical modification of antibodies have 
revealed  that  the  strategy  used  can  dramatically  affect  its  behaviour  in  vivo.  It  is 
essential that conjugates maintain the antigen binding character of the antibody, and in 
the  case  of  ADEPT  for  example,  not  block  the  activity  of  the  linked  enzyme.  In 
addition,  site-specific  couplings  are  required  in  order  to  control  the  number  of 
toxophores e.g. drug or radiolabel per antibody, as this is key to the pharmacokinetic 
properties  of  the  immunoconjugate.  Site-specificity  of  conjugation  is  even  more 
necessary when using antibody fragments, since it is increasingly likely that amino acid 
side chains will be involved in antigen-binding. In the case of bispecific therapeutics 
and ADEPT constructs, site-specificity is necessary to avoid large aggregates which 
would be taken up by the reticuloendothelial system, to achieve maximum penetration 
of  the  target  tumour,  and  prevent  blocking  of  antigen-binding  sites  by  the  other 
conjugated protein.  
 
1.8.1  Heterobifunctional cross-linkers 
Methods for the chemical modification of proteins have largely targeted the side chains 
of naturally occurring amino acid residues. Development of modification reagents for 
many of the hydrophilic amino acids has been attempted; these include lysine, cysteine,  
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histidine, tyrosine, aspartic acid, arginine, tryptophan, serine, threonine and glutamate 
residues (99,100). However, the majority of bioconjugation research, and certainly for 
antibody modification, has focused on the nucleophilic functional groups of two amino 
acids, lysine and cysteine (Figure 1.11) (101).  
 
 
Figure 1.11 Many bioconjugation reagents have been developed which target the amino 
acids lysine and cysteine, owing to the nucleophilic primary amine of lysine residues 
and the primary thiol of cysteine residues. 
 
The most widely used reagents for chemical conjugation are heterobifunctional, which 
react with the amino group of a lysine residue on one protein and the thiol group on a 
second.  Commonly  such  linkers  possess  an  amine  reactive  N-hydroxysuccinimide 
(NHS) ester, together with a maleimide or activated sulfhydryl for thiol modification. 
The basic structures of the two linkages formed between the antibody and conjugated 
protein  or  other  functional  molecule  are  shown  in  Figure  1.12.  The  key  difference 
between the two linker types is the formation of a thioether or disulfide bond, depending 
on  whether  the  reactive  thiol  group  is  a  maleimide  or  an  activated  sulfhydryl 
respectively.  
 
Figure 1.12 Two main types of linkages formed between antibody (blue) and conjugate 
(pink) e.g. enzyme, drug, radiolabel.  
 
Heterobifunctional  reagents  forming  thioether  linkages  are  by  far  the  most  popular 
commercial reagents currently available. They are preferable to disulfide linkers largely 
because of their stability, as the thioether linkage is maintained under a wide variety of 
conditions where the disulfide would be reduced. For example, disulfide linkages are 
Cysteine  Lysine  
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extremely unstable in blood plasma, a feature which would be highly undesirable for the 
production  of  most  therapeutic  and  diagnostic  conjugates.  The  most  popular  of  the 
thioether  heterobifunctional  reagents  are  succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate  (SMCC),  m-maleimidobenzoyl-N-
hydroxysuccinimide  ester  (MBS)  and  N-(γ-maleimidobutyryloxy)succinimide  ester 
(GMBS), the structures of which are shown in Figure 1.13. The linker SMCC is the 
most widely used as it less susceptible to maleimide hydrolysis (74). The aromatic ring 
adjacent to the maleimide of MBS causes this linker to be highly labile to ring opening 
in an aqueous medium.  In contrast, the maleimide of SMCC is adjacent to a bulky 
cyclohexane ring with no aromatic character.   
 
 
Figure 1.13 Common heterobifunctional linkers. 
 
In the case of all these linkers, the NHS ester moiety is generally first reacted with the 
amino group of a lysine residue of a protein or other functional molecule at a slightly 
alkaline pH (normally pH 7.5). Thus an amide bond is generated and the protein or 
other functional molecule is joined to active maleimide groups. Following purification 
the maleimide activated protein or functional molecule can be reacted with the thiol 
groups of an antibody. This process is shown in Scheme 1.1. The free sulfhydryl groups 
on the antibody may be endogenous or chemically introduced. Endogenous thiols are 
commonly obtained through incubation of the antibody with a reducing agent, cleaving 
the interchain disulfide bonds in the hinge and switch regions to reveal the requisite 
sulfhydryls.  Chemical  introduction  is  achieved  using  thiolation  reagents  such  as  N-
succinimidyl-S-acetylthioacetate (SATA) to modify the intact antibody, again utilising 
the reaction of lysine residues with an NHS ester (Scheme 1.2).  
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Scheme  1.1  Use  of  heterobifunctional  reagent  SMCC  (A)  to  generate  an  antibody 
conjugate (C). SMCC (A) is first reacted with the lysine residues of e.g. an enzyme, or 
the amine group of another functional molecule, e.g. a drug (pink). This generates B, an 
enzyme or drug with an active maleimide group attached. Subsequent addition of an 
antibody or antibody fragment with a free thiol group yields the antibody conjugate C. 
Addition of one SMCC molecule is shown here for simplicity; in reality multiple SMCC 
molecules  react  with  multiple  amine  groups,  and  subsequently  react  with  multiple 
thiols.  
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Scheme  1.2  Chemical  introduction  of  thiols  to  produce  e.g.  an  antibody-enzyme 
conjugate. Available lysine residues on an antibody may be modified with the NHS 
ester of SATA reagent to produce protected sulfhydryls. Following deprotection with 
hydroxylamine  at  alkaline  pH,  conjugation  to  a  maleimide  protected  enzyme  can 
proceed. 
 
A fundamental issue with current available methods for the chemical modification of 
antibodies,  particularly  in  the  production  of  antibody-protein  conjugates,  is  the 
dependence upon lysine residues. Amine groups are plentiful in most proteins; in fact 
there are an average of 100 lysine residues per antibody and their distribution within the 
three-dimensional structure is nearly uniform throughout the surface topology of the 
Fab  and  Fc  regions.  As  such,  conjugation  techniques  using  lysine  residues  will 
randomly cross-link to virtually all areas of the antibody molecule, resulting in a highly 
heterogeneous mixture of products. One such example is the conjugation of antibody 
huN901, which contains 86 lysine residues, with a drug molecule. Characterisation by 
mass  spectrometry  and  peptide  mapping  revealed  a  two-fold  heterogeneity  in  the 
conjugate; first, antibody conjugates were formed with between 1 and 6 drug molecules 
attached  and  second,  antibodies  with  the  same  drug  loading  were  conjugated  by  
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different lysine residues (102). In fact, 40 different lysine residues were involved in 
these  conjugates.  Hence  there  are  potentially  10
6  antibody-drug  conjugates  present 
(103). In addition, within these heterogeneous mixtures there is random orientation of 
the antibody within the modified structure and so the surface of another attached protein 
or molecule may block antigen binding sites. This produces a conjugate with decreased 
antigen binding activity compared to the unmodified antibody (102-105). This is also 
the case for conjugated enzymes, as the modification may occur at residues essential for 
protein function. Furthermore the use of heterogeneous mixtures in therapeutics is far 
from optimal, as each component of the mixture will have a different pharmacological 
profile  (103,106).  Certainly  for  the  production  of  ADCs  by  lysine  modification  a 
complete lack of stoichiometric control is observed, which leads to typical distributions 
of zero to eight drug molecules per antibody (107). Thus such conjugates often have a 
narrow therapeutic window (108) as well as over modification of a charged residue such 
as lysine resulting in decreased solubility and faster blood clearance rates (109,110). As 
a result regulatory approval is increasingly requiring homogeneity in biologicals.  
 
1.8.2  Site-directed conjugation 
Bioconjugation  to  antibodies  is  generally  more  successful  at  maintaining  biological 
activity if the functional groups used are present in low quantities and at particular sites 
on the molecule. A “site-directed conjugation” approach joins cross-linking reagents 
with residues that are present only at discrete positions on the antibody surface, distant 
from  antigen  binding  sites.  Such  approaches  use  existing  knowledge  of  antibody 
structure to determine where a chemical entity can be attached to the immunoglobulin 
without  interfering  with  its  binding  potential.  The  conjugated  products  of  these 
strategies are therefore generally more successful in maintaining antibody activity.  
1.8.2.1 Reduction of interchain disulfides 
Unlike lysine residues, there are no free cysteine residues in antibodies, the side chain of 
which is commonly used in protein modification owing to its nucleophilic sulfhydryl. 
Antibodies do however contain disulfide bonds in the hinge region between the heavy-
heavy chains and between the heavy-light chains in the Fab fragment (switch region). 
These interchain disulfides are distant to the antigen binding sites and so conjugation of 
proteins or molecules at the generated cysteine residues generally avoids the blocking of 
antigen binding regions, thus maintaining antibody activity.  
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A  common  strategy  for  antibody  interchain  disulfide  bond  reduction  is  to  use  the 
reductant 2-mercaptoethylamine (2-MEA). This relatively mild reducing agent has been 
used for many years for the reportedly selective cleavage of the interchain disulfides in 
the hinge region. Current improved analytical techniques have shown however that 2-
MEA  is  not  fully  selective  for  the  hinge  region  disulfides,  though  it  is  still  sold 
commercially by some companies as a selective reducing agent. Sun et al. revealed that 
treatment with 2-MEA produces a nearly 1:1 mixture of antibody where the heavy-light 
chains have been reduced and that where only the hinge region heavy-heavy chains 
have undergone reduction (111).  
 
Different reducing agents do demonstrate some preference for particular interchain 
disulfides, however this is not simple to control and appears to depend on a number 
of variables including concentration of protein and temperature (111). Despite this, 
the interchain disulfide reduction strategy holds significant advantages over lysine 
modification;  it  is  a  step  towards  control  of  conjugation  location  and  so  the 
production  of  homogenous  conjugates  (Figure  1.14).  One  of  the  two  clinically 
approved ADCs currently on the market, Brentuximab vedotin, is obtained through a 
partial reduction approach (112). Despite this approach being site-specific compared 
to lysine modification, a heterogeneous ADC still results, containing between 0 and 
8 drugs per antibody with a species holding 4 drugs being the predominant species. 
In addition, disulfide bonds play an important role in both the activity and stability 
of antibodies (103,113). Intact disulfides are necessary to stabilise antibodies when 
exposed to heat or chaotropic substances, and so their absence can lead to significant 
aggregation  during  storage  (114,115).  Furthermore,  it  has  been  demonstrated  by 
both reduction and mutation approaches that the hinge region disulfides are essential 
for Fc mediated effector functions, including ADCC and CDC (116-120). Therefore 
the ideal solution would be to use reagents that modify these native disulfide bonds 
whilst retaining a bridge between  the two cysteine residues,  maintaining this key 
stabilising feature (see Section 1.8.3).  
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Figure 1.14 Drug conjugation to cysteine residues by partial reduction of interchain 
disulfides. A partial reduction approach  yields less heterogeneity as the drugs are 
attached at defined sites. However, an average drug loading of 4 is still obtained due 
to the presence of small amounts of ADC with 0, 2, 6 and 8 drugs attached. 
1.8.2.2 Oxidation of carbohydrate chains 
 
Antibodies  are often  glycosylated on the CH2 domains  of the  Fc  fragment.  Another 
popular  site-directed  conjugation  approach  involves  the  oxidation  of  these 
polysaccharides  with  sodium  periodate  to  generate  free  aldehydes.  These  aldehyde 
groups  can  then  be  reacted  with  hydrazide-containing  cross-linking  reagents,  or 
molecules directly connected to the hydrazide group e.g. biotin-hydrazide. This method 
is generally very successful at maintaining the antigen binding activity of the antibody, 
since the site of conjugation is far removed from the variable fragments. However, a 
clear limitation of this strategy is the requirement for antibodies to be glycosylated. 
Although  polyclonal  antibodies  obtained  from  antisera  are  normally  glycosylated, 
monoclonals  obtained  using  hybridoma  technology  are  often  not  post-translationally 
modified (121). Antibodies and antibody fragments produced in bacteria are also free of 
carbohydrate.  
1.8.2.3 Cysteine introduction by mutagenesis 
 
As  mentioned  in  Section  1.8.2.1,  in  contrast  to  lysine  residues,  there  are  no  free 
cysteines in antibodies. Hence, the introduction of a cysteine by mutagenesis can be 
used to provide a single point of attachment in this “site-directed conjugation” approach 
(103,106,122-124).  In  2008,  Genentech  achieved  a  site-specific  ADC  through 
introducing  cysteine  substitutions  at  designated  positions  on  an  antibody,  termed  a 
‘Thiomab’ (Figure 1.15) (103). These engineered cysteine sites were chosen to produce 
reactive thiol groups without affecting the folding or assembly of the antibody, nor the 
antigen binding ability. This ADC was restricted to two drug molecules per antibody 
and was shown to possess similar activity to randomly labelled ADCs which can hold 
up  to  eight  drug  molecules.  Furthermore,  it  was  demonstrated  to  have  a  greater  
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therapeutic index and improved pharmacokinetic properties in rodents. The results of 
this  study  further  demonstrate  that  site  selective  chemical  conjugation  and 
stoichiometric control are key to the future of ADC therapeutic success. However, this 
approach is not without limitations, as cysteine mutagenesis commonly leads to reduced 
expression  yields  and  undesirable  properties  such  as  susceptibility  to  dimerisation, 
mixed disulfide formation or disulfide scrambling (103,122,125-127).   
 
 
Figure 1.15 Generation of a site-specific ADC using a Thiomab; a mAb carrying an 
A114C  mutation in the heavy  chain.  The introduced cysteines  are capped  by either 
cysteine or glutathione. Mild reduction followed by reoxidation produces two free thiols 
without disturbing the correct formation of the interchain disulfide bonds. These thiols 
can then be used to  generate a homogeneous  ADC (uniform  drug loading of 2 per 
mAb).   
1.8.2.4 Bioorthogonal reagents  
 
In recent years, several chemical reactions have been developed that are orthogonal to 
the  functional  groups  present  in  proteins.  Through  incorporating  a  bioorthogonal 
functional  group  into  an  antibody,  unprecedented  conjugation  selectivity  to  other 
functional  molecules  containing  a  specific  reaction  partner  has  been  achieved.  The 
leading  reaction  in  this  field  of  bioorthogonal  chemistry  is  the  azide-alkyne  [3+2] 
cycloaddition, often referred to as a ‘click’ reaction.  
 
The motivation  behind  click chemistry  was  to  produce  a  reaction that  would  ensue 
rapidly under ambient conditions to achieve a single product in high yield (128). In 
order for such a reaction to occur, a high thermodynamic driving force is required that is 
orthogonal to any other functional groups present. For this reason, the azide group is 
perhaps  the most popular bioorthogonal  click reagent; it is  highly  reactive but  in  a 
selective manner, in addition to being inert in the biological environment. Selective 
[3+2]  cycloaddition  between  an  azide  and  an  acyclic  alkyne  was  first  described  by 
Huisgen  (129);  however  this  required  large  amounts  of  heat  in  order  to  form  the  
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corresponding triazole. The click chemistry vision was realised in 2002 when Sharpless 
et al. and Meldal et al. simultaneously reported a dramatic acceleration in the rate of 
reaction through the use of copper(I) catalysts (130,131) (Scheme 1.3A). In addition, the 
copper-catalysed  cycloaddition  shows  greater  reaction  scope,  tolerates  aqueous 
conditions and a range of pH, and has improved chemo- and regioselectivity (132). This 
highly  selective  and  rapid  cycloaddition  was  hampered  in  its  use  however  by  the 
requirement for copper; protein damage was observed at the high metal concentration 
necessary for efficient labelling (133). Other metal-free bioorthogonal reactions were 
developed, including the Staudinger ligation which consists of the covalent ligation of 
phosphines to azides. Unfortunately these reactions are slow and the oxygen sensitivity 
of phosphines limits their use in biological applications. Then in 2004, a new generation 
of click chemistry was born, when Bertozzi et al. introduced strain-promoted azide-
alkyne cycloaddition (SPAAC) (134) (Scheme 1.3B).  
 
 
Scheme  1.3  Click  reactions  (A)  Copper-catalysed  azide-alkyne  cycloaddition 
(CuAAC); (B) Strain-promoted azide-alkyne cycloaddition (SPAAC). 
 
The incorporation of an alkyne into a strained cyclooctyne ring system dramatically 
increases  its  intrinsic  reactivity;  the  bond  angles  of  sp-hybridised  carbons  in 
cyclooctynes are ~160° and so less distortion energy is required to move towards the 
transition  state  of  the  cycloaddition  reaction  (Scheme  1.4).  In  fact,  the  significant 
deformation of the acetylene bond angle accounts for approximately 18 kcal/mol of ring 
strain (135). Thus resulting reactions with azides can occur at rates comparable to the 
copper-catalysed  click.    A  number  of  strained  cyclooctynes  have  successfully  been 
applied as bioorthogonal reagents, including DIFO, DIBO, DIBAC and BARAC (136-
138) (Figure 1.16). The application of strained cyclooctynes has been slightly mired by  
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their lengthy and difficult synthesis and consequent lack of commercial availability. 
Although  the  dibenzocyclooctynes  are  somewhat  simpler  to  synthesise,  these  suffer 
from increased lipophilicity and consequently non-specific binding to proteins.  More 
readily available strained cyclooctynes are being developed, with bicyclo[6.1.0]nonyne 
(BCN)  being  particularly  successful    (139)  (Figure  1.16).  Such  bicyclononyne 
derivatives are Cs symmetrical and exhibit excellent kinetics in SPAAC reactions, and 
can be obtained through the cyclopropanation of the low-cost 1,5-cyclooctadiene. A 
major  advantage  of  the  Cs  symmetry  of  BCN,  particularly  in  comparison  to  other 
popular  cyclooctynes  such  as  DIFO,  is  the  formation  of  a  single  regioisomer  upon 
cycloaddition.  This  is  crucial  for  future  therapeutic  applications  of  this  conjugation 
chemistry, including ADEPT and ADCs, where the formation of homogeneous products 
is desired.  
 
Scheme  1.4  Click  reactions  (A)  A  comparison  between  the  bond  angles  of  linear 
alkynes  and  triazoles;  (B)  A  comparison  between  the  bond  angles  of  strained 
cyclooctynes and its corresponding triazole product.  
 
Figure 1.16 Structures of commonly employed cyclooctynes.  
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Another bioorthogonal reaction that occurs with high reaction rates and in good yield 
without requiring metal catalysis is the strain-promoted inverse-electron-demand Diels-
Alder cycloaddition (SPIEDAC). Tetrazines are exceptional dienes, reacting irreversibly 
with a diverse range of strained alkenes and alkynes in this retro-[4+2] cycloaddition to 
yield N2 as the only byproduct (Scheme 1.5). The most reactive dienophile is trans-
cyclooctene and a variety of these reagents are currently being used in bioorthogonal 
reactions.  This  click  variant  carries  some  practical  advantages  over  the  SPAAC 
reaction.  The  trans-cyclooctene  starting  materials  are  easily  accessible  from 
commercially  available  cis-cyclooctenes,  and  unsymmetrical  tetrazine  can  be 
synthesised  on  a  large  scale  from  hydrazine  with  commercially  available 
cyanopyridines. In addition, several functionalisable handles can be incorporated into 
the tetrazines. The compatibility of SPIEDAC with strained cyclooctynes has recently 
been demonstrated using BCN, in which the alkyne demonstrated a comparable rate of 
reaction to a range of strained cyclooctenes (140). In fact, current literature suggests that 
BCN reagents are proving to be the key tool in bioorthogonal click chemistry (91,140). 
Many  fluorescent  and  fluorogenic  dyes  are  commercially  available  or  readily 
synthesised as the azide or tetrazine derivative, hence using a cyclooctyne reagent that 
can react with both would be a powerful tool for many biological applications.  
 
Scheme 1.5 Inverse-electron demand Diels-alder reaction of strained trans-cyclooctene. 
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1.8.2.4.1  Introduction of unnatural amino acids 
 
For bioorthogonal  click reactions  such as  SPAAC and SPIEDAC to  be used in  the 
production of homogeneous protein conjugates, individual functionalities must first be 
introduced to the proteins site-specifically. One approach is to introduce an unnatural 
amino acid (UAA) into the protein(s) to be conjugated, thus providing a means of site-
specific protein functionalisation. Schultz et al. recently produced a homogeneous anti-
HER2/anti-CD3  Fab  bispecific  using  this  approach  (91).  Using  an  evolved 
tRNA/aminoacyl-tRNA synthetase pair in  response to  an amber nonsense codon,  p-
acetylphenylalanine residues were introduced into each Fab site-specifically. These site-
specific residues could then be reacted with alkoxyamine linkers containing azide or 
cyclooctyne  moieties.  The  subsequent  click  reaction  of  these  two  Fab  fragments 
produced bispecifics with excellent activity in vitro, with no loss of antibody binding 
activity  or  stability.  Thus  this  combined  approach  has  successfully  produced  a 
chemically linked, site-specific, homogeneous antibody conjugate in good yield.  
 
Developments  in  mutation  technology  in  the  last  decade  have  made  it  possible  to 
incorporate  almost  any  functionality  into  a  protein  through  site-specific  genetic 
encoding  of  unnatural  amino  acids.  This  can  be  achieved  by  codon  reassignment 
(141,142) or suppression of the amber stop codon (143,144). Thus it was envisaged that 
copper-free click chemistry could be used to generate protein conjugates using artificial 
amino acids containing cyclooctyne and azide functionalities. Installing azide groups 
has proved problematic, since they can be reduced during the lengthy in vivo expression 
and purification steps (145). However, Schultz et al. recently successfully installed a 
variety of cyclooctene and a cyclooctyne containing UAAs into E. coli and mammalian 
cells through suppression of the amber stop codon (91,140).  The bioorthogonal reaction 
of  these  with  azide  and  tetrazine  labelled  fluorescent  and  fluorogenic  dyes  was 
subsequently demonstrated. This technique has great potential, particularly in cellular 
imaging, as it will facilitate site-specific labelling of proteins with small photostable 
fluorophores in mammalian cells, negating the need for large fluorescent proteins with 
less favourable photophysical properties.  
1.8.2.4.2  Enzymatic labelling of antibodies 
 
In  recent  years,  chemo-enzymatic  methods  for  the  site-specific  modification  of 
antibodies have become an increasingly active and developed area of research (146).  
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One such popular tool for site-specific modification is ‘sortagging’, which refers to the 
use  of  the  enzyme  sortase  for  protein  labelling.  Harrenga  et  al.  successfully 
demonstrated the conjugation of a single fluorophore to a Fab fragment using Sortase A 
(SrtA)  (147).  This  recognises  the  pentapeptide  sequence  LPXTG,  which  was 
incorporated at the C-terminus of the Fab fragment light chain. Upon recognition, SrtA 
cleaves  the  bond  between  the  threonine  and  glycine  residues  generating  a  thioester 
between  a  cysteine  of  SrtA  and  the  Fab  fragment.  This  thioester  subsequently 
underwent aminolysis with the addition of a fluorescent oligoglycine probe in good 
yield. A key limitation of sortagging is its reversibility; the glycine residue released by 
enzyme  cleavage  can  act  as  nucleophile,  reforming  the  original  protein  species.  To 
overcome this,  Turnbull  et  al. generated  a depsipeptide where  an ester replaces  the 
amide bond between the threonine and glycine of the pentapeptide recognition sequence 
(148). It was envisaged that the hydroxyacetyl byproduct would not be a substrate for 
the  reverse  reaction,  rendering  it  irreversible.  Indeed  this  strategy  vastly  improved 
reaction efficiency, enabling 100% conversion to the desired product using just a 1:1 
ratio of the two peptide starting materials. Thus the sortagging approach can now be 
used without the requirement for excess amounts of protein or peptide for sufficient 
labelling. The key advantage of this approach is that no limitations have been observed 
in the size of the modification that maybe introduced, avoiding the requirement for a 
two-step  chemo-enzymatic  strategy  (101).  However,  it  is  limited  to  N-terminal 
modifications, which is not ideal for every antibody or antibody fragment.  
 
A  number  of  two-step  chemo-enzymatic  approaches  have  recently  successfully 
generated  homogeneous  antibody-protein  or  antibody-small  molecule  conjugates  in 
good yield. For example, Bertozzi et al. achieved homogeneous chemical conjugation 
of whole human IgG to human growth hormone (hGH) and maltose-binding protein 
(MBP) using formylglycine generating enzyme (FGE) in combination with copper-free 
click chemistry (90). This was achieved through introducing the five-residue sequence 
(CXPXR)  recognised  by  FGE  at  specific  sites  in  the  antibody.  During  protein 
expression in E. coli or mammalian cells, FGE subsequently oxidises the cysteine in this 
sequence to the aldehyde residue formylglycine (fGly). This site-specific aldehyde tag 
can then be functionalised with a bioorthogonal reagent for further conjugation.  Using 
this  strategy,  Bertozzi  et  al.  successfully  site-specifically  conjugated  human  IgG 
functionalised with two strained alkynes to either hGH or MBP containing a single 
azide group (90).    
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Another  family  of  enzymes,  the  transglutaminases,  have  recently  been  applied  to 
generate  homogeneous  antibody-small  molecule  conjugates.  In  one  such  example, 
Schibli  et  al.  used  microbial  transglutaminase  (MTGase),  which  forms  isopeptidic 
bonds between glutamine and primary amines, to obtain homogeneous antibody-drug 
conjugates  (Figure  1.17)  (149).  MTGase  has  previously  been  shown  to  selectively 
recognise the Gln295 residue in the heavy chain of deglycosylated IgG molecules (150). 
Modification  of  Trastuzumab  using  MTGase  and  a  small  azido-PEG-amine  linker 
generated  antibody  with  two  sites  for  selective  attachment  in  quantitative  yield. 
Subsequent addition of only 2.5 equivalents of strained alkyne functionalised drug gave 
the  desired  homogeneous  antibody-drug  conjugate.  Thus  this  chemo-enzymatic 
approach generated an ADC with an exact DAR of 2 using minimal amounts of toxic 
drug,  a  crucial  advantage  when  producing  ADCs  on  a  large  scale.  This  combined 
approach can be transferred to any IgG1 molecule and will surely be a powerful tool in 
the development of the next generation ADCs.   
 
 
Figure  1.17  Generation  of  a  site-specific  ADC  using  microbial  transglutaminase 
(MTGase). Following deglycosylation, the antibody can be site-specifically modified at 
Gln295  by  MTGase  to  incorporate  two  azide  functionalities.  Strained  alkyne 
functionalised drug molecule (red circle) can then be directly attached to achieve a well-
defined ADC with a DAR of 2.  
 
The  use  of  bioorthogonal  reagents  in  combination  with  unnatural  amino  acids  and 
enzymatic  labelling  has  provided  an  excellent  route  to  homogeneous,  site-specific  
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antibody conjugates. Whilst this technology is elegant, it is not without limitations. The 
kinetics of many bioorthogonal reactions are still comparatively slow (151,152), thus 
requiring  high  reagent  concentrations  (153)  and  often  resulting  in  non-quantitative 
conversion  (154,155).  In  addition,  the  introduction  of  unnatural  amino  acids  or 
sequences  for  enzymatic  labelling  is  not  easily  transferred;  each  antibody  to  be 
conjugated must undergo prior investigation to determine appropriate mutation sites, the 
site of introduction may be restricted e.g. to the N- or C-terminus, and in the case of 
unnatural  amino  acids  substitution  is  often  incomplete  and  expression  yields  are 
generally  low  due  to  the  cellular  toxicity  of  artificial  amino  acids  at  the  high 
concentrations necessary (156,157). To avoid these difficulties, an ideal site-directed 
conjugation technique would use residues natural to the protein that are revealed for 
modification only under defined conditions.  
 
1.8.3  Bridging of disulfide bonds: a new class of reagents 
Currently, insertion of unnatural amino acids and enzymatic labelling for the site-
specific introduction of bioorthogonal click chemistry reagents has proved the most 
successful strategy for producing homogenous antibody conjugates in high yield. It 
would  be  ideal  if  site-directed  conjugation  could  be  simplified  and  use  residues 
natural to the protein. As previously discussed, cysteine residues have a low natural 
abundance  in  proteins,  constituting  only  0.2%  of  naturally  occuring  amino  acids 
(158), and are often found tied up in disulfide bonds (159). In the case of antibodies 
and  antibody  fragments  there  are  no  free  cysteine  residues,  and  site-directed 
conjugation  has  been  attempted  via  interchain  disulfide  bond  reduction  and 
subsequent conjugation of the free cysteines (see Section 1.8.2.1). However disulfide 
bonds in antibodies, and in the majority of proteins, play an essential role in both 
their activity and stability (103,113,115). Therefore the ideal solution would be to 
use  reagents  that  bridge  native  disulfide  bonds,  maintaining  this  key  stabilising 
feature.  
 
Chemical  modification  reagents  targeting  individual  cysteine  residues  are  well-
established  and  regularly  used  to  generate  bioconjugates.  Popular  cysteine 
modification  reagents  include  ʱ-halocarbonyls,  Michael  acceptors  such  as  the 
maleimide,  and  activated  disulfides  (Scheme  1.6).  In  addition,  dehydroalanine 
(DHA) can be formed by the activation and subsequent elimination of a cysteine  
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residue, providing a unique site for further modification (160) (Scheme 1.6c).  
 
Scheme 1.6 Reagents widely used for the modification of cysteine a) maleimides; b) ʱ-
halocarbonyls; c) formation of dehydroalanine (DHA); d) disulfides.  
Maleimides  are  perhaps  the  most  widely  employed  reagents  for  cysteine 
modification (161), undergoing rapid and highly selective reactions with thiols over 
a wide pH range (161-64). However traditional maleimides suffer from limitations.  
They  are  generally  considered  to  react  irreversibly,  preventing  cleavage  to 
regenerate the unmodified protein. Making this reaction reversible would be highly 
advantageous as it would allow for the temporary modification of proteins, which 
may be desirable for in vitro or in vivo applications. Recent literature has observed 
that maleimides conjugated to small molecule thiols can undergo retro and exchange 
reactions in the presence of free thiol at physiological pH and temperature (165). 
However,  this  is  very  slow  and  not  a  convenient  protocol  for  reversibility. 
Maleimides  are  further  limited  by  possessing  only  two  points  of  attachment  for 
bioconjugation. Hence only two entities of interest can be linked to each other via 
the maleimide, and it is not able to effectively bridge a disulfide bond. In the Baker  
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and Caddick groups we have recently reported a new class of maleimides, of which 
the bromomaleimides are the parent members, that provide new opportunities for 
protein  modification  at  cysteine  residues.  These  new  reagents  enable  rapid, 
selective,  and  reversible  modification  of  cysteine,  and  efficient  and  facile 
construction  of  triconjugates.  The  application  of  both  mono-  and 
dibromomaleimides has been demonstrated through single amino acid and protein 
studies (166-171). It is the incorporation of leaving groups such as bromine across 
the  maleimide  double  bond  that  allows  an  addition-elimination  sequence  to  take 
place on reaction with cysteine. For example, as shown in Scheme 1.7, the addition 
of  dibromomaleimide  to  the  L111C  mutant  of  the  Grb2  protein  1  formed  the 
monobromide  2  exclusively.  Bioconjugate  2  could  then  undergo  a  further  thiol 
addition with glutathione to afford dithiomaleimide bioconjugate  3. Both of these 
steps  are  near  quantitative    and  reversible,  as  they  can  be  cleaved  using  a  large 
excess of a thiol including 2-mercaptoethanol or glutathione.  
 
Scheme  1.7  Reversible  modification  of  the  Grb2  SH2  Domain  (L111C)  with 
Dibromomaleimide (167). 
In 2006, Brocchini et al. reported an enone-sulfonyl reagent 4 that provided the first 
example  of  a  reagent that  mimicked  the  role of  a  disulfide  bond, installing  a  3-
carbon  bridge  between  the two  cysteine  residues  (172-174)  (Scheme  1.8).  It  was 
envisaged that dibromomaleimides could also serve as disulfide bridging reagents 
and  provide  significant  advantages.  These  include  rapid  reaction  rate,  no 
introduction of a chiral centre, installation of a rigid two-carbon bridge minimising 
disulfide bond disturbance, and reversibility of disulfide bridging.  
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Scheme  1.8  Modification  of  protein  (purple)  disulfide  bond  using  a  PEG-
monosulfone reagent. The disulfide bond must be reduced before conjugation.  
 
The  disulfide  bridging  ability  of  this  new  class  of  maleimides  was  initially 
investigated using the cyclic peptide hormone somatostatin as a model system (167). 
This is a 14-amino acid peptide containing a single disulfide  bond. Treatment of 
somatostatin  with  1  equivalent  of  the  reducing  agent  TCEP  (tris(2-
carboxyethyl)phosphine)  followed  by  just  1.1  equivalents  of  dibromomaleimide, 
yielded fully bridged somatostatin 6 (Scheme 1.9). Furthermore, incubation of the 
fully bridged peptide with 2-mercaptoethanol for 1h at rt gave complete reversion to 
reduced somatostatin. Thus, dibromomaleimides were successfully demonstrated to 
be  the  second  class  of  reagents  suitable  for  disulfide  bridging,  and  the  first  to 
facilitate reversiblility.  
 
 
Scheme  1.9  Reversible  modification  of  the  disulfide  bond  of  somatostatin  by 
dibromomaleimide (167).  
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Both the stepwise bridging protocol initially developed using dibromomaleimides 
and the related procedure described by Brocchini and co-workers (166-175) suffer a 
potential  limitation.  These  methods  require  cleavage  of  the  disulfide  bond  with 
reducing agents releasing two free cysteines to which the bridging reagent can then 
be added.  It is possible that in the time between disulfide cleavage and completion 
of  the  bridging  reaction  structurally  sensitive  proteins  may  begin  to  unfold.  
Moreover,  even  in  the  case  that  disulfide  bond  opening  does  not  cause  any 
immediate  problems,  the  presence  of  free  thiols  in  a  structure  can  lead  to 
aggregation and disulfide scrambling (176). Thus the ideal bridging protocol would 
require a bridging reagent that can be used in tandem with a reducing agent, in order 
for disulfide bridging to occur immediately on thiol release. To this end, an in situ 
protocol was developed using a selection of new 3,4-substituted maleimide reagents 
(168).  
 
Development  of  an  efficient  in  situ  bridging  protocol  required  substituted 
maleimides  that  would  tolerate  the  presence  of  the  reducing  agent  TCEP.  Test 
reactions  suggested  that  halomaleimide  reagents,  for  example  dibromomaleimide 
and diiodomaleimide, show greater cross-reactivity with TCEP than thiomaleimides 
(168). In light of this, several dithiomaleimide reagents have been synthesised, and 
dibromomaleimide 8 and dithiophenolmaleimide 9 were used for comparison in the 
in  situ  trial  studies  (Scheme  1.10)  (168).  In  each  case,  5  equivalents  of  3,4-
substituted maleimide were added to somatostain, followed by varying quantities of 
TCEP. For dibromomaleimide, up to 60% bridged somatostatin was observed. Full 
conversion was prevented by the formation of TCEP-dibromomaleimide adducts, as 
observed by mass spectrometry. Dithiophenolmaleimide and TCEP however, gave 
fully bridged somatostatin within 20 minutes. Therefore, through the creation of a 
compatible  bridging  reagent,  the  in  situ  protocol  was  realised. 
Dithiophenolmaleimide is thus the first reagent to facilitate efficient in situ bridging 
of disulfide bonds.  
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Scheme  1.10  In  situ  modification  of  the  disulfide  bond  of  somatostatin  by 
dibromomaleimide and dithiophenolmaleimide (168).  
 
Given this success, it was proposed that other reducing agents could be used in the 
in  situ  protocol.  Somatostatin  is  maintained  in  solution  at  pH  6.2.  This  pH  is 
unsuitable  for  cleavage  of  disulfides  by  thiol-based  reducing  agents  such  as 
mercaptoethanol  or  dithiothretol  (DTT).  Selenol-based  reagents  are  known  to 
catalyse the cleavage of disulfide bonds and so the in situ bridging of somatostatin 
was  attempted  using  benzeneselenol  and  dithiophenol  maleimide.  Fully  bridged 
somatostatin  was  achieved  using  10  equivalents  of  dithiophenolmaleimide  and  5 
equivalents  of  benzeneselenol.  In  this  case,  the  thiophenol  released  from  the 
maleimide  acts  as  a  reducing  agent  alongside  selenol.  Control  studies  also 
demonstrate  that  benzeneselenol  is  unable  to  reduce  the  disulfide  bond  of 
somatostatin alone.  These model  in situ  studies on somatostatin demonstrate that 
different reducing agents can be used with the thiomaleimide bridging reagents. This 
is  applicable  to  other  peptides  and  proteins  where  the  relatively  sterically 
encumbered  reducing  agent  TCEP  may  have  difficultly  reducing  more  buried 
disulfide bonds.  
 
To  test  whether  clinically-relevant  modifications  could  be  made  to  somatostatin 
using the substituted maleimide reagents and the correct cysteine bridging network 
maintained, N-PEG dithiophenolmaleimide was synthesised (168). The maleimide-
PEG was inserted into somatostatin via the newly developed in situ protocol and its 
resulting  activity  examined  (Scheme  1.11).  Somatostatin  activates  G-protein 
inwardly  rectifying  potassium  (GIRK)  channels  via  somatostatin  receptors  in  the 
pituitary gland to control hormone release (177,178). To test the activity of modified 
somatostatin, human cell lines expressing such channels were examined for current 
activation on agonist application using whole-cell patch clamping.  Pleasingly, all  
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substituted  maleimide  bridged  conjugates  of  somatostatin  maintained  activity. 
Furthermore,  a  fluorescein-maleimide  was  also  used  to  bridge  the  disulfide  of 
somatostatin  and  this  too  demonstrated  sustained  activity.  This  early  evidence 
suggests that the 3,4-substituted maleimides are a new class of disulfide bridging 
reagents,  successfully  avoiding  the  negative  effects  previously  associated  with 
disulfide bond modification.   
 
Scheme 1.11 In situ modification of the disulfide bond of somatostatin with N-PEG 
dithiophenolmaleimide (168). 
 
This in situ approach has recently been applied to more complex protein systems, for 
example the artificial disulfide bond of an anti-carcinoembryonic antigen (CEA) scFv 
antibody fragment (ds-scFv) (170). The scFv disulfide has been bridged selectively and 
quantitatively  with  a  range  of  labelled  3,4-substituted  maleimides,  including 
fluorescein, biotin, a 5 kDa PEG chain and even a spin label (170) (Scheme 1.12). These 
conjugates  have been demonstrated to  maintain  full  binding activity by  ELISA  and 
Biacore assays, as well as functionality of the modifications. Having demonstrated that 
this bridging technology is reversible in the presence of excess thiol, the stability of 
bridged scFv in human plasma was next investigated.  
Scheme 1.12 The in situ bridging of the disulfide bond of an anti-CEA ds-scFv.  
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Human plasma typically contains around 18 µM of free thiol. The modified scFv was 
incubated in plasma for 7 days at physiological temperature. Gratifyingly, the antibody 
fragment  could  be  isolated  in  constant  amounts  and  LCMS  spectra  of  the  samples 
revealed no loss of the maleimide bridge over time (170). In addition, the modified 
fragment retains 80% of its binding activity after 7 days incubation. The bridged scFv 
was  also  incubated  in  buffer  containing  the  concentration  of  glutathione  or  other 
reducing agent found in the cytoplasm (7 mM). This resulted in a loss of the maleimide 
bridge over time (for glutathione 40% loss over 50 h), providing early evidence of a 
possible  intracellular  cargo-release  mechanism  for  antibodies  modified  with  the 
maleimide bridging technology under in vivo conditions.  
 
Recently, the Baker and Caddick groups have also reported the modification of the Fab 
fragment  of  Trastuzumab  with  a  single  molecule  of  the  drug  doxorubicin  (171). 
Generation of a homogeneous antibody-drug conjugate was achieved through linking 
doxorubicin  to  a  dithiomaleimide.  In  the  presence  of  TCEP,  the  single  interchain 
disulfide  bond  of  the  Fab  fragment  was  bridged  quantitatively  (Scheme  1.13).  The 
bridged conjugate displayed comparable antigen binding to unmodified Fab by ELISA.  
 
Scheme 1.13 The modification of anti-HER2 Fab with an N-arylthiophenolmaleimide-
PABC-doxorubicin linker to yield a homogeneous antibody-drug conjugate.   
The linker chemistry of the ADC generated in Scheme 1.13 was carefully designed. 
Previous  research  has  demonstrated  that  the  hydrolysis  of  N-aryl  functionalised 
substituted maleimides can be judiciously controlled by pH, with the maleamic acid 
derivative being readily generated at pH 7.4 (169). At acidic pH, maleamic acids are 
labile. Thus this provides a direct route to controlled cargo release of the amine linked 
through  the  amide  functionality.  An  antibody  fragment  functionalised  with  N-aryl 
substituted  maleimide  would  therefore  maintain  its  cargo  at  physiological  pH  and 
temperature, whilst readily cleaving at lysosomal pH to release the drug (Scheme 1.14). 
To achieve this, the linker used for the anti-HER2 Fab-doxorubicin conjugate contained  
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N-aryl  maleimide  linked  to  doxorubicin  via  the  known  self-immolative  p-
aminobenzyloxycarbonyl (PABC) spacer (179).  
 
Scheme 1.14 Cleavage of Fab ADC. (a) pH 7.4, 20 h; (b) pH 4.5, 72 h. 
 
Following the successful modification of ds-scFv and Fab antibody fragments without 
loss in biological activity, the next generation maleimides were recently applied to full 
antibodies. Two ADCs, Kadcyla and Adcetris, have been approved for use in the clinic. 
Many  more  ADCs  have  failed  in  the  development  stages,  often  due  to  detrimental 
effects of the employed conjugation chemistry. It was envisaged that disulfide bridging 
using substituted maleimides  would overcome  many of these issues,  providing site-
specific modification to deliver a homogeneous ADC whilst maintaining the stabilising 
effect of interchain disulfide bonds. Both sequential and in situ conjugation strategies 
were applied to the monoclonal IgG1 antibody Trastuzumab (Scheme 1.15) (180).  
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Scheme 1.15 Construction of ADCs using substituted maleimides via sequential and in 
situ approaches. The sequential bridging protocol yielded a mixture of correctly bridged 
ADC and incorrectly bridged half-antibody due to the formation of intrachain bridges. 
The  in  situ  bridging  protocol  avoided  the  formation  of  half-antibody,  yielding  a 
homogeneous ADC with a drug loading of 4.  
 
As can be seen in Scheme 1.15, the sequential bridging protocol yielded a mixture of 
ADC products; one in which the disulfide bridging connectivity is correctly maintained, 
and a second half-antibody product. This half-antibody species is produced as a result of 
intrachain bridges forming between cysteines on the same heavy chain in the hinge 
region. Misbridging is perhaps not surprising considering these cysteine residues are 
separated only by two amino acids. Hence, through complete reduction and subsequent 
rebridging some of the cysteines have formed intrachain bonds. This disulfide bond 
shuffling however is largely avoided using the developed in situ protocol, facilitating 
immediate rebridging of reduced disulfides. Indeed, using TCEP or benzeneselenol as 
the reducing agent, the in situ protocol produced a highly homogeneous ADC with a 
drug loading of 4 in good yield with maintained binding activity to HER2.  
 
In summary, substituted maleimides are a new class of bridging reagent which offer 
many advantages over previous cysteine and disulfide modification strategies. These 
include rapid and quantitative conversion to the modified product, no introduction of 
chiral centres, which avoids formation of diastereomers, installation of a two-carbon  
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bridge  providing  minimum  disturbance  to  the  disulfide  bond,  and  use  of  an  in  situ 
bridging protocol avoiding aggregation and disulfide scrambling products. In addition, 
the modification may be reversible or irreversible, as research within the group has 
demonstrated  control  of  maleimide  hydrolysis  (Scheme  1.16)  (169).  Successful 
bridging, conjugation and maintained activity of both the protein and the functionality 
have been demonstrated for a small peptide, ds-scFv, Fab and a full antibody. These 
studies suggest substituted maleimides could be utilised for a wide range of therapeutic 
and diagnostic applications in the site-selective modification of antibodies. 
 
 
Scheme 1.16 Reversible and irreversible protein modification using N-aryl substituted 
maleimides.  
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1.9  Project aims 
 
Research has demonstrated that 3,4-substituted maleimides offer a powerful approach to 
the  selective,  rapid,  quantitative  and  reversible  modification  of  peptide  and  protein 
disulfide bonds (166-171,180). Furthermore, in recent work it has been shown that next 
generation maleimides can be used for the extremely efficient re-bridging of disulfide 
bonds in Fab and disulfide-stabilised scFv antibody fragments, to produce fully active, 
homogeneous  protein  conjugates  (170,171).  The  principal  aim  of  this  project  is  to 
design and synthesise a range of optimised 3,4-substituted maleimide reagents to enable 
the efficient bioconjugation of antibodies, with a focus on applying this technology to 
the  construction  of  antibody-enzyme  conjugates  for  ADEPT  and  antibody-antibody 
conjugates for bispecifics.  
 
Synthesis of reagents for ADEPT 
 
A concept first described in the late 1980s, antibody-directed enzyme prodrug therapy 
(ADEPT) was developed with the aim of generating cytotoxic agents in vivo specifically 
at cancerous tissue (see Section 1.5.2.1). For ADEPT to be a viable and effective cancer 
therapy  the  antibody-enzyme  conjugates  must  maintain  both  antibody  and  enzyme 
activity.  Current  chemical  conjugation  techniques  based  on  natural  amino  acid 
modification  produce  highly  heterogeneous  conjugates  with  a  loss  of  bioactivity. 
Developments  in  molecular  biology  have  enabled  a  range  of  antibody-enzyme 
recombinant fusion proteins to be generated in recent years. This is currently the most 
efficient approach to producing active and homogenous antibody-enzyme conjugates. 
However, chemical conjugation still plays an important role as cross-linking proteins is 
a more practical, rapid, versatile and economic route.   
 
In this project, a range of 3,4-substituted maleimide based linkers will be produced to 
achieve more defined antibody-enzyme conjugates. A variety of human and non-human 
enzymes have undergone pre-clinical investigation for ADEPT and one of the earliest 
examples,  and  the  only  to  be  clinically  assessed,  is  the  bacterial  enzyme 
carboxypeptidase G2 (CPG2). In this project an anti-CEA disulfide-stabilised scFv (ds-
scFv)  fragment  will  first  be  used  as  a  model  system  for  the  proof-of-concept 
experiments. The zinc metalloenzyme CPG2 will act as the enzyme conjugate. CPG2 
does not contain any free cysteine residues or native disulfide bonds; initial research 
therefore will focus on developing reagents to the link the disulfide bond of the anti- 
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CEA scFv fragment and a native lysine residue on CPG2 (Figure 1.18). Hence this 
already  provides  a  significant  improvement  on  existing  chemical  conjugation 
techniques, as site-specific modification will be achieved at the antibody.  
 
Figure 1.18 Basic linker design for disulfide to lysine conjugation. The enzyme will 
first  be  functionalised  through  lysine  conjugation  via  NHS  ester  chemistry.  The 
antibody fragment disulfide bond can then be bridged with a substituted maleimide. 
Note: this is a simplified representation and some product heterogeneity will result due 
to lysine conjugation at the enzyme.  
 
Synthesis of reagents for bispecifics 
 
The limited ability of conventional monoclonal antibody therapies to induce significant 
anti-tumour  activity  has  led  to  the  development  of  bispecifics;  antibodies  that  can 
simultaneously bind two different antigens (see Section 1.6). Recombinant technologies 
have produced a diverse range of bispecific antibodies, generating 45 formats in the last 
two decades (87). Despite this variety of topologies, the approach is not suited to every 
protein combination. The fusion of proteins via their N or C termini can result in a 
reduction or loss of bioactivity and variable expression yields can be observed due to 
complications in folding and processing (80-83). An alternative and potentially more 
versatile approach to generating bispecific therapeutics is chemical conjugation. 
 
Antibody  fragments  including  Fabs  and  scFvs  are  commonly  used  in  a  range  of 
bispecific topologies. It is envisaged that the single interchain disulfide bond of such 
fragments could facilitate the generation of homogeneous bispecific constructs via next 
generation maleimide based cross-linking reagents. In this project, a range of disulfide  
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to  disulfide  based  cross-linking  reagents  will  be  designed,  synthesised  and  tested 
(Figure  1.19).  Direct  and  indirect  conjugation  strategies  will  be  investigated;  direct 
involves  the  chemical  modification  of  a  single  antibody  fragment  and  subsequent 
conjugation  to  the  second,  unmodified  fragment,  in  contrast,  indirect  conjugation 
comprises of the functionalisation of both fragments with a reactive moiety prior to 
conjugation.  It is anticipated that successful linkers can be readily translated to any 
disulfide or single cysteine containing protein, enabling the generation of a wide range 
of homogeneous antibody-protein conjugates.  
 
Figure 1.19 Basic linker designs for disulfide to disulfide conjugation via direct and 
indirect conjugation strategies. Using ds-scFv here as an example, direct conjugation 
involves  the  modification  of  a  single  scFv  fragment  and  subsequently  linking  to  a 
second, unmodified fragment. Indirect conjugation comprises of the functionalisation of  
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each  antibody  fragment  with  a  reactive  moiety  which  can  participate  in  a 
chemoselective reaction when the two modified fragments are incubated together. 
 
This thesis also investigates, with collaborators, the use of 3,4-substituted maleimide 
reagents for FRET and immuno-PET applications.  
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2  Results and Discussion 
2.1  Synthesis and application of a disulfide to lysine linker 
Investigations initially centred on the synthesis of an efficient disulfide to lysine linker, 
using an anti-CEA ds-scFv and CPG2 as the model system for conjugation. The design 
of this linker was based on widely used, currently available commercial linkers such as 
SMCC and GMBS (see Section 1.8.1). 
 
2.1.1  Synthesis of dibromomaleimide linker  
A dibromomaleimide analogue of the desired disulfide to lysine linker was considered 
the first synthetic target. The initial synthetic approach towards this linker 13 is outlined 
in Scheme 2.1. This strategy uses a method recently developed in the group towards the 
synthesis of N-substituted maleimides through an N-(methoxycarbonyl) derivative of 
dibromomaleimide 11. The introduction of a carbonyl group on the maleimide nitrogen 
effectively activates the maleimide to amine attack through creation of a better leaving 
group, facilitating N-substitution under mild conditions (181).  
 
 
Scheme  2.1  Reagents  and  conditions:  (a)  MeOCOCl,  NMM,  THF;  (b) 
H2N(CH2)3COOH, DCM; (c) NHS, DCC, EtOAc. 
 
The N-(methoxycarbonyl)-3,4-dibromomaleimide 11 was readily generated from 8 in 
97% yield. The most efficient conditions established for the production of N-substituted 
dibromomaleimides  from  the  activated  ester  11  simply  involve  the  addition  of  the 
desired amine in dichloromethane (181). However, these conditions proved unsuitable 
as the amine in this case is γ-aminobutyric acid, which exists as a zwitterion and as such 
will not dissolve in dichloromethane. Alternative solvents were used, including DMF  
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and acetic acid with gentle heating. Nevertheless, the reaction did not proceed. It is 
likely that due to the zwitterionic nature of γ-aminobutyric acid, there is insufficient 
uncharged amine present to promote ring opening of 11. This approach was further 
attempted in acetic acid at reflux, resulting in a mixture of products of which none were 
the  desired  compound  12.  In  parallel  to  this  route,  an  alternative  synthetic  strategy 
shown in Scheme 2.2 was attempted.   
 
Scheme  2.2  Reagents  and  conditions:  (a)  AlCl3,  Br2,  160°C,  20  h;  (b) 
H2N(CH2)3COOH, AcOH, reflux, 4 h; (c) NHS, DCC, EtOAc, 0°C to rt, overnight. 
 
An  alternative  approach  to  synthesising  N-substituted  maleimides  requires  harsh 
conditions, refluxing maleic anhydride with the desired amine in acetic acid for several 
hours (169). This synthetic strategy was applied towards linker 13. This approach first 
necessitates the generation of dibromomaleic anhydride 15, and this was achieved using 
the method of Dubernet from maleic anhydride 14 in 86% yield (182). The disubstituted 
maleic anhydride 15 was then heated at reflux with γ-aminobutyric acid in acetic acid 
for  4  h,  yielding  91%  of  the  desired  compound  12.  Coupling  of  the  N-substituted 
maleimide  12  with  N-hydroxysuccinimide  (NHS)  was  subsequently  achieved  using 
DCC, furnishing the proposed disulfide to lysine linker 13 (78% yield). Song et al. have 
reported a one-pot preparation of maleimido-carboxylic NHS-esters (183). This one-pot 
approach shown in Scheme 2.3 was applied to dibromomaleic anyhydride 15, however 
the desired linker 13 was not formed.  
 
Scheme 2.3 Reagents and conditions: (a) H2N(CH2)3COOH, DMF, rt; (b) NHS, DCC, 
0°C to rt (183).   
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2.1.2  Synthesis of dithiomaleimide linker  
Following the successful synthesis of the dibromomaleimide disulfide to lysine linker 
13,  it  was  considered  that  generation  of  a  dithiomaleimide  analogue  should  be 
attempted. The dithiomaleimides hold several advantages over the dihalomaleimides, 
for example lower cross-reactivity with the reducing agent TCEP. For a reagent to be 
suitable for in situ disulfide bridging tolerance to the presence of reducing agent is 
crucial.  In  addition,  in  combination  with  selenol,  dithiomaleimides  have  been 
demonstrated to efficiently reduce and bridge a disulfide bond. Bridging ability with a 
wide  range  of  reducing  agents  is  highly  desirable  as  different  protein  disulfides 
necessitate different reagents for successful reduction. Furthermore, the first reagent to 
be reported as suitable for in situ disulfide bridging is a dithiomaleimide (168).  
 
Initially  the  dithiosalicylic  acid  maleimide  16  was  the  choice  thiol  analogue  of  the 
disulfide to lysine linker (Scheme 2.4). At the time of synthesis, initial investigations 
into  using  thiosalicylic  acids  as  maleimide  leaving  groups  had  begun.  Through  the 
presence of carboxylic acids, it was proposed that the thiosalicyclic acid maleimide 
reagents would have increased solubility in the aqueous conditions required for protein 
modification (184).  
 
Scheme 2.4 Reagents and conditions: (a) HSPhCO2H, KOAc, MeCN.  
 
Synthesis of 16 initially proved troublesome; early attempts included the reaction of 13 
with thiosalicylic acid in methanol with an excess of base. This resulted in methanol 
attack at the NHS ester end of the linker. Several solvents were then investigated for use 
in  this  reaction  and  acetonitrile  was  established  as  the  best  choice,  since  it  readily 
dissolved  both  starting  materials  and  no  attack  on  the  NHS  ester  occurred  in  the 
presence  of  base.  Following  purification  by  column  chromatography,  linker  16  was 
achieved in 70% yield.  
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Unfortunately, attempts to scale up the synthesis outlined in Scheme 2.4 proved difficult 
due to challenging and lengthy purifications leading to hydrolysis of the NHS ester over 
time. In parallel to the synthetic work, bridging of a disulfide stabilised analogue of the 
anti-CEA  scFv  fragment  MFE-23,  was  attempted  using  both  dithiophenol  and 
dithiosalicylic acid maleimide (Figure 2.1).  
 
Figure 2.1 Dithiophenol 9 and dithiosalicylic acid 17 maleimide. 
 
An  in  situ  protocol  for  the  bridging  of  the  anti-CEA  ds-scFv  with  dithiophenol 
maleimide has been established in our group (170). This work was repeated and also 
applied using dithiosalicylic acid, and monitored by LCMS. The results of bridging with 
dithiophenol maleimide can be seen in Figure 2.2, which shows a deconvoluted LCMS 
spectrum  of  unmodified  ds-scFv  (Figure  2.2A)  and  after  bridging  with 
dithiophenolmaleimide (Figure 2.2B). Attempts at bridging the disulfide bond of the 
scFv  with  dithiosalicylic  acid  maleimide  were  also  monitored  by  LCMS;  however 
deconvolution  of  the  mass  spectra  either  failed  or  resulted  in  unusual  masses,  for 
example lower than the original mass of the antibody fragment.  Figure 2.3 shows the 
original  mass  spectra  obtained  for  anti-CEA  ds-scFv  modified  with  dithiophenol 
maleimide (Figure 2.3A) and dithiosalicylic acid maleimide (Figure 2.3B). The quality 
of the mass spectrum obtained after dithiosalicylic acid maleimide modification is very 
poor; there is a lack of clarity of the ‘charge envelope’ expected due to the presence of 
multiply charged species, which normally form a Gaussian-type distribution. Research 
within the group found that when the same dithiosalicyclic acid maleimide 17 was used 
on a peptide, one of the thiosalicyclic acid groups was not released on disulfide bridging 
(184).    
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Figure  2.2  Deconvoluted  LCMS  spectra  (A)  unmodified  anti-CEA  ds-scFv  (26,736 
Da);  (B)  ds-scFv  modified  with  dithiophenolmaleimide  (expected  26,831,  observed 
26,831). 
 
Figure  2.3  Original  LCMS  spectra  of  (A)  anti-CEA  ds-scFv  modification  with 
dithiophenolmaleimide 9; (B) anti-CEA ds-scFv modification with dithiosalicylic acid 
maleimide 17.  
 
The combination of an efficient synthesis of the dithiosalicyclic acid maleimide linker 
16 proving difficult, and the presence of charged groups apparently causing poor quality 
LCMS data, led focus away from this linker design to one using simply thiophenol as  
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the dithio analogue of the disulfide to lysine linker. A synthetic route to the dithiophenol 
linker 19 is outlined in Scheme 2.5.  
 
Scheme  2.5  Reagents  and conditions: (a) PhSH, NaHCO3, MeOH; (b) NHS, DCC, 
EtOAc, 0°C to rt, overnight. 
 
The first two steps of this synthetic strategy are analogous to those in the synthesis of 
the dibromomaleimide  disulfide to  lysine linker  13  (Scheme  2.2). The  N-substituted 
maleimide 12 was then converted from dibromo to dithiophenol in methanol with an 
excess of base to give 18 in an excellent 99% yield. The dithiophenol derivative 18 was 
then  coupled  to  N-hydroxysuccinimide  (NHS)  using  DCC  overnight,  to  furnish  the 
dithiomaleimide analogue of the disulfide to lysine linker 19 in 81% yield.  
 
2.1.3  Small molecule selectivity investigation 
In order for the linkers 13 and 19 to be effective in producing more defined antibody-
enzyme  conjugates,  these  chemical  cross-linkers  must  be  selective  for  particular 
residues on a protein. The two linkers synthesised here are designed to possess an amine 
reactive NHS ester moiety for reaction with lysine residues, and a thiol reactive 3,4-
substitiuted  maleimide,  for  rapid  disulfide  bridging.  In  our  model  protein  system, 
conjugation of an antibody fragment to the enzyme carboxypeptidase G2 (CPG2) will 
be attempted. This enzyme contains no cysteine residues or disulfide bonds and so will 
be  conjugated  to  the  linker  first,  with  the  view  of  free  lysine  residues  reacting 
selectively with the NHS ester to form a stable amide bond. Before moving on to this 
system, it was decided that the selectivity of the commercially available cross-linking 
reagent SMCC and the synthesised linkers should be investigated.  
 
These initial selectivity investigations were carried out in an organic solvent system for 
ease of solubility and also with a view of determining the potential limits of synthetic  
 
   
67 
 
   
routes  where  amines  may  be  reacted  with  compounds  containing  a  3,4-substituted 
maleimide. The first selectivity study is outlined in Scheme 2.6, where it was proposed 
that on reaction of benzylamine 20 with linker 13, compound 21 will result.   
 
 
Scheme 2.6 Reagents and conditions: (a) CH2Cl2. 
 
This reaction was first attempted using a 1:1 mixture of linker 13 and amine 20. The 
reaction was monitored by TLC every 15 minutes until after two hours the reaction was 
stopped, as no further changes were observed. The results are shown in Scheme 2.7.  
 
 
Scheme 2.7 Results of selectivity investigation. Reagents and conditions: (a) CH2Cl2. 
 
Three spots could be observed by TLC, of which one was the proposed product 21 as 
revealed by subsequent 
1H and 
13C NMR, obtained in a 52% yield (Scheme 2.7). In 
addition, the diaddition product 22 was isolated in a 29% yield. The third spot was due 
to the presence of hydrolysed linker 12 (19%) (Figure 2.4). The two reaction products 
21 and 22 were thus obtained in a 1.8:1 yield respectively.  
 
Figure 2.4 Result of NHS ester linker hydrolysis.  
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In  order  to  rule  out  the  possibility  that  the  diaddition  product  was  formed  as  a 
consequence  of  the  loss  of  the  amine  reactive  NHS  ester  through  hydrolysis,  this 
reaction was repeated using a 3:1 mixture of linker 13 to benzylamine 20. Indeed this 
reaction also yielded the diaddition product, however the ratio of the proposed product 
21 to diaddition product 22 increased to 2.5:1.  
 
Once more using a 3:1 mixture of linker to amine, the commercially available linker 
SMCC 23 was reacted with benzylamine under the same conditions (Scheme 2.8). In 
this case the proposed product 24 was formed exclusively, although NHS hydrolysis of 
this linker was also observed. 
 
Scheme 2.8 Reagents and conditions: (a) CH2Cl2. 
 
These  simple  selectivity  investigations  suggest  that  the  presence  of  bromine  on  the 
maleimide double-bond has altered its reactivity to amines. Moreover, in the presence of 
excess  linker  the  diaddition  product  22  was  still  formed,  demonstrating  that  the 
conjugate addition is indeed competitive with reaction at the NHS ester. In order to 
determine if a thiomaleimide achieves selectivity, the same investigation was carried out 
using 3 equivalents of thiophenol linker 19 to 1 equivalent of benzylamine 20 (Scheme 
2.9). A single product was observed by TLC after stirring for several hours. Even on the 
addition of another equivalent of amine, still only one product could be seen. Although 
another faint spot could be observed by TLC, this corresponded to compound 18, as 
hydrolysis of the NHS ester 19 had begun to occur. Following purification, 
1H NMR 
revealed the product to be the proposed monoaddition compound 25.   
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Scheme 2.9 Reagents and conditions: (a) CH2Cl2. 
 
The results of this selectivity investigation in organic solvent suggest that that there is 
competition  between  the  dibromomaleimide  and  NHS  ester  for  amine  addition. 
Although these results reveal the limits of synthetic routes where amines may be reacted 
with compounds containing a 3,4-substituted maleimide, they are not necessarily true 
for real protein systems. This is demonstrated in the following Section 2.1.4.  
 
2.1.4  Selectivity investigation using Carboxypeptidase G2 
The results of the small molecule selectivity investigation suggest that the dithiophenol 
disulfide to lysine linker 19 would be suitable for the production of antibody-enzyme 
conjugates, as only the NHS ester moiety reacts with amines, leaving the substituted 
maleimide free for conjugation via disulfide bridging. In contrast, the dibromo linker 13 
showed a lack of selectivity. In order to determine if these results are true for a real 
protein system, the enzyme carboxypeptidase G2 (CPG2) was incubated with 20 and 50 
equivalents of both dibromomaleimide and dithiophenol maleimide for 1 hour. CPG2 
contains no free thiols or disulfides, so any conjugation to these maleimides would be 
attributed to lysine residues.  
 
Liquid chromatography mass spectrometry (LCMS) was used to monitor the reaction, if 
any, of CPG2 with the excess of either dibromo- or dithiophenolmaleimide. CPG2 was 
first  analysed by  LCMS in  PBS buffer  (pH 7.2) and the original  and  deconvoluted 
spectra are shown in Figure 2.5. The spectrum of CPG2 shows a main peak at 42,403 
Da (Figure 2.5B). CPG2 naturally exists as a homodimer, held together at the dimer 
interface by hydrophobic interactions and hydrogen bonds. Using LCMS only the mass 
of the monomer is seen, as the non-covalent dimer forming interactions are disturbed  
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during the electrospray ionisation process. There is another prominent peak at 44,621 
Da in the deconvoluted spectrum. SDS-PAGE analysis of CPG2 shows one distinct 
band (Figure 2.6), the original mass spectrum shows a typical Gaussian distribution 
(Figure 2.14A), and peptide mapping and analytical FPLC all indicate only CPG2 is 
present (data not shown). The peak may be an artefact of the deconvolution software, or 
in fact a small trace of a differently synthesised form of CPG2, as it is produced in 
bacteria and purified only through use of an IMAC column. For analytical purposes, the 
main peak at 42,403 Da was used.  
 
 
Figure 2.5 LCMS analysis of CPG2 in PBS buffer. (A) Original mass spectrum; (B) 
Deconvoluted spectrum.  
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Figure  2.6  SDS-PAGE  analysis  of  CPG2.  Lane  1  contains  protein  ladder  in  kDa 
(SeeBlue® Plus2, Invitrogen). Lane 2 contains MFECP fusion protein as control (~72 
kDa). Lane 3 contains CPG2 monomer. 
 
Following incubation of CPG2 for 1 hour with 20 and 50 equivalents of dibromo- and 
dithiophenolmaleimide,  no  changes  were  observed  in  the  LCMS  spectrum.  This 
indicates that in a real protein system, bromo-substituted maleimides do not react with 
amines. There are two significant differences between the small molecule and protein 
selectivity investigations. Firstly, the incubation of CPG2 with substituted maleimide 
took place at pH 7.2, a pH typically employed for protein modification. At this pH the 
lysine  residues  will  be  protonated  and  therefore  have  significantly  attenuated 
nucleophilicity.  Secondly,  on  the  small  molecule  scale  there  is  a  much  higher 
concentration of amine to substituted maleimide compared to the protein system. In all, 
these results indicate that both versions 13 and 19 of the disulfide to lysine linker are 
suitable as conjugation reagents at pH 7.2 for the production of more defined antibody-
enzyme conjugates.  
 
2.1.5  Conjugation of linker to Carboxypeptidase G2 
The initial goal of this project was to produce a conjugate of the bacterial enzyme CPG2 
to  two  anti-CEA  disulfide-stabilised  scFv  antibody  fragments  (ds-scFv)  using  the 
designed  disulfide  to  lysine  linkers.  This  antibody-enzyme  ratio  corresponds  to  that 
found in the fusion protein MFECP, an ADEPT construct that has reached clinical trials 
(78). CPG2 contains no free cysteine residues or native disulfide bonds, so the first step 
would involve the reaction of CPG2 lysine residues with the NHS ester moiety of the 
linker. Thus, the enzyme would be functionalised with substituted maleimides, available 
for  disulfide  bond  conjugation  to  the  ds-scFv  fragments.  Owing  to  the  success  of  
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thiophenol  maleimides  in  the  in  situ  protocol,  and  their  significantly  lower  cross-
reactivity with reducing agents, the dithiophenolmaleimide-NHS ester linker 19 was 
used  in  this  conjugation.  A  visualisation  of  the  desired  route  to  production  of  this 
antibody-enzyme conjugate using linker 19 is shown in Scheme 2.10.  
 
 
Scheme 2.10 Generation of antibody-enzyme conjugate using disulfide to lysine linker 
19. The first step involves the attachment of linker 19 to CPG2 via its lysine residues, 
producing  CPG2  functionalised  with  two  dithiophenolmaleimide  molecules.  This 
construct can then be attached to anti-CEA ds-scFv through disulfide bridging to yield 
the desired antibody-enzyme conjugate. Note: this is a simplified representation and 
some product heterogeneity will result due to lysine conjugation at the enzyme.  
The  first  step  in  generating  an  anti-CEA  to  CPG2  conjugate  requires  the  selective 
attachment of linker 19 to the lysine residues of CPG2. In order for this step to be 
successful, the linker must only react with lysine residues at the NHS ester end, leaving 
the substituted maleimide free for later disulfide conjugation. The results in  Section 
2.1.3 and 2.1.4 confirm that linker 19 should be successful in this regard. Secondly, 
there should ideally be one linker attached to each CPG2 monomer. Therefore, the sites 
of attachment for scFv antibody fragments should aim to be limited to two per CPG2 
molecule.  This  control  of  conjugation  will  also  ensure  that  CPG2  activity  is  not 
significantly  affected.  Previous  attempts  at  similar  chemical  conjugates  have 
demonstrated that increasing substitution decreases CPG2 activity proportionally (74).  
 
There is no evidence in the literature of attempts to strictly control and monitor the level 
of lysine modification when generating conjugates. Typically, protocols advise using 
between a 10- to 50-fold molar excess of cross-linking reagent to the amount of amine  
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containing protein (185). In fact, the equivalents of reagent used depends only on the 
concentration of the protein to be modified. For example, for a protein of 1 mg/ml a 20-
fold excess is advised, whereas 50-fold would be recommended for 0.5 mg/ml (185). In 
order to  monitor the number of linkers  attached to  CPG2, and more specifically to 
determine the amount of linker 19 required for attachment of one substituted maleimide 
per CPG2 monomer, the samples were analysed by LCMS. CPG2 in PBS (0.5 mg/ml) 
was incubated with 2, 5, and 8 equivalents of linker 19 in DMF at room temperature for 
20, 40 and 60 minutes. At these time points the reaction was stopped by quenching with 
150-fold excess of glycine in PBS. 
 
The main peak in the spectrum shown in Figure 2.7B at 42,772 Da corresponds to one 
linker attached to CPG2 monomer (expected mass 42,785 Da). This was achieved with 
2 equivalents of 19 for 1 h. The yield observed by mass spectrometry did not change 
when the reaction was left for over 1 h. Using 5 equivalents of linker, the main peak 
observed for all time points corresponded to two linkers per CPG2 monomer (observed 
43,157, expected 43,167, Figure 2.7C).  In addition, weaker mass peaks corresponding 
to three or four linkers attached could be seen on every attempt. The conjugation with 8 
equivalents of 19 resulted in very poor ionisation of the sample, causing deconvolution 
to be unsuccessful. These chemical conjugation reactions are occurring on lysine and 
thus blocking basic residues of CPG2, resulting in a change in the ionisation properties 
of the enzyme. This has been reported to alter mass spectrometry results previously 
(186). Nevertheless, the results from 2 and 5 equivalents of linker suggest that at 8 
equivalents  many  more  lysine  residues  would  be  blocked  which  is  undesirable  for 
production of this antibody-enzyme conjugate.  
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Figure 2.7  LCMS results of CPG2 conjugation to disulfide to lysine linker  19. (A) 
Unmodified CPG2; (B) 2 equivalents of linker for 1h; (C) 5 equivalents of linker for 1h. 
The labels L0, L1,…Ln correspond to CPG2 conjugated to n linker molecules. 
These conjugation reactions were promising, as it appeared that limiting the number of 
equivalents of linker could be used to control the degree of modification. Furthermore, 
using just 2 equivalents of linker 19 for 1h gave a good yield of singly modified CPG2, 
as observed by  LCMS. Using this  result, the next step of the conjugation could be 
investigated.  
 
2.1.6  Conjugation of modified CPG2 to anti-CEA ds-scFv 
2.1.6.1 Preliminary conjugation reactions 
 
Conjugation of the ds-scFv fragments to modified CPG2 was initially attempted using 
two strategies. Firstly, a stepwise approach whereby the antibody is reduced with DTT 
(20  equivalents)  for  1h,  purified  away  from  the  reducing  agent  and  subsequently  
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incubated with modified CPG2. The second approach used was the in situ procedure; 
scFv  was  added  directly  to  modified  CPG2  and  the  reducing  agent  benzeneselenol 
added.    Conjugation  attempts  using  both  approaches  resulted  in  a  large  amount  of 
unreduced antibody remaining, even with low equivalents of ds-scFv. For the stepwise 
protocol,  this  was  due  to  reoxidation  of  the  scFv  disulfide  bond  before  successful 
maleimide bridging. In the case of the in situ conjugation ds-scFv reduction was not 
successful in the first instance, as little product or reduced antibody was present by 
SDS-PAGE. These issues therefore needed to be addressed to achieve the maximum 
yield of conjugate.  
 
Using the stepwise method, reoxidation of the scFv fragment was beginning to occur 
during the purification and concentration stages. To overcome this issue, two changes 
were made to the stepwise approach to maintain the antibody fragment in its reduced 
form. First, the ds-scFv was buffer exchanged from PBS to a 50 mM phosphate buffer 
at pH 6.8 containing 1 mM EDTA. The EDTA suppresses re-oxidation of the cysteines 
through divalent metals such as Cu
2+ and Zn
2+ (121). Secondly, different purification 
approaches were investigated. Centrifugal ultrafiltration was found to most efficiently 
maintain  the  reduced  antibody  during  purification  and  concentration.  The  improved 
stepwise approach is outlined in Scheme 2.11.  
 
 
Scheme 2.11 Modified CPG2 conjugation to anti-CEA ds-scFv via a stepwise reduction 
approach.  The  scFv  fragment  is  first  reduced  with  DTT  and  purified  away  from 
reducing agent via buffer exchange into 50 mM phosphate buffer containing 1 mM 
EDTA, pH 6.8. An excess of the reduced scFv is then added to the modified CPG2. 
Note: this is a simplified representation and some product heterogeneity will result due 
to lysine conjugation at the enzyme.  
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The  in  situ  approach  initially  suffered  low  conjugation  yields  due  to  poor  ds-scFv 
reduction. To combat this,  a portionwise addition  approach  was  developed (Scheme 
2.12). Through addition of benzeneselenol at timed intervals, starting with an initial 15 
equivalents and a subsequent 15 equivalents every 20 minutes for an hour, the scFv 
fragment was successfully reduced for the duration of the reaction. In comparison to 
other investigated strategies, this protocol allowed for greater amounts of the reducing 
agent  to  be  used  without  rapid  benzeneselenol  oxidation  or  loss  of  solubility. 
Furthermore, the proteins were maintained well in solution under these conditions.  
 
 
Scheme  2.12  Modified  CPG2  conjugation  to  anti-CEA  ds-scFv  via  an  in  situ 
portionwise approach. The scFv fragment is added directly to the modified CPG2, after 
which an initial 15 equivalents of benzeneselenol is added, followed by 15 equivalents 
every 20 minutes for an hour. Note: this is a simplified representation and some product 
heterogeneity will result due to lysine conjugation at the enzyme. 
 
Early  conjugation  reactions  also  revealed  that  the  concentration  of  modified  CPG2 
could not be accurately determined by standard means, as the chemically conjugated 
thiophenol groups absorb UV light at 280 nm. To provide a more accurate measurement 
of modified CPG2 concentration, and so improve the conjugation protocol, a Bradford 
assay was developed. This assay is based on the absorbance of Coomassie Brilliant Blue 
G-250 dye; whilst the dye is normally red or green in its unbound form, when bound to 
protein  it  turns  blue  with  an  absorbance  maximum  of  595  nm.  The  extent  of  this 
absorbance is proportional to the amount of bound dye, and thus the concentration of 
protein in the sample. Thus, all subsequent conjugation attempts used modified CPG2 
with a concentration based on that determined by Bradford assay.  
  
 
   
77 
 
   
During preliminary investigations, conjugation of scFv to CPG2 was also attempted 
using  CPG2  modified  according  to  current  published  protocols  (185).  Using  these 
results  for  comparison,  we  could  then  determine  if  we  had  indeed  succeeded  in 
producing a more defined antibody-enzyme conjugate. As anticipated this conjugation 
resulted  in  a  large  yield  of  high  molecular  weight  conjugates,  facilitated  by 
functionalising CPG2 with up to 50 substituted maleimides. In our efforts to produce a 
more defined antibody-enzyme conjugate, there are on average only two substituted 
maleimides per CPG2 molecule. Whilst our strategy successfully reduced the variety of 
conjugates produced, it also had a significant detrimental effect on conjugation yield. 
The very low yields achieved thus far highlighted a potential flaw; the likelihood of 
reduced antibody fragment conjugation via the two attached dithiomaleimides is low. 
Furthermore, the huge steric bulk of the attached CPG2 enzyme reduces the opportunity 
for conjugation at these two positions even further.  
 
The results of conjugation using the literature protocol for modification also revealed 
that  scFv  bridging  was  less  successful  using  the  stepwise  approach.  Early  signs  of 
success were seen with the newly developed in situ portionwise method. This strategy 
has the greatest opportunity to maintain reduced antibody for conjugation, as well as 
having the many  advantages  of an  in  situ protocol,  and so  efforts  were focused on 
conjugation using this technique. 
2.1.6.2 Conjugation following protocol development 
 
To determine the validity of conjugation results, a series of key controls were carried 
out  under the SDS-PAGE  conditions used for analysis  (Figure  2.8).  These  controls 
clearly demonstrate that no change in CPG2 is observed by SDS-PAGE in the presence 
of  modification  (lane  6),  DMF  (lanes  5  and  7)  and  reducing  agent  (lane  9).  The 
antibody fragment also remains unchanged by DMF (lane 4), and shows the expected 
shift  in  molecular weight  on reduction  (lane 10). Furthermore, no higher molecular 
weight bands are observed on incubation of modified CPG2 with the ds-scFv in the 
absence  of  reducing  agent  (lane  8).  These  controls  therefore  confirm  that  the 
conjugation conditions do not have any effect on either protein by SDS-PAGE, and no 
cross-linking occurs in the absence of reducing agent.   
 
   
78 
 
   
 
Figure 2.8 SDS-PAGE analysis of controls. Lane 1 contains protein ladder in kDa 
(SeeBlue® Plus2, Invitrogen). Lane 2 contains ds-scFv. Lane 3 contains CPG2. Lane 4 
contains  ds-scFv with  10% DMF.  Lane 5 contains  CPG2 with  10% DMF.  Lane 6 
contains CPG2 modified with linker 11. Lane 7 contains CPG2 modified with linker 11 
and with 10% DMF. Lane 8 contains CPG2 modified with linker 11, with 10% DMF 
and with ds-scFv. Lane 9 contains CPG2 modified with linker 11, with 10% DMF and 
benzeneselenol. Lane 10 contains ds-scFv with 10% DMF and benzeneselenol. 
 
Much effort was made to improve the success and therefore yield of conjugation by the 
portionwise in situ approach through investigation of a variety of modified CPG2 and 
scFv concentrations. In the example in Figure 2.9, CPG2 has been modified for 1 h 
using  2  equivalents  of  linker  11.  Following  purification,  modified  CPG2  at 
concentrations of 3.5 mg/ml and 6 mg/ml were incubated with 3 and 5 equivalents of 
ds-scFv (previous work indicated higher equivalents gave no improvement) at 7 mg/ml 
and 10 mg/ml. 15 equivalents of benzeneselenol were added at the start of the reaction, 
then a further 15 equivalents every 20 min for 1 h. Early work on this approach revealed 
that both the reducing agent and the protein would begin to come out of solution if more 
was added after this point.   
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Figure 2.9 SDS-PAGE analysis of an in situ portionwise conjugation. Lane 1 contains 
protein ladder in kDa (SeeBlue® Plus2, Invitrogen). Lane 2 is MFECP fusion protein 
(~72 kDa - this serves as a molecular weight guide of the desired product). Lane 3 is 
modified  CPG2.  Lane  4  is  modified  CPG2  and  ds-scFv.  Lanes  5  and  6  contain 
conjugations using modified CPG2 at 3.5 mg/ml with 3 and 5 equivalents of reduced 
scFv respectively, at 7 mg/ml. Lane 7 contains a conjugation using modified CPG2 at 
3.5 mg/ml with 3 equivalents of reduced scFv at 10 mg/ml. Lanes 8 and 9 contain 
conjugations using modified CPG2 at 6 mg/ml with 3 and 5 equivalents of reduced scFv 
at 7 mg/ml. Lane 10 contains a conjugation using modified CPG2 at 6 mg/ml with 3 
equivalents of reduced scFv at 10 mg/ml. Note: mostly reoxidised scFv is observed as 
reaction samples have been taken after 2 h.  
 
In all of the conjugation conditions in Figure 2.9, very faint bands can be seen at ~72 
kDa, in line with MFECP, and at ~100 kDa.  Both of these suggest the conjugation 
product; CPG2 with one or two scFvs attached respectively (CPG2 monomer is ~45 
kDa and scFv is ~27 kDa). However, stronger bands are also observed at ~60 kDa, just 
above the band for CPG2 monomer. This mass is unexpected, and given the results of 
the  control  experiments,  must  be  generated  only  when  scFv  is  reduced  in  the 
conjugation reaction. The band intensities observed in Figure 2.9 are typical of all of 
the results obtained through the in situ portionwise approach. No significant change in 
yield for the supposed conjugation bands at ~72 kDa and 100 kDa was observed for 
different concentrations, equivalents of scFv fragment, or reaction times. In addition, 
substantial  oxidised  antibody  was  seen  in  all  attempts.  As  earlier  discussed,  using 
current published modification protocols, CPG2 is generated with up to 50 substituted 
maleimides attached. Indeed, using this modified CPG2 for conjugation generated a  
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large yield of high molecular weight conjugates, with little to no free scFv remaining. 
Combined, these results suggest that in our efforts to produce a more defined antibody-
enzyme conjugate, re-oxidation of the antibody disulfide is occurring before reaction 
with  one  of  the  few  substituted  maleimides  on  CPG2  can  ensue.  Hence,  despite 
modified CPG2 and reduced antibody being present and in high concentration, the yield 
of the conjugate does not improve, as the ds-scFv simply reoxidises before meeting the 
desired reactive partner.  
 
The results in Figure 2.9 further indicate that modification with 2 equivalents of linker 
is limiting; the chance of reduced scFv reacting with a substituted maleimide is low and 
further restricted by reoxidation over time. Consequently, a series of conjugations were 
attempted using CPG2 functionalised with greater numbers of dithiophenolmaleimide. 
The aim was to establish if a balance could be achieved between increasing the yield of 
the desired conjugate without significantly increasing product heterogeneity.  
 
Figure 2.10 SDS-PAGE analysis of in situ conjugations. Lane 1 contains protein ladder 
in  kDa  (SeeBlue®  Plus2,  Invitrogen).  Lane  2  is  MFECP  fusion  protein  (molecular 
weight of ~72 kDa). Lane 3 contains modified CPG2. Lane 4 contains modified CPG2 
and ds-scFv. Lanes 5 and 6 contain in situ portionwise conjugations where CPG2 was 
modified with 5 equivalents of linker 19 for 1 h, and incubated with 3 and 5 equivalents 
of  ds-scFv  respectively.  Lanes  7  and  8  contain  in  situ  conjugations  using 
selenocystamine  dihydrochloride  and  TCEP,  where  CPG2  was  modified  with  5 
equivalents of linker 19 for 1 h, and incubated with 3 and 5 equivalents of ds-scFv 
respectively.  
 
   
81 
 
   
In Figure 2.10, lanes 5 and 6 show the conjugation results of CPG2 modification with 5 
equivalents of linker 19, followed by incubation with 3 and 5 equivalents of ds-scFv 
using the in situ portionwise addition method. Consistent with earlier results, the same 
band pattern is observed. The bands proposed to be conjugate seen previously at ~72 
kDa and ~100 kDa are present, as well as bands suggesting higher molecular weight 
conjugates. In addition, a strong band is once again seen just above CPG2 at ~60 kDa. 
In any conjugations attempted where over 5 equivalents of linker were used for CPG2 
modification,  the  yield  of  these  highly  heterogeneous  higher  molecular  weight 
conjugates  increased.  In  addition,  a  significant  amount  of  modified  CPG2  remains 
indicating that these reactions are still far from high yielding. Currently practised cross-
linking  approaches  for  the  production  of  antibody-enzyme  conjugates,  for  example 
using the linker SMCC, typically produce a 30% crude yield of desirable conjugate, 
with 15% or less normally being recovered after purification (74). Indeed, using the 
designed disulfide to lysine linker these yields are not improving.  
 
The results of an alternative in situ approach are also shown in Figure 2.10, where 
selenocystamine dihydrochloride 26 (Figure 2.11) and TCEP were used together as the 
reducing agent. In this case, the reducing ability of selenol is revealed through the in 
situ reduction of the diselenide bond of 26 with TCEP. Furthermore, a 4:1 ratio of 
TCEP to selenocystamine was used with the aim of preserving the reducing capacity of 
26 for longer. Therefore, the reduced scFv could be maintained for a greater duration in 
the  conjugation  reaction,  increasing  the  opportunity  for  reaction  with  substituted 
maleimide. These reagents also have the advantage of greater water solubility. Figure 
2.10  demonstrates  that  the  reduced  antibody  was  successfully  maintained  in  the 
conjugation reaction mixture. Despite this, the same results are once again observed 
indicating  that  despite  reduced  scFv  availability,  the  yield  of  conjugate  does  not 
increase. This observation raises the question once more of the identity of the band at 
~60 kDa. This may either be a product of conjugation running unexpectedly low, or the 
result of a side reaction which competes with the bridging of the antibody fragment with 
a substituted maleimide. In order to establish the identity of each of the bands shown in 
SDS-PAGE,  a  number  of  conjugation  reactions  were  repeated,  and  Western  blot 
analysis of these samples carried out.  
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Figure 2.11 Structure of selenocystamine dihydrochloride. 
 
Figure 2.12A shows three controls and three sets of conjugation conditions using the in 
situ portionwise methodology. These results were then analysed by Western blot using 
antibodies to detect for the scFv fragment (Figure 2.12B) and for CPG2 (Figure 2.12C). 
This analysis therefore reveals the proteins contained within each band. In both Western 
blots the bands at ~72 kDa and ~100 kDa are seen, albeit very faintly, indicating that 
these are conjugates of CPG2 and scFv. The most intense stain however is observed in 
Figure 2.12B at ~60 kDa, and this is not observed in the Western blot for CPG2 (Figure 
2.12C). This indicates that this strong band, observed in all of the conjugation reactions, 
is a product of ds-scFv alone. The molecular weight of the ds-scFv is ~27 kDa and so 
this band would correspond to two of these fragments. It is maintained despite prior 
heating of samples to 98°C in SDS, suggesting the fragments are covalently bonded. In 
the literature, the formation of ds-scFv dimers after reduction has been reported (187). 
The observation in the conjugation reactions that yield of conjugate did not improve 
despite  the  availability  of  reduced  scFvs  certainly  points  towards  a  competing  side 
reaction. In these conjugation reactions there is a very high concentration of reduced 
scFv  present  and  in  comparison  extremely  few  substituted  maleimides,  reaction  to 
which is further hindered by the steric bulk of the attached CPG2. The formation of 
disulfides between reduced scFvs is therefore much more favourable, and this in turn 
decreases the amount of reduced antibody available for conjugation. This explains why 
an  improvement  in  yield  was  not  observed  despite  the  high  concentrations  and 
equivalents  of  antibody  fragment  used.  In  fact,  to  turn  the  reaction  in  favour  of 
conjugation  would  require  greater  levels  of  modification  of  CPG2.  This  inevitably 
results in highly heterogeneous antibody-enzyme conjugate.   
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Figure 2.12 (A) SDS-PAGE analysis of in situ conjugations. Lane 1 contains protein 
ladder in kDa (SeeBlue® Plus2, Invitrogen). Lane 2 contains MFECP fusion protein. 
Lane 3 contains modified CPG2. Lane 4 contains modified CPG2 and ds-scFv. Lanes 
5, 6 and 7 contain in situ portionwise conjugation attempts. (B) Western blot of SDS-
PAGE shown in (A) for ds-scFv. (C) Western blot of SDS-PAGE shown in (A) for 
CPG2. 
 
Given that conjugation to CPG2 lysine residues and subsequent disulfide bridging of the 
scFv fragment led to poor yields of conjugate and dimerisation of the reduced antibody, 
a final alternative approach was taken using these linkers. The disulfide to lysine linker 
19 was reacted first with the ds-scFv under the in situ bridging conditions, with the aim 
of rapidly bridging the scFv leaving the NHS ester free for conjugation with CPG2. The 
ds-scFv was incubated with 2 and 5 equivalents of linker 19, and 25 equivalents of 
benzeneselenol  for  20  min.  The  results  were  then  analysed  by  LCMS  as  shown  in 
Figure 2.13.   
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Figure 2.13 LCMS results of ds-scFv conjugation to disulfide to lysine linker 19. (A) 
Unmodified scFv (26,738 Da). (B) Result of scFv modification in situ with both 2 and 5 
equivalents of linker 19 and 25 equivalents of benzeneselenol (26,902 Da). 
 
In both cases, an increase in mass of 164 was observed for the scFv fragment. This 
corresponds  to  a  single  linker  bridging  the  scFv  via  the  substituted  maleimide,  in 
addition to reacting with a lysine residue. The disulfide bridging reaction is very fast, 
thus it is conceivable that once the maleimide has bridged the NHS ester end of the 
linker can react with a nearby lysine. These results indicate that, as expected, the linker 
cannot be used with the antibody fragment first. The presence of lysine residues in this 
protein prevents subsequent conjugation to CPG2 via the NHS ester.  
 
In summary, employing a disulfide to lysine linker did not provide a route to better 
defined  antibody-enzyme  conjugates  in  reasonable  yield.  Remaining  strategies  to 
improve this yield would only result in increased product heterogeneity. In addition, 
several problems were encountered in this conjugation approach including difficulty in 
maintaining  reduced  scFv  for  the  duration  of  the  slow  conjugation  reaction,  the 
incompatibility of high protein concentrations required for efficient conjugation with 
organic solvent and formation of scFv dimers. This investigation further highlights that 
the successful production of therapeutic antibody-enzyme conjugate would require site-
specific conjugation at both the antibody and enzyme. For example, enzymes with a 
single incorporated cysteine or disulfide bond should be employed.  The focus of this 
project thus moved on to generating homogeneous antibody-antibody conjugates, where 
site-specific modification could be achieved.   
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2.2  Substituted maleimide reagents with a bioorthogonal handle 
 
Recent literature has demonstrated the successful production of homogeneous antibody-
protein conjugates through the site-specific introduction of bioorthogonal functionalities 
(90,91). This ‘indirect’ approach to conjugation, which requires modification of each 
protein, is demonstrated to be more successful than the traditional ‘direct’ approach, 
where  a single protein  undergoes  chemical  modification  before direct  attachment to 
another, unmodified protein (90). For example, Schultz et al. generated a homogeneous 
anti-HER2/anti-CD3 Fab bispecific (91). This homogeneity has been realised using the 
strain  promoted  azide-alkyne  cycloaddition  (SPAAC).  Production  of  homogenous 
antibody conjugates using SPAAC first requires that the azide and strained alkyne are 
introduced  to  the  proteins  site-specifically.  Presently  this  is  achieved  through 
introduction of an unnatural amino acid (UAA) to each of the proteins to be conjugated. 
These UAAs thus provide a means for site-specific chemical functionalisation. This 
technology, whilst elegant, is not readily transferred; each antibody to be conjugated 
must undergo prior investigation to determine appropriate mutation sites, substitution 
for the unnatural amino acid is often incomplete, and expression yields are generally 
low  due  to  the  cellular  toxicity  of  artificial  amino  acids  at  the  high  concentrations 
necessary  (151,152).  To  avoid  these  difficulties,  an  ideal  site-directed  conjugation 
technique would use residues natural to the protein that are revealed for modification 
only under defined conditions.  
 
Our next generation maleimides can be used for the extremely efficient re-bridging of 
disulfide  bonds  in  Fab  and  disulfide-stabilised  scFv  antibody  fragments  (170,171). 
Novel linkers were thus designed that incorporate the bioorthogonal handles necessary 
for the SPAAC reaction, an azide and strained alkyne, in addition to 3,4-substituted 
maleimides  for  selective  disulfide  bridging.  Using  these  site-specific  bioorthogonal 
handles, the project focused on generating homogeneous antibody-antibody conjugates 
with the ultimate aim of producing a homogeneous bispecific.  
 
2.2.1  Synthesis of an azide functionalised disulfide bridging linker 
 
A 3,4-subsituted thiophenol maleimide linker containing an azide group 28 was the first 
bioorthogonal reagent to be synthesised (Scheme 2.11). From review of the literature, it 
is suggested that the ideal indirect cross-linking reagent should possess reasonable water  
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solubility, flexibility, and provide up to a 40 Å distance between the two proteins (90, 
91). Thus, 28 was designed to contain a short PEG chain conferring reasonable aqueous 
solubility and flexibility to the linker, and this particular 3 unit PEG gives the desired 
~20 Å length for combination with a similarly designed linker.  
 
Scheme 2.11 Reagents and conditions: (a) PhSH, NaHCO3, MeOH; (b) MeOCOCl, 
NMM, EtOAc; (c) NH2(CH2CH2O)3CH2CH2N3, DCM. 
 
The azide linker 28 was simply obtained over just three steps. First, the commercially 
available dibromomaleimide 8 was converted to the thiophenol derivative 9 in 30 min at 
ambient  temperature  in  76%  yield.  The  thiol  maleimide  9  was  subsequently 
functionalised with an N-(methoxycarbonyl) to produce 27 in excellent yield (97%). 
Reaction  of  activated  dithiophenol  maleimide  27  with  the  commercially  available 
amine-PEG-azide under mild conditions furnished linker 28 in a good 78% yield.  
 
In an analogous approach, a dibromomaleimide version of the azide linker 29 was also 
synthesised (Scheme 2.12). Over just two steps, linker 29 was obtained in an overall 
76% yield.  
 
Scheme  2.12  Reagents  and  conditions:  (a)  MeOCOCl,  NMM,  EtOAc;  (b) 
NH2(CH2CH2O)3CH2CH2N3, DCM. 
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2.2.2  Synthesis of a strained alkyne functionalised disulfide bridging linker 
The first step towards synthesis of this linker required the selection of the appropriate 
strained alkyne. Dibenzocyclooctyne (DIBO) is a popular choice, owing to its relatively 
straightforward synthesis compared to alternatives (see Section 1.8.2.4). However, we 
felt  the  significant  lipophilicity  of  this  compound  and  others  e.g.  aza-
dibenzocyclooctyne  (DIBAC)  and  biarylazacyclooctynone  (BARAC),  to  be  a 
significant drawback as this can lead to non-specific binding to proteins (137). The 
bicyclo[6.1.0]nonyne (BCN) 32 was judged the most suitable as it displays excellent 
reaction  kinetics  (0.14  M
-1s
-1  for  endo-32  and  0.11  M
-1s
-1  for  exo-32)  and  it  is  Cs 
symmetrical  (139)  (Scheme  2.13).  Furthermore,  it  is  synthesised  through  the 
cyclopropanation of the cheaply available 1,5-cyclooctadiene 30.  
 
 
Scheme 2.13 Reagents and conditions: (a) EtOCOCHN2, Rh(OAc)2, DCM, 0°C; (b) 1. 
LiAlH4, Et2O, 0°C; 2. Br2, DCM; 3. KOtBu, THF, 0°C to reflux.  
 
The  synthetic  route  to  BCN  is  outlined  in  Scheme  2.13.  First,  cyclopropanation  of 
cyclooctadiene occurs readily over 40 h in an overall 83% yield. The diastereomers exo- 
and endo-31 are obtained separately after difficult and lengthy purification by flash 
column chromatography. The individual stereoisomers are then subjected to reduction, 
bromination  and  elimination  using  only  one  final  purification  step  to  yield  the 
corresponding hydroxyalkynes exo- and endo-32 in 47% and 58% yield respectively. 
The difference in rate in the SPAAC reaction for these diastereomers is marginal, and so  
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both isomers were used in linker synthesis. The devised synthetic route for the strained 
alkyne linker 36 is exemplified for endo-32 in Scheme 2.14.  
 
 
Scheme  2.14  Reagents  and  conditions:  (a)  p-NO2PhOC(O)Cl,  pyridine,  DCM;  (b) 
NEt3, DCM; (c) DCM. 
In the first step towards linker 36, the hydroxyalkyne 32 was functionalised with a para-
nitrophenyl group to give 33 in 72% yield. The aim was to then couple 33 to 4,7,10-
trioxa-1,13-tridecanediamine  34,  economically  providing  the  desirable  3  PEG  unit 
linker length. However, several attempts at this step using 5, 10 and 15 equivalents of 
the  diamine-PEG  simply  resulted  in  addition  of  the  alkyne  at  both  amines.  Higher 
equivalents successfully achieved monoaddition; however purification by flash column 
chromatography resulted in co-elution with the diamine PEG starting material (product 
35  contained  10%  diamine  PEG  by  NMR).  The  next  step  c  would  have  involved 
reaction  of  N-(methoxycarbonyl)  thiophenol  maleimide  27,  synthesised  as  shown  in  
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Scheme 2.11, with the free amine of 35. Prior protection of the diamine-PEG 34 using 
27 was attempted (Scheme 2.15). Nevertheless, the large excess of diamine-PEG 34 
used to prevent reaction of the maleimide at both amines resulted in undesired product 
37. 
 
Scheme 2.15 Reagents and conditions: (a) Silica, DCM.  
 
The observed addition of the strained alkyne at both amines using the synthetic strategy 
outlined  in  Scheme  2.14,  and  the  unsuccessful  monoprotection  using 
dithiophenolmaleimide derivative 27, led to the generation of a new synthetic approach. 
This is outlined in Scheme 2.16. 
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Scheme 2.16 Reagents and conditions: (a) Boc2O, 1,4-dioxane; (b) NEt3, silica, DCM; 
(c) 1. TFA, DCM; 2. Endo-33, NEt3, DCM. 
 
The diamine-PEG 34 was successfully monoprotected using Boc-anhydride to give 38 
in 93% yield. The activated thiophenol maleimide 27 was subsequently able to react 
with the free amine generating 38 in 70% yield. It should be noted that triethylamine 
and  silica  are  necessary  in  this  step  in  order  to  produce  the  closed  maleimide  ring 
product (181). The next and final step in the synthesis of strained alkyne linker 36 is the 
removal  of  the  Boc  group  and  coupling  to  the  para-nitrophenyl  activated  strained 
alkyne  33.  However,  this  route  was  terminated  here  as  it  was  superseded  by  an 
alternative strategy that was being explored in parallel.  
 
In  tandem  to  the  synthetic  route  towards  the  thiophenol  maleimide  strained  alkyne 
linker shown in Scheme 2.16, an alternative approach was also pursued (Scheme 2.17).   
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Scheme 2.17 Reagents and conditions: (a) NEt3, DMF; (b) DMF, overnight; (c) HBTU, 
HOBt, DIPEA, DMF, overnight.  
 
The  synthetic  strategy  outlined  in  Scheme  2.17  first  requires  the  successful 
monoaddition  of  commercially  available  1,8-diamino-3,6-dioxaoctane  40.  This  short 
diamine PEG is successfully used in the original BCN synthesis paper (139). Following 
literature procedure, the desired product 41 was readily formed in a pleasing 99% yield. 
It was then proposed that the previously synthesised dithiophenol maleimide linker 19 
could be used for simple functionalisation of the strained alkyne. Indeed, addition of 
monoamine strained alkyne 41 to linker 19 in DMF generated the desired target 42 in a 
good  73%  yield.  Since  this  approach  negates  the  requirement  for  protection  and 
deprotection steps and proceeds with good yield, no further work towards the synthetic 
route using diamine 34 was carried out (Scheme 2.16). Later resynthesis of strained 
alkyne linker 42 also established that HBTU coupling could successfully be applied to 
directly  link  dithiophenolmaleimide  carboxylic  acid  18  to  strained  alkyne  41  in  an 
excellent 80% yield (Scheme 2.17).  
 
Following the success of the synthetic route outlined in Scheme 2.17, the same approach 
was used to produce dibromomaleimide strained alkyne linker 43 (Scheme 2.18). This 
instead used the previously synthesised linker 13, and suffered a slightly lower yield  
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due to competing attack of monoamine 41 on the dibromomaleimide, as observed in 
Section 2.1.3.  
 
Scheme 2.18 Reagents and conditions: (a) DMF, overnight. 
 
 
2.2.3  Synthesis of a linear alkyne functionalised disulfide bridging linker 
Despite the development of several strained alkyne structures, the rate of the strain-
promoted azide-alkyne cycloaddition (SPAAC) still remains low by comparison to its 
copper-catalysed  parent  reaction  (CuAAC)  (188).    In  construction  of  antibody 
conjugates such as bispecifics, a chemical conjugation approach with a high rate of 
reaction has distinct advantages; large excesses of expensive reagents are not required to 
promote reaction and shorter reaction times reduce the opportunity for loss of protein 
activity through degradation or aggregation. Previously, concerns have been raised of 
protein  damage  in  the  CuAAC  reaction  through  the  copper  mediated  generation  of 
reactive oxygen species. However, recent advances in CuAAC optimisation have now 
enabled the use an in situ reducing agent for fast and efficient bioconjugation without 
damage to the biological environment (189) (see Section 2.2.7). In order to explore the 
potential of copper-catalyzed bioconjugation, synthesis of a linear alkyne functionalised 
substituted maleimide was thus also pursued. 
 
Using a simple synthetic route, both dibromo- and dithiophenolmaleimide versions of 
the  desired  linear  alkyne  could  be  generated  from  their  corresponding  N-
(methoxycarbonyl)  maleimides  11  and  27  respectively  (Scheme  2.19).  First,  the 
commercially available alkyne chloroformate 44 underwent successful monoaddition to  
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diamine 34 (86%). After purification, the amino PEG alkyne 45 could then be added to 
the desired dibromo- or dithiophenolcarbamate to generate 46 and 47 respectively in 
good yield (74%, 77%).  
 
Scheme 2.19 Reagents and conditions: (a) NEt3, DMF; (b) DCM; (c) DCM. 
 
2.2.4  Functionalisation of an anti-CEA ds-scFv fragment 
As  earlier  discussed,  the  scFv  is  the  smallest  antibody  fragment  which  retains  full 
binding activity, and is a common component of many bispecific antibody formats e.g. 
BiTEs  (Bispecific  T-cell  Engager)  and  DARTs  (Dual-Affinity  Re-Targetting),  and 
antibody-enzyme conjugates. To examine the feasibility of our ‘click’ disulfide bridging 
approach to producing homogeneous protein-protein conjugate, we decided to first work 
with the anti-CEA disulfide-stabilised scFv fragment. Attempting to bring together two 
ds-scFv fragments homogeneously using this technology will give good precedent as to 
whether this approach could be used to readily generate homogeneous bispecifics in 
good yield.  
 
The  first  step  towards  successful  homogeneous  bispecific  production  requires  the 
efficient and site-specific introduction of the linker into the antibody fragment to be 
conjugated.  Thus  initial  investigations  focused  on  the  development  of  suitable 
conjugation methods for each linker to the ds-scFv.   
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2.2.4.1 Disulfide bridging with an azide functionalised linker 
 
As  discussed  previously,  dithiomaleimide  can  be  used  with  the  reducing  agent 
benzeneselenol for the in situ disulfide bridging of the ds-scFv fragment. Using this 
protocol, bridging of the scFv was first attempted using 2, 5 and 15 equivalents of the 
dithiophenolmaleimide  azide  linker  28  and  between  15  and  25  equivalents  of  the 
reducing  agent  benzeneselenol  (Scheme  2.20).  The  results  were  analysed  by  LCMS 
(Figure 2.14).  
 
Scheme 2.20 Bridging of anti-CEA ds-scFv with azide linker 28 via the in situ protocol.  
 
 
 
Figure 2.14 LCMS analysis of bridging with linker 28. (A) Unmodified anti-CEA ds-
scFv (mass 26,742). (B) Modified with linker 28 (expected 27,038, observed 27,038). 
 
The LCMS results of bridging with linker 28 are shown in Figure 2.14. The disulfide 
bond of the anti-CEA fragment was successfully bridged in all cases, using as little as 2 
equivalents  of  linker  28  with  25  equivalents  of  reducing  agent  for  full  conversion. 
Achieving fully bridged material with low equivalents of linker is particularly desirable 
for future applications where these modifications may be carried out on a large scale.  
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For the dibromomaleimide azide linker 29 an in situ approach using benzeneselenol 
cannot be adopted, since this method relies on the release of the thiophenol groups from 
the  maleimide  by  selenol  for  efficient  reduction.  Instead,  sequential  or  stepwise 
disulfide  bridging  approaches  can  be  used.  In  contrast  to  the  in  situ  method,  these 
protocols are based on reduction of the disulfide prior to bridging. In fact, the sequential 
and stepwise bridging strategies differ only in that there is an additional purification 
step in the latter; reducing agent is removed prior to bridging in the stepwise procedure.   
 
Dithiothreitol (DTT) is established in the group as the choice reducing agent for the 
sequential  or  stepwise  reduction  of  the  ds-scFv.  The  developed  sequential  protocol 
employs  20  equivalents  of  DTT  for  1  h,  followed  by  30  equivalents  of 
dibromomaleimide. In order to use less reducing agent and so linker in this conjugation 
approach, a series of optimisation experiments were carried out using linker 29 with ds-
scFv to  determine if  efficient  bridging  could  be maintained with  lower equivalents. 
Analysis  by  LCMS  revealed  that  complete  bridging  of  ds-scFv  with  29  could  be 
achieved using 10 equivalents of DTT for 15 min, followed by 15 equivalents of 29 
(Scheme 2.21).   
 
 
Scheme  2.21  Bridging of anti-CEA ds-scFv with  azide linker  29 via the sequential 
protocol. 
 
At this point, it should be noted that optimisation of alternative bridging protocols to the 
in situ approach were sought due to reliance on benzeneselenol. Benzeneselenol is an 
intensely malodorous compound, does not dissolve in water and oxidises rapidly in air, 
becoming inactive as a reducing agent. For our protocols to be adopted generally for the 
production  of  homogeneous  bispecifics,  we  endeavoured  to  develop  methods  using 
common, water soluble reagents such as DTT and TCEP. Unfortunately TCEP was 
found not to reduce the disulfide bond of the ds-scFv fragments used in this project, 
thus efforts focused on using DTT.  
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Disulfide bridging attempts using the sequential protocol with dithiophenolmaleimide 
azide linker 28 resulted in incomplete bridging. The large amount of free thiol generated 
through the combination of DTT and thiophenol leaving groups on the maleimide is the 
likely cause.  
 
Stepwise bridging differs only from sequential in that a purification step is included 
after reduction. This should ensure that no free reducing agent is present prior to linker 
addition, and thus allows for significantly lower equivalents of valuable linker to be 
used  for  bridging.  Furthermore,  this  protocol  can  be  used  in  combination  with 
dithiomaleimide based reagents. Following reduction with DTT (10 to 30 equivalents) 
for up to 1 h, scFv purification from free reducing agent was attempted using buffer 
exchange via desalting column or spin column, or a combination of the two. Using both 
linkers 28 and 29, complete bridging was not observed via the stepwise approach. A 
small amount of unmodified scFv (up to ~10%) could always be seen by LCMS and 
analysis by SDS-PAGE revealed this to be re-oxidised ds-scFv. The re-oxidation of this 
disulfide occurs rapidly in the absence of reducing agent. This issue was overcome in 
later work (see Section 2.3.2).  
2.2.4.2 Disulfide bridging with a strained alkyne functionalised linker 
 
Pleasingly, the in situ and sequential conditions optimised for the azide linkers 28 and 
29 were readily transferred to the dithiophenol- and dibromomaleimide analogues of the 
strained alkyne linkers 42 and 43. The results were analysed by LCMS, and the desired 
mass increase of 487 can be observed (Figure 2.15).  
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Figure 2.15 LCMS analysis of bridging with linkers 42 and 43. (A) Unmodified anti-
CEA  ds-scFv  (mass  26,737).  (B)  Modified  with  linker  42  or  43  (expected  27,224, 
observed 27,224). 
 
Although the correct mass was observed for disulfide bridging of the ds-scFv with the 
strained alkyne linker in the first instance, this did not remain the case when bridging 
was repeated.  
2.2.4.2.1  Stability of the strained alkyne  
 
Upon  repeating  disulfide  bridging  of  the  scFv  fragment  with  both  strained  alkyne 
linkers 42 and 43, a different mass was observed by LCMS after modification. The 
expected mass is an increase of 487 Da on the unmodified ds-scFv; however an increase 
of 519 was observed (Figure 2.16). Linkers 42 and 43 were prepared as a concentrated 
stock in DMF and stored at -20 °C. The repeat modification used the same stock as the 
initial analysis, and had been stored in the freezer for one week.   
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Figure  2.16  Repeat  LCMS  analysis  of  ds-scFv  bridging  with  linkers  42  and  43. 
Expected 27,224, observed 27,256, a +32 increase.    
 
To establish whether the strained alkyne linker is unstable in DMF, fresh stocks of both 
linkers 42 and 43 were prepared. Disulfide bridging with  the newly prepared DMF 
stock was repeated, and the original expected mass of 27,224 was once again observed. 
However, on repeating  this  reaction  a day later, the major peak observed was now 
27,256. In fact, in the initial modification analysis using these linkers in Figure 2.15B, a 
minor peak can be seen at the very similar mass of 27,260. Thus it appears that this +32 
species is rapidly generated in DMF.  
 
The unexpected +32 species observed in DMF does not affect the efficiency of disulfide 
bridging, suggesting that no alterations have occurred to the substituted maleimide of 
molecules 42 and 43. To investigate if the strained alkyne had been affected, an azide-
fluorophore Chromeo 546, was added in large excess (100 equivalents) to a sample of 
the strained alkyne functionalised scFv that contained only the +32 species by mass 
spectrometry. After 1 h the reaction was analysed by LCMS to reveal no increase in 
mass  for  the  attachment  of  the  fluorophore.  In  fact,  the  lack  of  reaction  could  be 
observed  by  eye,  since  after  purification  by  desalting  column  to  remove  free 
fluorophore, no pink/red colour could be seen in the protein fractions. This suggests 
therefore, that the +32 species of the strained alkyne linker is no longer active, and 
cannot be used to produce homogeneous antibody-antibody conjugate.  
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In  the  literature,  the  reactivity  of  cyclooctynes  is  described  as  “explosive”  towards 
azides,  but  also  “is  air-sensitive  and  rearranges  and  polymerizes  easily”  (190).  In 
regards to instability, many papers refer to early work describing the oxidation of the 
triple bond of cyclooctynes in air to form the corresponding cyclooctane-dione (191). It 
is plausible that through storage in DMF, over time any small amount of molecular 
oxygen present may react with the strained alkyne. This would account for the increase 
in 32 Da on the expected modified mass. Reaction at the strained alkyne triple bond 
would also explain the lack of reactivity on incubation with a large excess of azide. 
Unfortunately, re-isolation of the strained alkyne linkers from DMF was not achieved. 
In  order  to  successfully  use  the  strained  alkyne  linkers  42  and  43  in  conjugation, 
alternative stock storage conditions were devised.  
 
After screening a number of solvents for solubility to enable storage of linkers 42 and 
43, producing a DMSO stock was the most successful strategy. Storage of the strained 
alkyne linkers in DMSO at -20 °C resulted in the correct mass on disulfide bridging of 
the scFv fragment (Figure 2.17). LCMS analysis was repeated using the same linker 
stock in DMSO over a period of 6 months, and the correct expected mass was detected 
in each case. However, one drawback to using a DMSO stock was discovered; it is not 
compatible with the reducing agent benzeneselenol. Any trace of DMSO present in the 
reaction  rapidly  oxidises  benzeneselenol,  rendering  it  useless  as  a  reducing  agent. 
Consequently the in situ protocol cannot be adopted for ds-scFv modification with the 
strained alkyne linkers, and so sequential or stepwise protocols must be practiced.   
 
Figure 2.17 LCMS analysis of ds-scFv bridging with linkers 42 and 43 prepared in a 
DMSO stock. Expected 27,224, observed 27,222.  
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The azide linkers 28 and 29, and linear alkyne linkers 46 and 47, did not show any 
change in mass by LCMS, and appear to be stable in DMF for over 12 months.  
2.2.4.3 Disulfide bridging with a linear alkyne functionalised linker 
 
Disulfide bridging of the ds-scFv was also attempted using linear alkyne linkers 46 and 
47. The developed in situ procedure was followed using dithiophenolmaleimide linker 
47,  and  the  sequential  procedure  using  dibromomaleimide  linker  46.  Both  disulfide 
bridging  protocols  proceeded  efficiently,  yielding  full  conversion  to  the  modified 
product as observed by LCMS (Figure 2.18).  
 
 
Figure 2.18 LCMS analysis of bridging with linkers 46 and 47. (A) Unmodified anti-
CEA  ds-scFv  (mass  26,737).  (B)  Modified  with  linker  46  or  47  (expected  27,131, 
observed 27,131). Note: A different LCMS system is used here and in all proceeding 
mass spectrometry analysis.  
 
Following the successful functionalisation of the ds-scFv antibody fragment with the 
azide, strained and linear alkyne linkers, bridging of a Herceptin Fab fragment was 
investigated.  Both  Fabs  and  scFvs  are  commonly  used  in  a  range  of  bispecific 
topologies.  
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2.2.5  Functionalisation of Herceptin Fab 
The  monoclonal  IgG1  antibody  Trastuzumab  (Herceptin
TM)  targets  the  HER2/neu 
receptor and has successfully been used to treat HER2+ breast cancer patients (192). 
The  Fab  fragment  of  this  clinically  relevant  antibody  can  be  readily  obtained  by 
enzymatic digest, and its incorporation into bispecific formats has therapeutic potential 
(91). Thus we decided to modify the single interchain disulfide bond of this fragment 
with our bioorthogonal linkers.  
 
The Trastuzumab Fab was obtained using a sequential digest protocol with pepsin and 
papain. This is an established protocol in the group, and achieves yields of between 50-
70%. Following digest, size exclusion chromatography purification was used to remove 
any undigested full antibody or F(ab’)2 fragment (Figure 2.19). This ensures that all 
results are due to reaction with the disulfide bond of the Fab fragment alone.  
 
Figure 2.19 Size exclusion chromatography purification of Fab digest. Lane L contains 
protein ladder in kDa (New England Biolabs). Lane B contains digest mixture before 
purification. Lanes 1-4 correspond to isolated peaks 1-4, with lane 4 containing pure 
Fab (~50 kDa).  
2.2.5.1 Disulfide bridging with an azide functionalised linker 
 
Unlike the ds-scFv, the single disulfide bond of the Fab fragment could be reduced with 
the water-soluble reducing agent TCEP, yielding the component heavy and light chains. 
Using either azide linker 28 or 29, the Fab could be successfully fully modified using a 
sequential  bridging  protocol  (Scheme  2.22).  This  was  reliably  achieved  using  5 
equivalents of TCEP for 1 h, followed by 8 equivalents of either linker 28 or 29 for 30 
min. The reaction was monitored by LCMS and SDS-PAGE (Figure 2.20).   
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Scheme  2.22  Bridging  of  Herceptin  Fab  with  either  azide  linker  28  or  29  via  the 
sequential protocol. 
 
 
 
Figure 2.20 [i] LCMS analysis of bridging with linkers 28 and 29. (A) Unmodified Fab 
(mass 47,655). (B) Modified with linker 28 or 29 (expected 47,951, observed 47,952). 
[ii] SDS-PAGE analysis of Fab reduction and bridging. Lane 1 contains protein ladder 
in kDa (New  England  Biolabs).  Lane 2  contains  unmodified Fab.  Lane 3  contains 
reduced Fab after treatment with TCEP. Lane 4 contains Fab modified with linker 28.  
Efficient in situ bridging could also be achieved using dithiophenolmaleimide linker 28 
(3 equivalents) and TCEP (5 equivalents) (Scheme 2.23).  
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Scheme 2.23 Bridging of Herceptin Fab with dithiophenolmaleimide azide linker 28 via 
the in situ protocol. 
2.2.5.2  Disulfide bridging with a strained alkyne functionalised linker 
 
Pleasingly, the sequential and in situ protocols developed using the azide linkers 28 and 
29 could be applied to strained alkyne linkers 42 and 43 (Figure 2.21).  
 
 
 
Figure 2.21 [i] LCMS analysis of bridging with linkers 42 and 43. (A) Unmodified Fab 
(mass 47,655). (B) Modified with linker 42 or 43 (expected 48,142, observed 48,144). 
[ii] SDS-PAGE analysis of Fab reduction and bridging. Lane 1 contains protein ladder  
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in kDa (New  England  Biolabs).  Lane 2  contains  unmodified Fab.  Lane 3  contains 
reduced Fab after treatment with TCEP. Lane 4 contains Fab modified with linker 42. 
2.2.5.3 Disulfide bridging with a linear alkyne functionalised linker 
 
Again, disulfide bridging could be achieved using the appropriate sequential or in situ 
protocol for linear alkyne linkers 46 and 47 (Figure 2.22).  
 
 
 
Figure 2.22 [i] LCMS analysis of bridging with linkers 46 and 47. (A) Unmodified Fab 
(mass 47,655). (B) Modified with linker 46 or 47 (expected 48,049, observed 48,048). 
[ii] SDS-PAGE analysis of Fab reduction and bridging. Lane 1 contains protein ladder 
in  kDa (New  England  Biolabs).  Lane 2  contains  unmodified Fab.  Lane 3  contains 
reduced Fab after treatment with TCEP. Lane 4 contains Fab modified with linker 47. 
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2.2.6  Copper-free conjugation towards homogeneous bispecifics 
Before attempting to conjugate two antibody fragments, we decided to first investigate 
the  scope  of  the  SPAAC  reaction.  Initial  tests  focused  on  the  attachment  of  small 
molecules to the azide or strained alkyne functionalised antibody fragments. First, the 
addition  of  an  azide  functionalised  fluorophore,  Chromeo  546,  to  strained  alkyne 
functionalised ds-scFv or Fab was investigated.  
 
In the literature, SPAAC reactions using the BCN strained alkyne synthesised in this 
project, as well as other popular alternatives such as DIBAC, typically use PBS buffer 
at pH 7.4 for conjugation (90,91,139). Accordingly, after disulfide bridging, the strained 
alkyne  functionalised  ds-scFv  was  buffer  exchanged  into  PBS.  This  also  served  to 
remove  any  free  linker  present.  After  concentrating  the  antibody  to  100  µM  (2.7 
mg/ml), 20 equivalents of azide Chromeo 546 were added, and the reaction incubated at 
37 °C (Scheme 2.24). The results of this early test SPAAC reaction between ds-scFv 
functionalised with  strained alkyne linker  42 and azide Chromeo 546 are shown in 
Figure 2.23.  
 
Scheme 2.24 Cycloaddition of azide Chromeo 546 to strained alkyne functionalised 
scFv. 
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Figure 2.23 LCMS analysis of reaction between strained alkyne functionalised ds-scFv 
and azide Chromeo 546. Expected 27,912, observed 27,912. 
 
Pleasingly, the strained alkyne ds-scFv was functionalised with Chromeo 546 after only 
1 h at 37 °C (Figure 2.23). No unmodified strained alkyne could be detected by LCMS.  
 
The reaction of strained alkyne functionalised Fab with azide Chromeo 546 was also 
investigated.  After  disulfide  bridging  with  either  linker  42  or  43,  the  modified  Fab 
fragment  was  buffer  exchanged  into  PBS.  At  concentrations  around  100  µM  (4.8 
mg/ml),  the  Fab  fragment  underwent  complete  modification  with  Chromeo  546  (20 
equivalents) at room temperature after 1 h (Scheme 2.25). This reaction was monitored 
by LCMS (Figure 2.24).  
 
Scheme 2.25 Cycloaddition of azide Chromeo 546 to strained alkyne functionalised 
Fab.  
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Figure 2.24 LCMS analysis of reaction between strained alkyne functionalised Fab and 
azide Chromeo 546. Expected 48,830, observed 48,833.  
 
Compared to its copper-catalysed relative, the slow rate of the SPAAC reaction is often 
stated as its foremost disadvantage. Our initial investigations certainly reveal this to be 
the case; a minimum of 20 equivalents of azide Chromeo 546 is required to achieve 
complete addition to strained alkyne functionalised ds-scFv or Fab  at 100 µM within 1 
h at room temperature.  
 
Reaction  with  azide  Chromeo  546  confirmed  that  the  strained  alkyne  was  able  to 
participate  in  the  SPAAC  reaction  once  conjugated  to  ds-scFv  and  Fab  fragments. 
Construction  of  a  homogeneous  bispecific  would  require  reaction  between  strained 
alkyne and azide functionalised antibody fragments. Thus the reactivity of azide linkers 
28 and 29 was also verified. To this end, azide functionalised ds-scFv and Fab were 
reacted  with  monoamine  PEG  strained  alkyne  41  (20  equivalents)  for  1  h  at  room 
temperature. This is shown schematically for the scFv fragment in Scheme 2.26. The 
reaction was followed by LCMS (Figure 2.25).   
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Scheme 2.26 Cycloaddition of strained alkyne 41 to azide functionalised scFv. 
 
 
Figure 2.25 LCMS analysis of reaction with strained alkyne 41 (324 Da). (A) Addition 
of 41 to azide functionalised ds-scFv. Expected 27,362, observed 27,362. (B) Addition 
of 41 to azide functionalised Fab. Expected 48,275, observed 48,276. 
 
As shown in Figure 2.25, the azide group of linkers 28 and 29 remains active when 
conjugated  to  both  of  the  model  system  antibody  fragments,  ds-scFv  and  Fab. 
Following this success, the ability of these linkers to produce homogeneous antibody 
fragment homodimer was investigated (Scheme 2.27).   
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Scheme 2.27 Generation of scFv homodimer via SPAAC reaction. 
 
First, the generation of scFv homodimer was pursued. In the literature, there are limited 
examples of site-specific protein-protein conjugation using the SPAAC reaction. The 
most relevant example was recently demonstrated by Schultz et al., who successfully 
produced both a Fab homodimer and heterodimer using SPAAC chemistry (see Section 
1.8.2.4) (91). To achieve this, strained alkyne and azide functionalised Fab fragments 
were concentrated to 10 mg/ml, and mixed in a 1:1 ratio in PBS at 37 °C for 72 h. Given 
the slow rate of reaction observed when using these linkers to attach small molecules, 
and such literature precedent, generation of scFv homodimer was first attempted at high 
concentration (Figure 2.26).  
 
Figure 2.26 SDS-PAGE analysis of generation of scFv homodimer. Lane 1 contains 
protein ladder in kDa (New England Biolabs).  Lane 2 contains azide functionalised 
scFv. Lane 3 contains strained alkyne functionalised scFv. Lane 4 contains homodimer 
reaction sample after 1 h. Lane 5 contains homodimer reaction sample after 24 h.  
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After disulfide bridging with the strained alkyne and azide linkers, the modified scFv 
fragments  were  purified  by  desalting  column  and  subsequently  concentrated  to  10 
mg/ml.  The  desalting  column  ensures  no  free  linker  remained  after  bridging.  The 
functionalised  fragments  were  then  mixed  in  a  1:1  ratio.  Figure  2.26  shows  the 
formation of a small amount of homodimer after 1 h (lane 4), and this yield increases 
slightly after 24 h (lane 5). However, these long reaction times also resulted in the 
appearance  of  higher  molecular  weight  aggregates,  as  can  be  seen  in  lane  5.  To 
investigate the source of these aggregates, the reaction was repeated with key controls 
(Figure 2.27).  
 
Figure 2.27 SDS-PAGE analysis of generation of scFv homodimer with key controls at 
37 °C. Lane 1 contains protein ladder in kDa (New England Biolabs). Lane 2 contains 
scFv  control.  Lane  3  contains  scFv  incubated  for  48  h.  Lane  4  contains  azide 
functionalised scFv incubated for 48 h. Lane 5 contains strained alkyne functionalised 
scFv incubated for 48 h. Lanes 6 to 10 contain homodimer reaction sample after 1, 16, 
24, 36 and 48 h respectively. 
 
Samples of unmodified, azide functionalised and strained alkyne functionalised scFv 
were individually incubated at 37 °C at 10 mg/ml over 48 h (Figure 2.27, lanes 3 to 5). 
In all three controls there is a band at ~50 kDa, the same mass that would correspond to 
the formation of scFv dimer. Furthermore, strained alkyne functionalised scFv shows 
distinct formation of higher molecular weight aggregates (Figure 2.27, lane 5). These 
correspond to the aggregates observed in the homodimer reaction over time (Figure 
2.27, lanes 6 to 10).  
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The results in Figure 2.27 reveal a potential problem with the strained alkyne linker 
under the reaction conditions. In addition, the controls indicate the formation of non-
specific scFv homodimer for all controls at this temperature and concentration, as a 
band  at  the  expected  mass  of  ~50  kDa  is  observed  without  incubation  of  the  two 
SPAAC reaction partners. To determine if these issues are temperature dependent, the 
reaction was repeated at room temperature and 4 °C (Figure 2.28).  
 
Figure 2.28 SDS-PAGE analysis of generation of scFv homodimer with key controls at 
room temperature. Lane 1 contains protein ladder in kDa (New England Biolabs). Lane 
2 contains scFv control. Lane 3 contains scFv incubated for 48 h. Lane 4 contains azide 
functionalised scFv incubated for 48 h. Lane 5 contains strained alkyne functionalised 
scFv incubated for 48 h. Lanes 6 to 10 contain homodimer reaction sample after 1, 16, 
24, 36 and 48 h respectively. 
 
Figure 2.28 shows the SDS-PAGE analysis of the homodimer reaction and controls at 
room  temperature.  The  unmodified  scFv  control  and  that  incubated  for  48  h  are 
identical,  suggesting  the  formation  of  non-specific  homodimer  for  this  sample  was 
indeed temperature dependent (lanes 2 and 3). In the case of the azide functionalised 
scFv  control  the  band  at  ~50  kDa  is  still  present,  though  it  is  significantly  less 
prominent than it was at 37 °C (lane 4). However, the strained alkyne functionalised 
scFv reveals an almost identical result to that at 37 °C (lane 5). Furthermore, the sample 
taken from the homodimer reaction after 48 h shows the same bands as observed in the 
strained alkyne control. Analogous results were observed when repeated at 4 °C.  
 
Figures 2.27 and 2.28 suggest the presence of the strained alkyne linker is causing non-
specific binding between scFv molecules over time, resulting in high molecular weight  
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aggregates.  This  observation  has  previously  been  reported  in  the  literature,  and  is 
thought to be due to the hydrophobic nature of strained alkynes (139,189). Furthermore, 
a significant proportion of the homodimer is formed non-specifically, as this band can 
be seen by SDS-PAGE when azide and strained alkyne modified scFv fragments are 
incubated alone. This is a likely side effect of the high protein concentration and long 
reaction  time.  Thus  the  actual  yield  of  site-specific  homodimer  observed  in  these 
reactions is very poor. The yield did not improve when using an excess of either the 
azide or strained alkyne functionalised scFv reaction partners. Reactions using modified 
scFv at lower concentrations (1 mg/ml to 5 mg/ml) were also attempted.  Although this 
significantly  reduced  the  non-specific  binding  of  both  azide  and  strained  alkyne 
functionalised scFv fragments, a negligible yield of homodimer was achieved.  
 
The  low  homodimer  yield  achieved  by  the  SPAAC  reaction  and  the  previous 
observation of strained alkyne instability, led us to question if the strained alkyne was 
still active over the time course of the reaction, and if so for how long. To test this, a 5 
kDa azide PEG was used (Scheme 2.28 and Figure 2.29).  
 
 
Scheme 2.28 Investigating strained alkyne stability under reaction conditions; a 5 kDa 
azide PEG was added to samples of strained alkyne functionalised scFv incubated at 37 
°C for 0, 2, 16, 24 and 48 h.  
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Figure 2.29 SDS-PAGE analysis of reaction between strained alkyne scFv and 5 kDa 
azide PEG (20 equivalents) at 37 °C.  Lane 1 contains protein ladder in kDa (New 
England Biolabs). Lane 2 contains unmodified scFv. Lane 3 contains strained alkyne 
functionalised scFv incubated for 48 h. Lane 4 is addition of azide at 0 h. Lane 5 is 
addition of azide at 2 h. Lane 6 is addition of azide at 16 h. Lane 7 is addition of azide 
at 24 h. Lane 8 is addition of azide at 36 h. Lane 9 is addition of azide at 48 h.  
 
Aliquots  of  strained  alkyne  functionalised  scFv  were  incubated  at  37  °C  and  20 
equivalents of azide PEG were added to samples at 0, 2, 16, 24 and 48 h. The band at 
~30 kDa corresponds to the successful addition of the PEG azide to the strained alkyne 
scFv (Figure 2.29). The presence of this band at all time points reveals that there is 
active  strained  alkyne  present  over  a  48  h  time  period.  However,  this  yield  does 
decrease over time, suggesting the strained alkyne is not stable. Moreover, addition of a 
large excess of azide PEG (20 equivalents) at 0 h still does not yield a single product; a 
significant amount of unreacted scFv remains.    
 
Attempts at producing scFv homodimer using the SPAAC disulfide bridging linkers 
have revealed two key issues. Firstly, the high concentration and long reaction times 
required for conjugation of two antibody fragments results in significant aggregation 
due  to  non-specific  protein  binding.  Second,  the  rate  of  reaction  is  very  slow, 
particularly  when  linking  two  sterically  hindered  molecules  via  this  approach.  The 
reaction yield is further hampered by the instability of the strained alkyne. To determine 
if  this  is  a  scFv  specific  problem,  the  generation  of  a  Fab  homodimer  was  also 
attempted (Scheme 2.29 and Figure 2.30).   
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Scheme 2.29 Generation of Fab homodimer via SPAAC reaction. 
 
 
Figure 2.30 SDS-PAGE analysis of generation of Fab homodimer at 37 °C. Lane 1 
contains protein ladder in kDa (New England Biolabs). Lane 2 contains unmodified 
Fab.  Lane  3  contains  unmodified  Fab  incubated  for  48  h.  Lane  4  contains  azide 
functionalised Fab incubated for 48 h. Lane 5 contains strained alkyne functionalised 
Fab incubated for 48 h. Lane 6 contains homodimer reaction sample at 0 h. Lane 7 
contains homodimer reaction sample at 48 h.  
 
Attempts  at  generating  Fab  homodimer  using  the  SPAAC  linkers  showed  marked 
similarity to the result of the pursued scFv dimerisation. As can be seen in Figure 2.30, 
the  azide  functionalised  Fab  control  lane  4  contains  a  faint  band  at  ~100  kDa. 
Furthermore, the strained alkyne control reveals two distinct bands running at ~100 and 
~150 kDa (lane 5).  The same two bands are apparent in the reaction mixture of 1:1 
azide to strained alkyne functionalised Fab after 48 h, though in slightly higher yield 
(lane 7).   
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The  results  shown  in  Figure  2.30  are  representative  of  several  attempts  at  Fab 
dimerisation. The appearance of multiple bands in lane 5 indicates that non-specific 
protein binding is not limited to strained alkyne functionalisation of the scFv fragment. 
Furthermore,  lowering  concentration  and  temperature  yielded  the  same  effects;  a 
reduction in non-specific aggregates at lower concentrations, however temperature did 
not  reduce  strained  alkyne  functionalised  Fab  non-specific  binding.  The  two  bands 
present in reaction lane 7, although the same weight as those in the strained alkyne 
control, are more pronounced. This suggests that these are also a result of incubating the 
two  SPAAC  Fab  reaction  partners.  Nevertheless  this  result  is  unexpected,  since 
dimerisation of Fab should in theory yield a single band at ~100 kDa.   
 
2.2.7  Copper-catalysed conjugation towards homogeneous bispecifics 
In organic and materials synthesis, the use of an in situ reducing agent provides a fast, 
efficient and convenient CuAAC procedure. Sodium ascorbate is the choice reducing 
agent for synthesis; however it has long been avoided for bioconjugation due to the 
copper mediated generation of reactive oxygen species. These species have been shown 
to cause oxidation, cleavage, cross-linking and even precipitation of biomolecules (194-
196). However, recent advances in CuAAC optimisation have now enabled the use of 
sodium ascorbate for fast and efficient bioconjugation without damage to the biological 
environment (189).  
 
The CuAAC protocol used in this project is based on that devised by Finn et al. (189). 
This  procedure  employs  the  water-soluble  ligand  THPTA  (tris-
(hydroxypropyltriazolylmethyl)amine). This ligand intercepts and reduces the reactive 
oxygen species generated by ascorbate reduction of dissolved oxygen, protecting the 
proteins from potential damage. Aminoguanidine is also added to the reaction to divert 
any by-products of ascorbate oxidation that have the capacity to covalently modify or 
cross-link proteins. Furthermore, due to the efficiency of sodium ascorbate as a reducing 
agent, copper need only be used in low concentrations. The source of copper in all of 
the CuAAC reactions in this project is CuSO4.  
 
To develop the ideal conditions for the CuAAC using the ds-scFv and Fab antibody 
fragments, it was decided to first use azide PEG reagents. Successful addition of PEG to 
the linear alkyne functionalised antibody fragments is visible by SDS-PAGE. Thus this  
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avoids the requirement for mass spectrometry, which would necessitate prior thorough 
purification  of  CuAAC  reactions  to  remove  all  of  the  small  molecule  components, 
resulting in loss of valuable antibody fragment. Initial attempts at the copper-catalysed 
click between linear alkyne functionalised scFv and azide PEG (2 or 5 kDa) resulted in 
little or no product for a variety of scFv concentrations (50 to 200 µM) and excesses of 
PEG (10 to 100 equivalents). A review of the literature soon revealed the probable 
issue;  protein  hexahistidine-tags  can  strongly  bind  copper  ions,  leaving  copper 
unavailable for catalysis and even inducing protein precipitation (189).  To overcome 
this, it is suggested that the concentration of the metal-ligand complex may be increased 
to a maximum of 0.5 mM (Scheme 2.30 and Figure 2.31).  
 
Scheme 2.30 CuAAC between a 5 kDa azide PEG and linear alkyne functionalised 
scFv. 
 
 
Figure 2.31 SDS-PAGE analysis of reaction between linear alkyne functionalised scFv 
(100 µM) and azide PEG (5 kDa), 0.5 mM CuSO4: 2.5 mM THPTA. Lane 1 contains 
linear  alkyne  functionalised  scFv  left  overnight  under  reaction  conditions.  Lane  2  
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contains linear alkyne scFv + 20 equivalents PEG azide, 1 h, rt. Lane 3 contains linear 
alkyne scFv + 100 equivalents PEG azide, 1 h, rt. Lane 4 contains linear alkyne scFv + 
20 equivalents  PEG azide, overnight,  rt.  Lane 5 contains linear alkyne scFv + 100 
equivalents PEG azide, overnight, rt. 
 
The  copper  and  ligand  concentration  were  increased  accordingly  to  promote  the 
CuAAC between linear alkyne functionalised scFv and a 5 kDa azide PEG. As can be 
seen in Figure 2.31, site-specific PEGlyated scFv was formed. However, these results 
represent the highest yielding CuAAC achieved using the linear alkyne functionalised 
scFv. Greater copper concentrations resulted in multiple higher molecular weight bands 
by  SDS-PAGE,  suggesting  protein  cross-linking  or  aggregation.  In  fact,  the  slight 
appearance of these bands can be seen in  Figure 2.31. Furthermore, longer reaction 
times and reaction at 37 °C did not improve yield.  
 
In  tandem,  the  reaction  of  azide  PEG  with  linear  alkyne  functionalised  Fab  was 
investigated. As the Fab is obtained by digest of a human IgG, it does not possess a 
hexahistidine-tag. The results of the reaction between linear alkyne Fab and azide PEG 
(2 and 5 kDa) are shown in Figure 2.32.  
 
 
Figure 2.32 SDS-PAGE analysis of reaction between linear alkyne functionalised Fab 
(100 µM) and azide PEG (2 and 5 kDa), 0.2 µM CuSO4: 1.0 mM THPTA. Lane 1 
contains linear alkyne functionalised Fab. Lanes 2 to 4 contain linear alkyne Fab + 1, 
20 and 100 equivalents PEG azide (2 kDa) respectively 1 h, rt. Lanes 5 to 7 contain 
linear alkyne Fab + 1, 20 and 100 equivalents PEG azide (2 kDa) respectively left 
overnight, rt. Lanes 8 to 10 contain linear alkyne Fab + 1, 20 and 100 equivalents PEG 
azide  (5  kDa)  1  h,  rt.  Lanes  11  to  13  contain  linear  alkyne  Fab  +  1,  20  and  100  
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equivalents  PEG  azide  (5  kDa)  left  overnight,  rt.  Lane  14  contains  linear  alkyne 
functionalised Fab left overnight at rt. 
 
The reaction of linear alkyne Fab with 1, 20 and 100 equivalents of azide PEG (2 and 5 
kDa) was analysed after 1 h and overnight (Figure 2.32). CuAAC worked well using 
200 µM CuSO4, and higher concentrations did not improve reaction yield. Pleasingly, as 
can be seen in lane 14, no aggregation or cross-linking products can be seen for the 
linear alkyne Fab control incubated under the CuAAC conditions overnight. Lane 12 
clearly reveals that reaction with 20 equivalents of azide PEG overnight achieves almost 
complete site-specific PEGylation of the Fab fragment. Furthermore, lane 13 indicates 
that increasing to 100 equivalents azide PEG does not improve the yield. This perhaps 
suggests that the remaining Fab is not able to participate in the CuAAC reaction, despite 
appearing to be fully functionalised with linear alkyne linker by mass spectrometry.  
 
An unexpected result is observed in Figure 2.32; selective PEGylation of the Fab heavy 
chain. This can be clearly observed in lanes 3, 4, 6 and 7 on reaction with the 2 kDa 
azide PEG, and lanes 9, 10, 12 and 13 using the 5 kDa PEG. For heavy chain specific 
PEGylation to occur, this chain must also have been selectively modified with the linear 
alkyne Fab maleimide. Free heavy and light chain has been found to always be visible, 
to some degree, by SDS-PAGE after Fab disulfide bridging. However, LCMS analysis 
of the same samples would suggest that the Fab is fully re-bridged, and that there is no 
free heavy or light chain present.  
 
There are several possible explanations for this unusual result. Firstly, this may simply 
be an effect of SDS-PAGE. Samples are prepared for analysis in SDS and heated to 98 
°C for 2 min, thus these harsh conditions may have cleaved the maleimide bridge (this 
was found not to be the case, see Section 2.3.4). A second possible reasoning is slow 
reactivity of the light chain cysteine; research within the group has established that the 
heavy  chain  cysteine  released  by  disulfide  bond  reduction  reacts  rapidly  with 
modification reagents compared to the equivalent cysteine of the light chain. In fact, the 
light chain cysteine is C-terminal and hence this result is consistent with the expected 
higher pKa of this residue.  A final  explanation is the possibility of  decarboxylative 
enamide formation; the group is also investigating the observation of photochemical 
decarboxylation of C-terminal maleimide functionalised cysteine residues mediated by 
high intensity UV light (Scheme 2.31) (197).   
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Scheme  2.31  The  light  chain  cysteine  residue  of  the  Fab  interchain  disulfide  is  C-
terminal. Under high intensity UV light, maleimide functionalised C-terminal cysteine 
residues can undergo a photo-electron transfer and subsequent decarboxylation to form 
the enamide (197). 
 
One  concern  was  the  possibility  of  heavy  chain  selective  modification  via  enamide 
formation promoted by solar UV. To determine if this is the case, disulfide bridging of 
the Herceptin Fab fragment was repeated using simple dithiophenol maleimide in the 
light and dark, and the two bridged samples left overnight (Figure 2.33, lanes 1 and 2). 
In addition, CuAAC of the linear alkyne functionalised Fab to 5 kDa azide PEG was 
repeated under these conditions (Figure 2.33).  
 
 
Figure 2.33 SDS-PAGE analysis of disulfide bridged Fab fragment in the light and 
dark.  Lane  1  contains  maleimide  bridged  Fab  left  overnight  in  the  light.  Lane  2 
contains maleimide bridged Fab left overnight in the dark. Lanes 3 and 9 contain linear 
alkyne Fab under CuAAC conditions 1 h, rt. Lanes 4 and 10 contain linear alkyne Fab 
+ 20 equivalents azide PEG 1 h, rt. Lanes 5 and 11 contain linear alkyne Fab + 100 
equivalents azide PEG, 1 h, rt. Lanes 6 and 12 contain linear alkyne Fab under CuAAC 
conditions overnight, rt. Lanes 7 and 13 contain linear alkyne Fab + 20 equivalents 
azide PEG overnight, rt. Lanes 8 and 14 contain linear alkyne Fab + 100 equivalents 
azide PEG overnight, rt.  
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Lanes  1  and  2 show the results  of Fab fragment  bridging with  simple dithiophenol 
maleimide under light or dark conditions respectively, and left overnight (Figure 2.33). 
This reveals no significant difference in the amounts of heavy and light chain in either 
sample. Furthermore, the same is observed for the repeated CuAAC reactions in the 
light (lanes 3 to 8) and dark (lanes 9 to 14). Thus this suggests that enamide formation 
is not occurring as a result of UV exposure from light during the modification reaction.  
 
It was decided to repeat PEGylation using the strained alkyne functionalised Fab. The 
purpose of this reaction was two-fold; to determine if this site-specific PEGylation of 
the heavy chain was CuAAC specific, and to directly compare the efficiency of the two 
‘click’ reactions on the Fab fragment. The results are shown in Figure 2.34.  
 
 
Figure 2.34 SDS-PAGE analysis of CuAAC and SPAAC reaction between alkyne Fab 
and 5 kDa azide PEG. Arrows indicate PEGlyated products. Lane 1 contains protein 
ladder in kDa (New England Biolabs). Lane 2 contains unmodified Fab control. Lane 3 
contains linear alkyne functionalised Fab. Lane 4 contains linear alkyne bridged Fab + 
20 equivalents azide PEG 1 h, rt. Lanes 5 to 7 contain reaction sample after 2 h, 3 h and 
overnight  respectively.  Lane  8  contains  strained  alkyne  functionalised  Fab.  Lane  9 
contains strained alkyne functionalised Fab + 20 equivalents azide PEG 1 h, rt. Lanes 
10 to 12 contain reaction sample after 2 h, 3 h and overnight respectively.  
 
Figure 2.34 clearly demonstrates that selective PEGlyation of the heavy chain is not 
CuAAC specific. Furthermore, the difference in efficiency for the CuAAC and SPAAC 
reactions is very clear. For the same concentration, reaction time and temperature, little 
alkyne functionalised Fab remains in lane 7 for the CuAAC reaction compared to that  
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remaining in lane 12 for the SPAAC equivalent. As the linear alkyne Fab has shown no 
tendency for non-specific protein binding at high concentrations, and the CuAAC shows 
a greater efficiency and rate of reaction, it was anticipated that this approach would be 
more successful at generating homogeneous bispecific.  
 
As attempted using the SPAAC disulfide bridging linkers, synthesis of scFv homodimer 
using the CuAAC alternative was sought. However, this was not successfully achieved. 
At  a  range  of  both  scFv  and  Cu  concentrations,  either  no  homodimer  product  was 
obtained or at high Cu concentrations multiple bands appeared suggesting protein cross-
linking or aggregation. As previously observed, the failing of this CuAAC coupling is 
likely to be due to the hexahistidine-tag of this antibody fragment.  
 
The lack of a hexahistidine-tag on the Fab fragment, combined with the relative success 
of Fab via the CuAAC reaction, boded well for the construction a  Fab homodimer 
(Scheme 2.32).  
 
 
Scheme 2.32 Generation of Fab homodimer via CuAAC reaction. 
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Figure 2.35 SDS-PAGE analysis of generation of Fab homodimer at rt. Lane 1 contains 
azide  functionalised  Fab  left  overnight  at  rt.  Lane  2  contains  linear  alkyne 
functionalised  Fab  left  overnight  at  rt.  Lane  3  contains  2:1  mixture  of  azide 
functionalised Fab to linear alkyne functionalised Fab under CuAAC conditions 0 h, rt. 
Lane 4 contains reaction sample after 1 h, rt. Lane 5 contains reaction sample after 
leaving overnight at rt.  
 
The results of the Fab-Fab conjugation via a CuAAC approach shown in Figure 2.35 
reveal the same two bands that were observed in Figure 2.30 using the SPAAC method. 
However, in this case the same bands could not be seen for the alkyne functionalised 
Fab control. This suggests that the linear alkyne linkers 46 and 47 do not cause non-
specific protein binding under the reaction conditions, unlike the strained alkyne linkers 
42 and 43. Furthermore, this indicates that the bands observed in lanes 3 to 5 of Figure 
2.35  are  a  result  of  CuAAC  between  azide  and  linear  alkyne  functionalised  Fab 
fragments.  
 
The  results  observed  in  Figure  2.35  are  representative  of  several  attempts  at  Fab 
dimerisation using the copper-catalysed click disulfide bridging linkers. Using a 2:1 
ratio of azide:alkyne (100 µM) overnight at room temperature produced the greatest 
yield of the two observed product bands (lane 5).  Again however, these two bands were 
not anticipated; dimerisation of Fab fragments would be expected to result in a band at 
~100  kDa.  The  identity  of  the  two  bands  is  unclear,  though  perhaps  related  to  the 
unusual result of selective heavy chain PEGylation observed in Figures 2.32 and 2.34. 
These results will be discussed further in Section 2.3.4.  
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2.3  Synthesis and application of a disulfide to disulfide linker 
 
The  conjugation  of  two  antibody  fragments  site-specifically  modified  with  a 
bioorthogonal  handle  was  rapidly  proving  a  problematic,  low  yielding  approach  to 
homogeneous  antibody-antibody  conjugate  production.  In  tandem  to  this  work, 
homobifunctional 3,4-substituted maleimide linkers for the direct conjugation of two 
antibody fragment disulfide bonds were also designed and developed. It was anticipated 
that the issues identified by conjugation attempts in the project thus far would aid the 
progress of this simple approach.  
 
2.3.1  Synthesis of homobifunctional linkers 
The linker design is simple; two disubstituted maleimides linked by a PEG chain to 
confer some flexibility and solubility to the molecule. The conjugation attempts thus far 
have indicated that it is difficult to obtain good yields using a site-specific approach, as 
the opportunity for reaction partners to meet is low. To determine if linker length can 
improve  these  yields,  commercially  available  homogeneous  PEG  chains  of  distinct 
length were sought. Two diamine PEGs of distinct length were identified, and used to 
readily  synthesise  the  bis-dibromomaleimide  (BDBM)  cross-linker  molecules  thus 
termed BDBM(PEG)2 and BDBM(PEG)19 (Scheme 2.33).  
 
 
Scheme  2.33  Reagents  and  conditions:  (a)  MeOCOCl,  NMM,  THF;  (b)  For 
BDBM(PEG)2:  NH2CH2CH2(OCH2CH2)2NH2,  DCM,  20  min.  For  BDBM(PEG)19: 
NH2CH2CH2(OCH2CH2)19NH2, overnight.  
 
The  synthesis  used  the  N-(methoxycarbonyl)-3,4-dibromomaleimide  11  readily 
generated  from  commercially  available  dibromomaleimide  8  in  97%  yield  (Scheme 
2.33). The carbamate 11 could then be taken on directly to react with either diamine 
PEG2 or PEG19 to obtain BDBM(PEG)2 and BDBM(PEG)19 in good yields, 70% and 
65% respectively. This two-step reaction thus required only a single purification step.  
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2.3.2  Generation of scFv homodimer 
To  examine  the  feasibility  of  using  bis-dibromomaleimide  linkers  to  produce 
homogeneous antibody-antibody conjugate, we decided to first attempt to generate a 
homodimer of the ds-scFv fragment (Scheme 2.34).  
 
 
Scheme  2.34  Generation  of  scFv  homodimer  using  linkers  BDBM(PEG)2  and 
BDBM(PEG)19.  
 
For  the  production  of  homodimer,  a  stepwise  protocol  was  adopted;  the  scFv  was 
reduced with DTT (20 equivalents) and following buffer exchange, incubated with 0.5 
equiv  of  linker  BDBM(PEG)2  or  BDBM(PEG)19.  The  conjugation  reaction  was 
monitored by SDS-PAGE, and a distinct band at ~50 kDa was observed on incubation 
of BDBM(PEG)19  with reduced scFv after only 1 h at room temperature (Figure 2.36). 
This corresponds to the molecular weight of scFv dimer. In contrast, the reduced scFv 
incubated with linker BDBM(PEG)2, although re-bridged, reveals only a faint band at 
~50 kDa, suggesting poor dimer formation.  
 
Figure  2.36  SDS-PAGE  analysis  of  initial  investigation  into  the  formation  of  scFv 
homodimer with linkers BDBM(PEG)2 and BDBM(PEG)19. Lane 1 contains protein 
ladder  in  kDa  (New  England  Biolabs).  Lane  2  contains  unmodified  scFv.  Lane  3 
contains scFv + DTT to afford reduced scFv. Lane 4 contains reduced scFv (after buffer 
exchange)  left  for  duration  of  experiment.  Lane  5  contains  reduced  scFv  + 
BDBM(PEG)2 to afford mainly disulfide bridged scFv (~25 kDa).  Lane 6 contains  
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reduced scFv + BDBM(PEG)19 to afford scFv homodimer (~50 kDa) and disulfide 
bridged scFv monomer (~25 kDa). Lane 7 contains a sample from lane 4 + reducing 
loading buffer. Lane 8 contains a sample from lane 5 + reducing loading buffer.  
 
The longer length of linker BDBM(PEG)19 (19 PEG units, ~1 kDa), in combination 
with its flexibility, is likely to significantly reduce the steric hindrance which creates 
difficulty when attempting to link two large proteins. This is observed in the far greater 
conversion to homodimer obtained compared to linker BDBM(PEG)2 (Figure 2.36). It 
was  therefore  decided  that  conditions  for  homogeneous  protein-protein  conjugation 
should  be optimised using linker BDBM(PEG)19.  Generation of homogeneous  scFv 
dimer  was  further  pursued  in  order  to  determine  ideal  conditions  for  maintaining 
antibody fragments in their reduced form whilst promoting bridging. 
 
Following reduction, the scFv was eluted over a sephadex column to remove DTT and 
to  buffer  exchange  the  protein  into  conditions  suitable  for  maintaining  the  reduced 
antibody. As discussed in Section 2.1 and 2.2, the disulfide bond of the scFv fragment 
rapidly re-forms in the absence of reducing agent. In the literature, reduced antibodies 
are often transferred into phosphate buffers containing up to 10 mM EDTA (121). To 
determine  the  ideal  buffer  conditions  for  maintaining  the  reduced  scFv  fragment  a 
number of phosphate buffer concentrations (10-40 mM) with varying levels of EDTA 
(1-10 mM) were investigated. This study established that a 20 mM phosphate buffer 
containing 5 mM EDTA, pH 7.4 was sufficient for maintaining the reduced scFv for 
these conjugation reactions. 
 
Following purification, the antibody fragment was concentrated to no greater than 1 
mg/ml; higher concentrations promoted disulfide re-oxidation, as observed in Section 
2.1.  A series of optimisation experiments revealed incubation with 0.42 equiv of bis-
dibromomaleimide cross-linker BDBM(PEG)19 for 1 h at room temperature, or 4°C 
overnight, yielded the highest levels of homogeneous dimer (Figure 2.37).   
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Figure  2.37 SDS-PAGE analysis of scFv homodimer  yield  optimisation  by varying 
equivalents  of  linker  BDBM(PEG)19.  Lane  1  contains  protein  ladder  in  kDa  (New 
England Biolabs). Lane 2 contains reduced scFv. Lane 3 contains scFv + 0.42 equiv. 
BDBM(PEG)19. Lane 4 contains scFv + 0.5 equiv. BDBM(PEG)19. Lane 5 contains 
scFv + 1.0 equiv. BDBM(PEG)19. Lane 6 contains scFv + 2.0 equiv. BDBM(PEG)19. 
 
After  optimisation,  the  reaction  was  repeated  using  1  mg  of  scFv  and  SDS-PAGE 
analysis revealed that after 1 h approximately 80% of starting material was consumed 
(Figure 2.38[i], measured using ImageJ). After purification of the homodimer by size 
exclusion chromatography, an excellent 64% yield of pure, homogeneous scFv-scFv 
conjugate was obtained from 1 mg of scFv (Figure 2.38[iii], 75% yield with respect to 
the limiting reagent BDBM(PEG)19). This yield represents a significant improvement 
on previous reports of direct chemical cross-linking of antibodies using natural amino 
acids,  which  have  achieved  yields  in  the  10-40%  range  (198-201).  Notably  the 
conjugate is homogeneous due to the site-selectivity of the methodology.  
 
Figure 2.38 Application of optimised conditions to large scale dimerisation of scFv: [i] 
SDS-PAGE analysis: Lane 1 contains protein ladder in kDa (New England Biolabs). 
Lane 2 contains unmodified scFv. Lane 3 contains scFv + 20 equiv DTT to afford 
reduced scFv. Lane 4 contains reduced scFv + 0.42 equiv BDBM(PEG)19, 1h rt to  
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afford scFv homodimer (~50 kDa) and disulfide bridged scFv monomer (~25 kDa). [ii] 
Size exclusion chromatography purification of pure scFv homodimer (peak a, ~50 kDa) 
from monomer starting materials (peak b) and unreacted linker (peak c) (Superdex 75, 
GE Healthcare).  
 
Having successfully brought together two scFv fragments homogeneously in excellent 
yield  using  linker  BDBM(PEG)19,  a  strategy  was  subsequently  developed  to  bring 
together two scFv fragments with different target antigens. It was envisaged that this 
technology could be used to generate BiTEs (Bispecific T-cell Engager). The anti-CEA 
ds-scFv fragment was used to develop this method of producing scFv based bispecifics 
alone, as it is readily available from our collaborators (Scheme 2.35).  
 
 
Scheme 2.35 Developing a method suitable for bispecific production using the ds-scFv 
fragment. 
 
Production of bispecific constructs using this technology first requires a single antibody 
fragment  to  be  bridged  with  BDBM(PEG)19  and  thus  functionalised  with  a 
dibromomaleimide (Scheme 2.35). A scouting reaction revealed single modification is 
easily  achieved  using  30  equivalents  of  linker  to  antibody  (Figure  2.39).  For  the 
addition  of  the  second  antibody  fragment  to  be  successful,  the  dibromomaleimide 
functionalised  fragment  must  first  be  purified  away  from  any  free  linker.  Desalting 
columns proved ineffective for purification from BDBM(PEG)19, perhaps due to the 
large size of the PEG molecule. The excess linker was however successfully removed 
via buffer exchange (repeated 3 times) using centrifugal ultrafiltration with a 10 kDa 
cut-off (Amicon Ultra-4 Centrifugal Filter Units).  
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Figure  2.39  SDS-PAGE  analysis  of  generation  of  scFv-scFv  conjugate  via  a  route 
suitable for bispecific generation. Lane 1 contains protein ladder in kDa (New England 
Biolabs). Lane 2 contains unmodified scFv. Lane 3 contains reduced scFv. Lane 4 
contains  scFv  bridged  with  BDBM(PEG)19.  Lane  5  contains  scFv  bridged  with 
BDBM(PEG)19  after  purification.  Lane  6  contains  second  reduced  scFv.  Lane  7 
contains reduced scFv (1 mg/ml) + bridged scFv (1 mg/ml) left overnight at 4 °C. Lane 
8 contains reduced scFv (1 mg/ml) + bridged scFv (2 mg/ml) left overnight at 4 °C. 
Lane 9 contains reduced scFv (1 mg/ml) + bridged scFv (3 mg/ml) left overnight at 4 
°C. Lane 10 contains reduced scFv (1 mg/ml) + bridged scFv (4 mg/ml) left overnight 
at 4 °C. 
 
Following purification into conjugation buffer (20 mM phosphate buffer, 5 mM EDTA, 
pH  7.4)  the  dibromomaleimide  functionalised  scFv  was  incubated  with  purified, 
reduced scFv. Using reduced scFv at 1 mg/ml, a variety of bridged scFv concentrations 
and equivalents were trialed to determine the conditions required to obtain the greatest 
yield  of  homogeneous  scFv-scFv  conjugate.  Some  examples  are  included  in  Figure 
2.39.  The  greatest  yield  was  obtained  using  a  3:1  ratio  of  dibromomaleimide 
functionalised scFv to reduced scFv (Figure 2.39, lane 9). This yield could be achieved 
using  a  3:1  ratio  by  either  concentration  or  volume.  Purification  by  size  exclusion 
chromatography  gave a 61%  yield of pure, homogeneous  scFv-scFv  conjugate with 
respect to the limiting reagent, reduced scFv. Note, an excess of reduced scFv over 
bridged  scFv  was  also  attempted,  however  as  expected  this  resulted  in  significant 
reoxidation and formation of reoxidised scFv dimers.  
 
  
 
   
129 
 
   
2.3.3  Generation of a homogeneous bispecific: scFv-Fab heterodimer 
After the successful production of homogeneous scFv homodimer in high yield and the 
development of a strategy towards bispecific conjugates, it was next decided to target 
the generation of a true bispecific. For this it was decided to utilise the Herceptin Fab 
fragment investigated in Section 2.2.5, since it can be readily obtained by enzymatic 
digest and its incorporation into bispecific formats has therapeutic potential (91). Thus it 
was  envisaged  that  the  ds-scFv  could  be  linked  to  the  Fab  fragment  using 
BDBM(PEG)19, generating a conjugate that could simultaneously bind two different 
antigens (CEA and HER2) as a proof of concept (Scheme 2.36).  
 
 
Scheme 2.36 Generation of anti-CEA/anti-HER2 scFv-Fab bispecific. 
 
To  efficiently  link  these  two  different  antibody  fragments,  it  was  decided  to  first 
functionalise the scFv with BDBM(PEG)19, as the Fab fragment was found to reoxidise 
less rapidly than the scFv disulfide. This was cleanly achieved by reducing the scFv as 
previously described, purifying by sephadex column and subsequently adding linker (30 
equivalents).  This  reaction  was  complete  in  less  than  5  min  at  room  temperature, 
yielding dibromomaleimide functionalised scFv in quantitative yield. Excess linker was 
removed by buffer exchange. In tandem to this, the Fab fragment was reduced with 
TCEP (10 equivalents) and purified from reducing agent into the conjugation buffer. 
The  concentrations  of  bridged  scFv  and  reduced  Fab  were  adjusted  to  37.2  µM  (1 
mg/ml for the scFv), and the antibodies mixed in a 2:1 ratio by volume (2.0 equivalents 
bridged scFv to 1.0 equivalent reduced Fab). This slight excess of functionalised scFv 
was found to be sufficient to promote bridging of the reduced Fab. The reaction was 
monitored by SDS-PAGE, and after 1 h at room temperature a strong band at ~80 kDa  
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could  be observed,  corresponding to  the  scFv-Fab  conjugate  (Figure  2.40[i]). After 
purification by size exclusion chromatography, a pleasing 52% yield of homogeneous 
scFv-Fab bispecific was achieved (Figure 2.40[ii]).  
 
 
Figure 2.40 Production of homogeneous scFv-Fab: [i] SDS-PAGE analysis: Lane 1 
contains protein ladder in kDa (New England Biolabs). Lane 2 contains unmodified 
scFv. Lane 3 contains scFv + 20 equiv DTT to afford reduced scFv. Lane 4 contains 
reduced scFv + 30 equiv BDBM(PEG)19 to afford disulfide bridged scFv monomer. 
Lane 5 contains Fab. Lane 6 contains Fab + 10 equiv TCEP to afford component heavy 
and light Fab chains. Lane 7 contains bridged scFv + reduced Fab (2:1), 1 h rt to afford 
scFv-Fab conjugate (~80 kDa), re-oxidised Fab (~50 kDa) and scFv starting material 
(~25  kDa).  [ii]  Size  exclusion  chromatography  purification  of  pure  scFv-Fab 
heterodimer  (peak  a)  from  starting  materials  (peak  b  and  c)  (Superdex  75,  GE 
Healthcare). 
 
 
2.3.4  Generation of Fab homodimer 
It  was  decided  to  next  apply  the  optimised  dimerisation  protocol  to  generate  Fab 
homodimer; many bispecific constructs are based on two Fab fragments and this would 
further demonstrate the scope of our conjugation technology. Using Herceptin Fab, the  
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fragment was reduced with TCEP (10 equivalents) and following purification incubated 
with BDBM(PEG)19 (0.42 equivalents) for 1 h at room temperature (Scheme 2.37). The 
results of this conjugation are shown in Figure 2.41.  
 
 
Scheme 2.37 Generation of Fab homodimer using BDBM(PEG)19. 
 
Figure 2.41 Production of Fab homodimer: [i] SDS-PAGE analysis: Lane 1 contains 
protein ladder in kDa (New England Biolabs). Lane 2 contains unmodified Fab. Lane 3 
contains Fab + 10 equiv TCEP to afford component heavy and light Fab chains. Lane 4 
contains reduced Fab after purification from TCEP. Lane 5 contains reduced Fab left 
for experiment duration. Lane 6 contains Fab + 0.42 equiv BDBM(PEG)19, 1 h rt. [ii] 
Size  exclusion  chromatography  purification  of  Fab-Fab  reaction  to  separate  product 
bands (peak a) from starting material (peak b) (Superdex 75, GE Healthcare).  
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The results of Fab homodimer generation with BDBM(PEG)19 are consistent with those 
observed using the SPAAC and CuAAC linkers; two product bands, ~150 kDa and 
~100 kDa using a 12% gel, are observed (Figure 2.41[i], lane 6). As can be seen in 
Figure  2.41[ii],  size  exclusion  chromatography  (SEC)  purification  of  the  reaction 
mixture resulted in two peaks with the apparent two product bands being inseparable. 
This reaction was repeated with the Fab fragment of Rituximab, an anti-CD20 antibody 
regularly used to treat non-Hodgkin lymphomas. The same result was obtained, ruling 
out the possibility that this result is Herceptin Fab specific.   
 
Given that these two bands are not separable by SEC, the possibility that this unusual 
result may be a result of preparation for SDS-PAGE analysis was tested. Generally 
samples are prepared in SDS and heated to 98 °C for two minutes. In the literature, the 
loss of maleimide-PEG as a result of this high temperature incubation in SDS has been 
described (202). This instability is reported to be avoided by heating samples below 60 
°C.  To  test  this  theory,  the  Fab-Fab  reaction  samples  were  prepared  in  SDS  and 
incubated at room temperature and between 40 to 100 °C for up to 30 min. However, no 
significant  differences  in  these  samples  could  be  observed  by  SDS-PAGE,  each 
contained the two product bands at ~150 kDa and ~100 kDa.   
 
To  investigate  the  formation  of  these  two  bands  further,  variations  of  the  Fab 
dimerisation protocol were tested. For example, the Fab homodimer was generated via 
the two-step approach described in Section 2.3.3, as would be employed to produce a 
Fab-Fab bispecific. Furthermore, an in situ protocol was attempted. Both approaches 
again resulted in the appearance of two product bands by SDS-PAGE. Generation of 
Fab homodimer was also attempted using DTT as the reducing agent to determine if 
TCEP was the cause of this unusual result. However, the same results were observed. 
Fab homodimer reaction samples were left over 5 days to determine if the quantity of 
the two bands changed over this time; no change was observed.  
 
The fractions  collected  from  SEC purification  of the  Fab homodimer  reaction were 
submitted  for  analysis  by  LCMS,  the  deconvoluted  spectra  of  which  are  shown  in 
Figure 2.42.   
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Figure 2.42 Analysis of purified Fab homodimer reaction by LCMS. Spectra [a] and 
[b]  correspond  to  SEC purified  peaks  a  and  b respectively.  SDS-PAGE  analysis  is 
shown for comparison.  
 
As  can  be  seen  in  Figure  2.42,  the  predominant  species  observed  by  LCMS  from 
analysis of SEC product peak a is the expected Fab homodimer at 96344 (calculated 
96324).  The  +20  difference  between  the  observed  and  calculated  mass  of  the  Fab 
homodimer is  likely  to  be due to  hydrolysis of one of the bridging  maleimides.  In 
addition to this peak, a mass of 47746 is observed. This corresponds to a 110 mass 
increase on unmodified Herceptin Fab (unmodified Fab mass is 47636). LCMS analysis 
of peak b reveals masses for the unmodified Fab observed at 47635 and a small amount 
of free Fab heavy and light chain. The presence of free heavy and light chain in peak b 
is not unexpected, as these chains are held together by strong non-covalent interactions 
which although not disturbed by SEC, would dissociate by mass spectrometry analysis. 
In addition to the purified SEC samples, Fab singly-bridged with BDBM(PEG)19 was 
prepared (Scheme 2.38) and analysed by LCMS (Figure 2.43). 
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Scheme 2.38 Generation of Fab singly-bridged with BDBM(PEG)19. 
 
 
Figure  2.43  Analysis  of  singly-bridged  Fab  by  LCMS.  Observed  47747,  expected 
48846.  
 
As can be seen in Figure 2.43, LCMS analysis of singly-bridged Fab yielded a mass of 
47747, rather than the expected 48846. Furthermore, this is the same mass additionally 
observed in analysis of SEC purification peak a (Figure 2.42[a]). Again this mass is 
approximately  110  units  greater  than  unmodified  Herceptin  Fab.  Review  of  the 
literature soon revealed that conventional electrospray ionisation mass spectrometry, as 
employed  here,  normally  leads  to  the  fragmentation  of  PEGs  or  complete 
‘dePEGylation’ from proteins (203). Thus, this unexpected mass result seen for singly-
bridged Fab and the Fab homodimer product is likely to be due to mass spectrometry 
promoted  dePEGylation.  Indeed  the  mass  increase  of  110  on  unmodified  Herceptin 
corresponds to a Fab fragment with dePEGylated maleimide attached.  
 
Analysis of the Fab homodimer reaction by SEC and LCMS indicates that the reaction 
mixture contains the desired Fab homodimer product and unmodified Fab. The SEC 
purification  generates  two  distinct  peaks,  which  elute  at  the  expected  times  for  the 
approximately 100 kDa product and 50 kDa Fab starting material (Figure 2.41). The 
LCMS analysis of these two peaks reveals the mass of the desired Fab homodimer in 
SEC peak a and the unmodified Fab in peak b (Figure 2.42). This evidence strongly  
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suggests that the two product bands observed by SDS-PAGE are a result of the gel 
electrophoresis conditions.  
 
Overall, an excellent 60% yield of pure Fab-Fab conjugate was obtained from 1 mg of 
Fab (71%  yield with respect to the limiting reagent BDBM(PEG)19). The immuno-
reactivity of all three antibody conjugates, the scFv-scFv, Fab-Fab and scFv-Fab, was 
then analysed by ELISA.   
 
2.3.5  Analysis of conjugates by ELISA 
An  enzyme-linked  immunosorbent  assay  (ELISA)  is  a  plate-based  assay  regularly 
employed  for  the  detection  and  quantification  of  proteins.  Typically  an  antigen  is 
immobilised on the surface of a 96-well polystyrene plate, which passively binds to 
protein.  The  antigen  can  then  be  complexed  with  an  antibody-enzyme  conjugate. 
Detection is subsequently achieved through incubation of the conjugated enzyme with a 
substrate to produce a measureable product.  
Having successfully generated scFv and Fab homodimer and an anti-CEA/anti-HER2 
scFv-Fab  bispecific,  it  was  next  decided  to  use  an  ELISA  to  assess  the  immuno-
reactivity of the purified conjugates in comparison to the  unmodified scFv and Fab 
fragments that bound either CEA or HER2 respectively (Figure 2.44[i] and [ii]).  
 
 
 
Figure  2.44  ELISA  analysis  of  conjugates  and  unmodified  antibody  fragments:  [i] 
ELISA against full length CEA. [ii] ELISA against HER2. 
Against  CEA,  the  activity  of  the  scFv  homodimer  was  not  only  maintained,  but 
remained high at low dilutions, suggesting dimerisation has successfully increased the  
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avidity  of  the  antibody  (Figure  2.44[i]).  Pleasingly,  the  Fab  homodimer  also 
demonstrated  an  increase  in  avidity  compared  to  unmodified  Fab  monomer  (Figure 
2.44[ii]).  Most  importantly,  the  scFv-Fab  conjugate  showed  comparable  antigen 
binding activity against both CEA and HER2 (Figure 2.44[i] and [ii]).  
Given this success, the next target was to demonstrate that our heterodimeric conjugate 
could simultaneously bind its two target antigens. To achieve this, a sandwich ELISA 
was developed (Figure 2.45[i]). A 96-well plate was coated with CEA and the sample 
to be tested, e.g. scFv-Fab conjugate, was applied. Subsequent incubation with HER2-
Biotin  and  Extravadin-Peroxidase  would  thus  only  lead  to  a  signal  if  the  sample 
successfully bound both CEA and HER2 antigens. Pleasingly, simultaneous binding 
activity was confirmed (Figure 2.45[ii]).  Hence a homogeneous antibody conjugate 
with  bispecific  ability  has  successfully  been  produced  using  our  disulfide-bridging 
technology.  
 
 
Figure  2.45  Sandwich  ELISA  using  [i]  full  length  CEA  coated  plates  and  HER2 
conjugated to Biotin, followed by Extravadin-Peroxidase. [ii] ELISA results. 
 
2.3.6  Analysis of conjugates by FACS 
 
Fluorescence activated cell-sorting (FACS) is a type of flow cytometry, described in 
Section 1.7.3. In a final investigation, FACS was used to assess the binding of our scFv 
homodimer  and  scFv-Fab  bispecific  to  a  CEA-positive  cell  line,  A375  CEA,  and  a  
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HER2-positive cell line, BT-474. The monomer controls in Figure 2.46 demonstrate 
that anti-CEA scFv binds only to A375CEA cells and anti-HER2 Fab only to BT474 
cells  (full  set  of  controls  in  Section  4.7.10).  Application  of  our  scFv  homodimer 
conjugate  reveals  that  CEA  binding  activity  and  selectively  is  maintained  after 
conjugation, with a shift in fluorescence being observed only on the A375CEA cell line 
(Figure 2.46, homodimer). Following this success, we tested our bispecific construct 
(Figure 2.46, heterodimer). In this case, scFv and Fab were detected both in the CEA-
positive cell line A375CEA and the HER2-positive BT474. This demonstrates that the 
antibody fragments have maintained their distinct selectivity and binding activity  in 
vitro, whilst being successfully chemically linked.  
 
Figure  2.46  Flow  cytometry  based  binding  assay  of  unmodified  scFv  and  Fab 
(monomer), scFv dimer (homodimer) and scFv-Fab conjugate (heterodimer) to a CEA-
positive cell line (A375CEA) and HER2-positive cell line (BT474). 
 
To date, the generation of bispecifics for the clinic by chemical cross-linking has been 
unsuccessful, due to low yields and product heterogeneity. Here the rapid production of 
two  homogeneous  conjugates  in  high  yield  has  been  presented;  an  anti-CEA  scFv 
homodimer and an anti-CEA/anti-HER2 scFv-Fab heterodimer. A third conjugate, anti-
HER2 Fab homodimer has also been generated, which appears to be a single product by 
SEC  and  LCMS  analysis,  although  the  SDS-PAGE  results  remain  unclear.  These 
conjugates  have  been  achieved  using  a  bis-dibromomaleimide  PEG  linker,  readily 
synthesised  over  two  steps  from  the  commercially  available  dibromomaleimide. 
Through targeting and bridging the disulfide bond of antibody fragments, the conjugates 
produced exhibit retention of activity by ELISA and cell binding assays. This platform 
has the potential to enable the facile generation of bispecifics from a range of antibody  
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fragment formats, and could be readily translated to other protein conjugates of choice, 
exploiting the versatility of the chemical conjugation approach. 
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2.4  Disulfide bridging for diagnostic applications 
Several  small  side  projects  have  been  carried  out  to  apply  the  disulfide  bridging 
technology described herein to diagnostic applications, and efforts in these areas will 
now be covered.  
 
2.4.1  Functionalisation of a scFv-Fc antibody construct 
ScFv-Fc fusion proteins are widely used full antibody derivatives (Figure 2.47). The 
key advantage of these constructs over conventional monoclonal antibodies is their ease 
of  production;  they  are  generated  by  fusion  of  scFv  fragments  to  the  Fc  region  of 
different  antibody  isotypes  (204).  Hence  only  one  polypeptide  chain  requires 
transfection  and  expression,  simplifying  production.  Furthermore,  they  are  readily 
purified by standard protein A chromatography, mediate the effector functions  of the Fc 
fragment as would the whole antibody and have a lower molecular weight (~105 kDa) 
which can improve their tumour penetrating ability (204).  
 
 
Figure 2.47 Structure of a whole IgG (150 kDa) and a scFv-Fc construct (105 kDa). 
 
Professor Tony Ng’s group (King’s College London) is investigating the use of labelled 
scFv-Fc  constructs  as  tools  for  imaging  protein-protein  interactions  in  patient  cell 
samples. This will be achieved by Fluorescence Resonance Energy Transfer (FRET) 
experiments.  To obtain high-quality FRET data, the acceptor and donor chromophores 
must  be  installed  site-specifically  and  in  a  defined  number,  and  not  affect  the 
biophysical  properties  of  the  proteins  under  investigation  (205).  ScFv-Fc  molecules 
contain only two disulfide bonds, located in the hinge region. Thus, modification of 
these  disulfide  bonds  using  our  next  generation  maleimide  disulfide  bridging 
technology was investigated for FRET application.   
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First, a reduction study of a scFv-Fc construct was pursued using the water-soluble 
reducing agents, TCEP and DTT (Figure 2.48).  
 
Figure 2.48 SDS-PAGE analysis of scFv-Fc reduction study. Lane 1 contains protein 
ladder  in  kDa  (SeeBlue®  Plus2,  Invitrogen).  Lane  2  contains  unmodified  scFv-Fc. 
Lanes 3 to 8 contain scFv-Fc + 3, 5, 8, 12, 20 and 50 equiv TCEP respectively. Lanes 9 
to 14 contain scFv-Fc + 3, 5, 8, 12, 20 and 50 equiv DTT respectively.  
 
DTT was identified as a more effective reducing agent for the scFv-Fc construct (Figure 
2.48).  Following  identification  of  the  appropriate  reduction  conditions,  disulfide 
bridging with dithiophenolmaleimide 9 was attempted. After reduction with DTT, the 
scFv-Fc was buffer exchanged into conjugation buffer (20 mM phosphate buffer, 5 mM 
EDTA, pH 7.4) and varying equivalents of dithiophenolmaleimide added (Figure 2.49).  
 
Figure  2.49  SDS-PAGE  analysis  of  scFv-Fc  disulfide  bridging  with 
dithiophenolmaleimide 9 (represented as red circles). Lane 1 contains reduced scFv-Fc 
left for experiment duration (1 h, over ice). Lanes 2 to 8 contain reduced scFv-Fc with 
2, 3, 4, 5, 8, 12 and 16 equivalents dithiophenolmaleimide respectively (1 h, over ice). 
 
Disulfide bridging using dithiophenolmaleimide worked very effectively, as can be seen 
in Figure 2.49. Using up to 16 equivalents, almost complete bridging is achieved, with 
very little ‘half-antibody’ remaining. Significant yields of incorrectly bridged construct  
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as observed for the hinge region disulfides of full antibody molecules (described in 
Section  1.8.3),  were  not  seen  using  this  scFv-Fc  construct.    The  same  results  were 
obtained using dibromomaleimide 8 for bridging. Knowing that the two disulfide bonds 
of  the  scFv-Fc  construct  could  be  successfully  bridged  using  our  next  generation 
maleimides, a strategy for the introduction of fluorophores was devised.  
 
Many fluorophores of interest are now commercially available as the azide derivative. 
This enables the synthesis of a single molecule for bioconjugation for which the desired 
fluorophore can be attached by click chemistry. In Section 2.2, the rate and efficiency of 
the CuAAC was found to be far beyond its copper-free SPAAC derivative. Thus it was 
decided to functionalise the scFv-Fc construct with a simple linear alkyne. To this end, 
a simple N-alkyne maleimide was generated (Scheme 2.39).  
 
Scheme  2.39  Reagents  and  conditions:  (a)  MeOCOCl,  NMM,  THF;  (b) 
NH2CH2C≡CH, DCM.  
 
The  linear  alkyne  maleimide  48  was  readily  synthesised  from  the  commercially 
available dibromomaleimide 8 via the established carbamate chemistry over two steps 
in an overall 81% yield. This simple N-alkyne dibromomaleimide was then used for 
disulfide  bridging  of  the  reduced  scFv-Fc  construct.  Using  DTT  (20  equivalents) 
followed  by  purification  into  conjugation  buffer,  the  scFv-Fc  was  incubated  with 
alkyne dibromomaleimide 48 (20 equivalents). After 1 h over ice, almost complete 
rebridging to the original scFv-Fc was achieved (Figure 2.50). Only a small amount of 
half-antibody was observed. Note, at this stage it was not investigated if this small 
amount of half-antibody was the incorrectly bridged construct.   
  
 
   
142 
 
   
 
Figure  2.50  SDS-PAGE  analysis  of  scFv-Fc  modification  with  N-alkyne 
dibromomaleimide 50. Lane 1 contains protein ladder in kDa (New England Biolabs). 
Lane  2  contains  unmodified  scFv-Fc.  Lane  3  contains  reduced  scFv-Fc.  Lane  4 
contains reduced scFv-Fc + 48 (20 equivalents). 
 
Following successful installation of two alkyne molecules per scFv-Fc, CuAAC was 
attempted. For this, the azide derivative of the FRET suitable fluorophore Atto-565 
(purchased from ATTO-TEC) was employed. Using the CuAAC conditions developed 
for the Fab fragment in Section 2.2.7, it was found that using 20 equivalents of the azide 
fluorophore for 1 h was sufficient to achieve a fluorophore to protein ratio (F/P) of 2.1 
as measured by UV-Vis. This fluorescent scFv-Fc conjugate is due to be employed by 
Professor Ng’s group.  
 
This work demonstrates the facile transfer of the next generation maleimide disulfide 
bridging  technology  to  other  antibody  constructs,  successfully  generating  a 
homogenously modified product. Modification of scFv-Fc constructs is of particular 
interest to the group as these would provide an excellent platform for the production of 
homogeneous ADCs with the increasingly desired DAR of 2 and significantly reduced 
production cost compared to full antibody constructs (103,149,206).   
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2.4.2  Disulfide bridging for Immuno-PET applications 
As described in Section 1.7.4, immuno-positron emission tomography (PET) facilitates 
non-invasive  tumour  diagnosis.  It  is  also  a  key  technique  in  the  growing  field  of 
theranostics  and  personalised  medicine,  effectively  enabling  “comprehensive 
immunohistochemical  staining  in  vivo”  (207).  Antibody  conjugates  prepared  for 
immuno-PET  imaging  currently  rely  on  conventional  modification  methods  which 
target lysine residues or cysteines, released through the reduction of interchain disulfide 
bonds. As discussed in Section 1.8, these approaches result in a heterogeneous mixture 
of conjugated antibody products, with variable numbers of chelators and different sites 
of attachment which can have a detrimental impact on the biophysical properties of the 
targeting  antibody.  In  collaboration  with  Professor  Philip  Blower’s  group  at  King’s 
College London, the application of the disulfide bridging technology described herein to 
full  antibodies  and  antibody  fragments  for  immuno-PET  applications  is  being 
investigated.  
 
Antibody  labelling  with  a  suitable  positron  emitter  such  as  zirconium-89  (
89Zr)  or 
gallium-67 (
67Ga) is generally achieved by first labelling the antibody with a suitable 
chelator.  Initial  investigations  thus  focused  on  a  general  synthetic  route  to  chelator 
functionalised  next  generation  maleimides.  Many  chelators  are  incorporated  into 
structures suitable for protein conjugation via a primary amine. Deferoxamine (DFO) is 
a  commonly  used  chelator  and  is  commercially  available  as  the  mesylate  salt. 
Generation  of  a  DFO  functionalised  disubstituted  maleimide  was  therefore  the  first 
synthetic target.  
 
Synthesis  of  a  DFO  functionalised  disubstituted  maleimide  was  first  attempted  as 
outlined  in  Scheme  2.40.  Using  the  commercially  available  DFO  mesylate  salt  49, 
reaction with the previously described dibromomaleimide carbamate 11 was attempted. 
DFO  is  a  highly  insoluble  compound  and  so  DMF  was  employed  as  the  solvent. 
Nevertheless,  after  24  h  no  reaction  between  DFO  49  and  the  carbamate  11  was 
observed.  This  synthetic  route  was  also  attempted  using  the  dithiophenolmaleimide 
carbamate derivative 27 with up to 3 equivalents NEt3; however the desired product was 
not obtained.  
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Scheme 2.40 Reagents and conditions: (a) NEt3, DMF. 
 
 
As  an  alternative  simple  synthetic  route  to  chelator  functionalised  next  generation 
maleimides, the synthesis in Scheme 2.41 was attempted.  
 
 
Scheme 2.41 Reagents and conditions: (a) AcOH, reflux.  
 
Given  previous  success  on  employing  the  dibromomaleic  anhydride  15,  it  was 
anticipated that the harsher conditions outlined in Scheme 2.41 would readily yield 
dibromomaleimide-DFO 50. This reaction routinely proceeds in acetic acid at reflux. 
On heating, the DFO mesylate 49 dissolved in acetic acid at approximately 65 °C. 
However, at reflux the reaction mixture rapidly changed to dark brown/black colour. 
TLC analysis of the solution revealed many spots, suggesting breakdown of the DFO 
compound. At temperatures slightly below reflux the same effect was observed.   
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In the literature, DFO conjugation to an antibody has been achieved using traditional 
maleimide chemistry (208). In this case, the DFO primary amine 49 was linked to the 
maleimide via NHS ester chemistry. Thus it was decided to take a similar route, and 
dithiophenolmaleimide-NHS ester linker 19 described in Section 2.1 was employed. 
The synthetic route is shown in Scheme 2.42.  
 
 Scheme 2.42 Reagents and conditions: (a) DIPEA, DMF, H2O.   
 
Using a mixture of DMF and water, dithiophenolmaleimide-NHS ester linker 19, DFO 
mesylate 49 and DIPEA were dissolved and stirred at room temperature for 1 h. After 
this time, water was added and the resulting solution left on ice for 1 h. This caused 
precipitation of the desired dithiophenolmaleimide-DFO product 51, in a good 56% 
yield.   
 
Following  the  successful  synthesis  of  a  DFO  functionalised  next  generation 
maleimide,  a  suitable  disulfide  bridging  protocol  for  combination  with  this 
modification reagent was investigated. Prostate-specific membrane antigen (PSMA) is 
a transmembrane protein expressed in all types of prostatic tissue, and is one of the 
best characterised oncogenic markers. Bridging of the single disulfide bond of an anti-
PSMA ds-scFv provided by Dr Florian Kampmeier (Blower group, King’s College 
London), was attempted. A DFO modified anti-PSMA ds-scFv is of interest to the 
group for immuno-PET imaging.  
 
After establishing that the anti-PSMA ds-scFv had similar reducing properties to the 
anti-CEA ds-scFv employed in the project thus far, a stepwise bridging protocol was 
trialed. The results are shown in Figure 2.51.   
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Figure 2.51 First attempt at anti-PSMA ds-scFv modification using DFO functionalised 
dithiophenolmaleimide 53. [i] SDS-PAGE analysis. Lane 1 is reaction mixture before 
purification by SEC. Lane 2 is post SEC. [ii] LCMS analysis of conjugation. Expected 
28085, obtained 28086.  
 
The  results  in  Figure  2.51  indicate  that  whilst  bridging  was  achieved  using 
dithiophenolmaleimide 51, it was incomplete. This first attempt used 51 dissolved in 
DMF however, the DFO-dithiophenolmaleimide rapidly precipitated out  of solution. 
Even using dilute stocks for modification and heating to 37 °C could not sufficiently 
maintain  this  reagent  for  efficient  conjugation.  Although  dithiophenolmaleimide  51 
does not dissolve well in water, its solubility was found to be slightly improved in 
DMSO. In fact, using a low stock concentration and 20% DMSO in buffer, complete 
modification of the ds-scFv was achieved after 2 h at 37 °C (Figure 2.52).  
 
Figure  2.52  SDS-PAGE  analysis  of  improved  conjugation  between 
dithiophenolmaleimide-DFO 51 and anti-PSMA ds-scFv. Lane 1 is reduced scFv (70  
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µM) + 51 (6 equivalents, 2 mM stock in DMSO) after 2 h at 37 °C to yield bridge scFv. 
Lane 2 is a reduced scFv control.  
 
The successfully DFO modified anti-PSMA scFv is currently undergoing investigation 
as an immuno-PET conjugate. The long-term aim of this collaboration is to synthesise a 
range  of  dithiophenolmaleimide  based  chelators  as  described  in  Scheme  2.42  and 
employ these reagents  for the preparation of full antibody immuno-PET conjugates. 
Successful combining of our disulfide bridging technology with radiometal chelators 
will facilitate the facile production of homogeneous radioimmunoconjugates.   
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3  Summary 
 
In this thesis, a range of 3,4-substituted maleimide based linkers have been designed, 
synthesised and applied towards the development of homogeneous antibody conjugates 
for ADEPT and bispecific therapeutics. Initially, the generation of a disulfide to lysine 
linker for more defined antibody-enzyme conjugates was investigated (Figure 3.1).  It 
was anticipated to provide a significant improvement on existing chemical conjugation 
techniques, as site-specific modification would be achieved at the antibody.  
 
 
Figure 3.1 Synthesised disulfide to lysine linkers. 
 
Selectivity investigations revealed the dithiophenolmaleimide derivative of the disulfide 
to lysine linker to be a promising cross-linker design and so it was applied to the model 
system;  an  anti-CEA  ds-scFv  to  CPG2  antibody-enzyme  conjugate  (Figure  3.2). 
Despite no evidence in the literature of attempting to strictly control and monitor the 
level of lysine modification when generating conjugates, a method for the relatively 
controlled  conjugation  of  two  linker  molecules  per  CPG2  was  achieved.  For  the 
conjugation  of  this  modified  CPG2  to  the  anti-CEA  ds-scFv  fragment,  an  in  situ 
portionwise  reduction  approach  was  developed.  This  required  the  addition  of  the 
reducing agent benzeneselenol in 15 equivalent portions initially and every 20 minutes, 
for up to 1 h, successfully maintaining the antibody in its reduced form to promote 
conjugation.  However,  this  approach  generated  only  very  low  yields  of  the  desired 
scFv-CPG2 conjugate.  
 
 
 
X = Br  Overall 61% yield, 3 steps 
X = SPh  Overall 63% yield, 4 steps 
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Figure 3.2 Desired anti-CEA ds-scFv to CPG2 conjugate through employing a disulfide 
to lysine linker. 
 
This strategy was largely impeded by a competing side reaction; the formation of scFv 
dimer. The dimer was generated as a result of the slow rate of conjugation due to the 
sterically  encumbered  macromolecules  and  the  low  number  of  3,4-substituted 
maleimides with which the scFv cysteines must react. Remaining strategies to improve 
the yield of desired conjugate and decrease scFv dimerisation only served to increase 
product heterogeneity. This investigation demonstrated that the successful production of 
therapeutic antibody-enzyme conjugate would require site-specific conjugation at both 
the antibody and enzyme. For this to be achieved, mutagenesis of the CPG2 enzyme to 
incorporate a single cysteine or disulfide bond would be required. Whilst feasible, the 
focus of this research project shifted attention to consider the linking together of two 
antibody fragments already containing single disulfide bonds, to generate bispecifics.  
 
Generation  of  homogeneous  antibody-antibody  conjugates  via  site-specific  disulfide 
bridging  was  attempted  via  two  main  strategies;  an  indirect  approach,  where  each 
antibody  to  be  conjugated  is  first  modified  site-specifically  with  a  chemoselective 
functional group, and a direct approach where one antibody fragment is modified site-
specifically and then directly linked to a second, unmodified fragment.   
 
For the indirect  cross-linking strategy, disulfide bridging linkers for participation in 
strain-promoted  and  copper-catalysed  azide-alkyne  cycloadditions  were  synthesised 
(Figure 3.3). Both reactions held advantages; the SPAAC is simple, eliminating the 
requirement for copper, whereas the CuAAC alkyne linker is readily synthesised and 
has a considerably greater rate of reaction. All of the synthesised bioorthogonal linkers 
displayed efficient and quantitative bridging of scFv and Fab antibody fragments. In 
addition, the azide and alkyne functionalities were demonstrated to be excellent site-
specific  chemical  handles  for  the  installation  of  small  molecules,  for  example 
fluorophores, on to the antibody.   
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Figure 3.3 3,4-substituted maleimide linkers synthesised with azide, strained alkyne 
and linear alkyne functionalities suitable for SPAAC and CuAAC reactions.  
 
Despite  success  site-specifically  conjugating  small  molecules  to  antibody  fragments 
using the SPAAC and CuAAC linkers, joining together two antibody fragments through 
this  bioorthogonal  approach  proved  troublesome.  The  high  concentrations  and  long 
reaction  times  required  to  promote  the  SPAAC  reaction  between  two  antibody 
fragments resulted in significant protein aggregation. The strained alkyne component 
itself  was  found  to  be  unstable  under  conditions  suitable  for  antibody-antibody 
conjugation. The CuAAC reaction in comparison was found to be much more efficient; 
Herceptin  Fab  was  readily  modified  with  large  PEG  molecules  within  1  h  at  room 
temperature. However, this reaction also required a large excess of either the azide or 
alkyne component to proceed to completion and was not readily compatible with the 
scFv fragment, the His tag of which immobilised the essential copper catalyst.  
 
In  tandem  to  the  indirect  cross-linking  strategy,  homobifunctional  3,4-substituted 
maleimide linkers for the direct conjugation of two antibody fragment disulfide bonds 
were also designed and developed. The conjugation attempts thus far have indicated that 
X = Br  Overall 76% yield, 2 steps 
X = SPh  Overall 58% yield, 3 steps 
X = Br  Overall 10% yield, 7 steps (LLS) 
X = SPh  Overall 18% yield, 7 steps (LLS) 
X = Br  Overall 64% yield, 2 steps (LLS) 
X = SPh  Overall 66% yield, 2 steps (LLS) 
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it is difficult to obtain good yields using a site-specific approach, as the opportunity for 
reaction partners to meet is low. To determine if linker length can improve these yields, 
two bis-dibromomaleimide linkers of distinct length were synthesised (Figure 3.4).   
 
 
Figure 3.4 Synthesised bis-dibromomaleimide cross-linkers. 
 
The issues identified by conjugation attempts in the project thus far aided the rapid 
progress of this simple direct conjugation approach. Optimisation experiments yielded 
ideal  buffer  conditions  to  preserve  antibody  fragments  in  their  reduced  form,  and 
maintaining reduced antibody concentrations below 1 mg/ml prevented unwanted side 
reactions. These improved conditions revealed not only that the disulfide to disulfide 
linkers are very effective in generating homogenous antibody-antibody conjugate, but 
also that linker length has a significant effect on conjugate yield. In fact, using linker 
BDBM(PEG)19, a 64% yield of pure, homogeneous scFv-scFv from 1 mg scFv was 
achieved  (75%  with  respect  to  the  limiting  reagent  BDBM(PEG)19).  This  yield 
represents  a  substantial  improvement  on  previous  reports  of  direct  chemical  cross-
linking of antibodies using natural amino acids, which have achieved yields in the 10-
40% range (193-196). Notably the conjugate is homogeneous due to the site-selectivity 
of the methodology.   
 
Following  the  successful  generation  of  homogeneous  scFv  homodimer,  the 
BDBM(PEG)19 linker technology was also applied to the generation of a true bispecific 
(Scheme 3.1).  Through first site-selectively functionalising the anti-CEA scFv fragment 
with  a  single  dibromomaleimide,  anti-HER2  reduced  Fab  could  be  conjugated  by 
Overall 70% yield, 2 steps  
Overall 65% yield, 2 steps  
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disulfide  bridging  to  generate  a  site-specific,  homogeneous  anti-CEA/anti-HER2 
bispecific in 52% yield after purification.  
 
 
Scheme  3.1  Generation  of  anti-CEA/anti-HER2  scFv-Fab  bispecific  using  bis-
dibromomaleimide cross-linker.  
 
The  direct  conjugation  approach  using  bis-dibromomaleimide  linker  BDBM(PEG)19 
represents the first example of homogeneous bispecific production through modification 
of naturally occurring amino acids. Through targeting and bridging the disulfide bond of 
antibody  fragments,  site-specificity  was  achieved  whilst  retaining  antibody  binding 
activity, as demonstrated by ELISA and cell binding assays. Furthermore, a sandwich 
ELISA was designed and developed which successfully demonstrated the ability of the 
anti-CEA/anti-HER2 construct to bind both of its antigen targets simultaneously. This 
direct conjugation approach by disulfide bridging thus delivers as an exciting chemical 
tool for the production of homogeneous bispecific therapeutics.  
3.1  Future outlook  
 
The research presented in this thesis demonstrates the facile transfer of our disulfide 
bridging technology to a variety of antibody fragments and constructs. The efficiency 
and site-selectivity of next generation maleimide bridging has facilitated the production 
of antibody-antibody conjugates homogeneously and in high yield. Having successfully 
created  a  bispecific  with  maintained  antigen  binding  activity  and  demonstrated  true 
bispecificity, application of the bis-dibromomaleimide cross-linker to the generation of 
a clinically relevant bispecific construct would be an exciting next step. Key to this 
would be the production of a bispecific T-cell engager (BiTE). Research into these  
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constructs has not yet established the ideal length of the cytolytic synapse generated by 
BiTEs  (see  Section  1.6).      Using  the  bis-dibromomaleimide  cross-linker  design,  a 
variety of different length PEG spacers could be readily incorporated between the two 
bridging maleimides. This would enable the rapid production of homogeneous BiTE 
constructs with an assortment of spacer lengths, enabling the cell-killing efficiency of 
the resulting cytolytic synapses to be readily compared. Indeed, the greater flexibility 
and  rapid  production  of  antibody  conjugates  offered  by  this  chemical  conjugation 
approach provides a distinct advantage over recombinant protein synthesis.   
 
The attempted construction of an improved antibody-enzyme conjugate suitable for the 
therapeutic system ADEPT revealed that success of this approach would require site-
specificity at both the antibody and enzyme. In the case of CPG2, which contains no 
disulfide bonds or free cysteine residues, the ideal solution would be to introduce a 
single  cysteine  residue  at  a  defined  site  by  mutagenesis.  This  would  indeed  be  the 
simplest approach for many antibody-protein conjugates where a disulfide or cysteine 
residue is not naturally available in the protein. Therefore, as a necessary next step the 
applicability of the bis-dibromomaleimides to disulfide to cysteine conjugation should 
be  investigated,  as  this  would  provide  a  valuable  tool  for  homogeneous  antibody-
enzyme conjugate production and more generally for antibody-protein conjugates.  
 
Having  successfully  linked  two  antibody  fragments  homogeneously  using  our  next 
generation  maleimides,  an  exciting  further  extension  of  this  work  would  be  the 
construction of triconjugates. Through installing a third point of attachment within the 
bis-dibromomaleimide linker design, this would open the door to a valuable and novel 
range of conjugates.  
 
In conclusion, the versatility of the next generation maleimides in antibody bridging 
combined with  the simplicity of the  bis-dibromomaleimide linker approach  yields  a 
huge variety of options for development of this technology. It is hoped that the bis-
dibromomaleimide cross-linkers will become an essential part of the protein chemists 
modification ‘toolbox’, realising the full potential of this efficient and simple approach.  
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4  Experimental 
4.1  General Experimental Procedure 
 
Solvents  and  reagents  were  purchased  from  suppliers  and  used  without  any  further 
purification. All petroleum ether used had a boiling point range of 40 to 60 °C unless 
otherwise stated. All reactions were carried out at atmospheric pressure under argon 
with stirring unless otherwise stated. All buffer solutions were prepared with distilled 
water and filter-sterilised. 
 
Normal phase silica gel (BDH) and sand (VWR) were used for flash chromatography. 
All reactions were monitored by thin layer chromatography  (TLC) unless otherwise 
stated. TLC plates pre-coated with silica gel 60 F254 on aluminium (Merck KGaA) were 
used. Visualisation was carried out by absorption of UV light (254 or 365 nm) or by 
dipping with potassium permanganate solution [KMnO4 (1.25 g), Na2CO3 (6.25 g), H2O 
(250 mL)].   
 
Infra-red (IR) spectra were recorded on a Perkin Elmer Spectrum 100 FT-IT Shimidasu 
8700 spectrophotometer. Wavelengths of maximum absorbance (Vmax) are quoted in 
cm
-1,  and  the  abbreviations  s,  br,  m,  w  indicate  sharp,  broad,  medium  and  weak 
absorptions respectively.  
 
1H Nuclear Magnetic Resonance (NMR) spectra were recorded at 400 MHz, 500 MHz 
and  600  MHz  and 
13C  NMR  at  100  MHz,  125  MHz  and  150  MHz  on  a  Bruker 
AMX400,  AMX500  and  AMX600  at  ambient  temperature.  Chemical  shifts  were 
measured in parts per million (ppm) and are quoted as ʴ. Coupling constants, J, are 
quoted in Hertz (Hz) to 1 decimal place. Multiplicities for 
1H are shown as s (singlet), d 
(doublet), t (triplet), q (quartet), quin (quintet), m (multiplet), or a combination of these.  
All  peaks  should  be  taken  as  sharp  unless  otherwise  described.  Where  necessary, 
assignments  were made with  the aid  of DEPT, COSY, HMQC, HMBC or NOESY 
correlation experiments. 
 
High and low resolution mass spectrometry were obtained by the EPSRC UK National 
Mass Spectrometry Facility (NMSF), Swansea or performed at UCL using a VG70 SE 
operating  in  modes  ES,  EI,  FAB  or  CI  (+  or  -)  depending  on  the  sample.  For  the  
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majority of compounds, the purity was determined by accurate mass spectrometry and 
NMR spectroscopic analysis.   
 
Melting points were measured on a Gallenkamp heating block and are not corrected. 
 
Protein conjugation reactions were monitored by 16 or 12% glycine-SDS-PAGE with a 
4% stacking gel under non-reducing conditions unless otherwise stated. A few examples 
employed pre-cast 4-12% Tris-Glycine gels (Novex®).  
4.2  Proteins 
 
Anti-CEA ds-scFv was kindly provided by Maria Livanos and Dr Berend Tolner (UCL 
Cancer Institute) and expressed following literature procedure (170). CPG2 was kindly 
provided by Mologic Ltd and MFECP fusion protein by the Chester and Sharma groups 
(UCL Cancer Institute) and expressed following literature procedure (78). Trastuzumab 
(Herceptin)  was  purchased  from  UCLH  pharmacy.  ScFv-Fc  construct  was  kindly 
provided by Dr Gregory Weitsman, King’s College London (unpublished work). Anti-
PSMA ds-scFv was kindly provided by Dr Florian Kampmeier, King’s College London 
(unpublished work).  
4.3  Abbreviations 
 
Within this text, room temperature is defined as between 19-22 ºC. The term in vacuo 
refers  to  the  removal  of  solvents  by  means  of  evaporation  at  a  reduced  pressure, 
provided by the in-house vacuum or an oil pump, using a Buchi® rotary evaporator. For 
NMR experiments, CDCl3 is fully deuterated chloroform, DMSO is fully deuterated 
(D6) dimethyl sulfoxide, and MeOD is fully deuterated (D4) methanol. Solvents were 
chosen according to the position of solvent peak in spectra and solubility of substrate.  
THF is tetrahydrofuran, DCM is dichloromethane, EtOAc is ethyl acetate, MeOH is 
methanol, petrol is petroleum ether, Et2O is diethyl ether, MeCN is acetonitrile, DMF is 
dimethylformamide and AcOH is acetic acid.  
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4.4  Synthesis 
N-(methoxycarbonyl)-3,4-dibromomaleimide (11)
181 
 
 
 
To a solution of 3,4-dibromomaleimide (1.00 g, 3.92 mmol) and N-methyl morpholine 
(0.43 ml, 3.92 mmol) in THF (35 ml), methyl chloroformate (0.30 ml, 3.92 mmol) was 
added and the reaction stirred for 20 min at room temperature. Then DCM (50 ml) was 
added to dissolve all solids. The organic phase was washed with H2O (3 x 40 ml), dried 
with MgSO4, filtered and concentrated in vacuo to yield 11 as a pale pink solid (1.18 g, 
97%). 
   
m.p. 116 – 118 °C (lit. m.p. 115 – 118 °C)
181; 
1H NMR (500 MHz, CDCl3) ʴ 4.03 (s, 
3H, CH3); 
13C NMR (125 MHz, CDCl3) ʴ 159.7 (C), 147.4 (C), 131.8 (C), 55.2 (CH3); 
IR (solid, cm
-1) 2962 (s), 1765 (s), 1725 (s), 1600 (s); MS (EI) 315 (
81,81M
+, 35), 313 
(
81,79M
+, 75), 310 (
79,79M
+, 35), 283 (45), 190 (75), 131 (100); Exact Mass calculated for 
C6H3NO4
79Br2 310.84233, observed 310.84297 (EI). 
 
3,4-dibromofuran-2,5-dione (15)
182 
 
 
A solution of maleic anhydride (1.50 g, 15.3 mmol), aluminium trichloride (0.30 g, 0.21 
mmol) and bromine (1.57 ml, 30.6 mmol) was heated to 160 °C with stirring in a sealed 
ampule, behind a blast shield, for 20 h. The reaction mixture was then cooled to room 
temperature and carefully opened to air through aqueous K2CO3 solution. EtOAc was 
added and the solid filtered off and repeatedly washed with EtOAc. The filtrate was 
concentrated in vacuo to give 15 as a yellow solid (3.35 g, 86%).  
 
m.p. 108-110ºC, (lit. m.p. 113 – 114 °C)
182; 
13C NMR (125 MHz, CDCl3) ʴ 164.4 (C), 
125.9 (C); IR (solid, cm
-1) 1767 (s), 1591 (m); MS (EI) 258 (
81,81M
+, 40), 255 (
81,79M
+, 
20), 253 (
79,79M
+, 40), 169 (85), 167 (90), 133 (85), 131 (90); Exact Mass calculated for 
C4O3
79Br2 253.82087, observed  253.82040 (EI).  
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4-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-butanoic acid (12) 
 
 
A  mixture  of  γ-aminobutyric  acid  (340  mg,  3.29  mmol)  and  2,3-dibromomaleic 
anhydride 15 (843 mg, 3.29 mmol) in AcOH (30 ml) was heated to reflux for 4 h. The 
AcOH was then removed in vacuo using repeated additions of toluene. EtOAc was 
added  and  the  solid  filtered  and  repeatedly  washed  with  EtOAc.  The  filtrate  was 
concentrated in vacuo to give 12 as a yellow powder (1.02 g, 91%).* 
 
m.p. 101-104ºC; 
1H NMR (500 MHz, MeOD) ʴ 3.65 (t, 2H, J = 6.8, NCH2CH2), 2.33 
(t, 2H, J = 7.1, CH2COOH), 1.87 (quin, 2H, J = 6.9, NCH2CH2); 
13C NMR (125 MHz, 
MeOD) ʴ 176.5 (C), 165.5 (C), 130.3 (C), 39.9 (CH2), 32.0 (CH2), 24.7 (CH2); IR 
(solid, cm
-1) 3479 (w), 2930 (s), 1779 (s), 1704 (s), 1591 (m); MS (EI) 343 (
81,81M
+, 5), 
341 (
81,79M
+, 10), 339 (
79,79M
+, 5), 297 (15), 295 (35), 293 (15), 282 (55), 270 (50), 268 
(100),  266  (50),  133  (55),  131  (50);  Exact  Mass  calculated  for  C8H7O4N
79Br2 
338.87363, observed  338.87323 (EI). 
 
*Note  –  for  smaller  scale  reactions  purification  was  achieved  by  column 
chromatography (1 : 1 EtOAc : Petrol). 
 
 
2,5-dioxopyrrolidin-1-yl 4-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)butanoate (13) 
 
 
 
To a stirred solution of acid 12 (100 mg, 0.293 mmol) and N-hydroxysuccinimide (34 
mg, 0.293 mmol) in EtOAc (3 ml) at 0 °C was added N,N'-dicyclohexylcarbodiimide 
(61 mg, 0.293 mmol). The reaction mixture was allowed to warm to room temperature 
and  stirred  overnight.  The  formed  dicyclohexylurea  was  filtered  off  and  the  filtrate 
concentrated in vacuo. EtOAc (30 ml) was added and the solution washed with aqueous 
saturated NaHCO3 (20 ml), H2O (10 ml) and brine (10 ml). The organic layer was  
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separated and dried over MgSO4. Purification by column chromatography (40% EtOAc 
in petrol) yielded 13 as a fine white powder (100 mg, 78%).  
 
m.p. 149 - 150 ºC; 
1H NMR (600 MHz, CDCl3) ʴ 3.74 (t, 2H, J = 7.2, NCH2), 2.83 (s, 
4H, COCH2CH2CO), 2.66 (t, 2H, J = 7.2, CH2CO), 2.00 (quin, 2H, J = 7.2, NCH2CH2); 
13C NMR (150 MHz, CDCl3) ʴ 169.0 (C), 167.7 (C), 164.0 (C), 129.7 (C), 38.6 (CH2), 
28.5 (CH2), 25.7 (CH2), 23.6 (CH2); IR (solid, cm
-1) 2982 (m), 1781 (m), 1726 (s), 1709 
(s), 1624 (m), 1601 (m) 1574 (m); MS (CI) 441 (
81,81M
+, 10), 439 (
81,79M
+, 25), 437 
(
79,79M
+, 10), 326 (45), 324 (100), 322 (45); Exact Mass calculated for C12H11O6N2
79Br2 
436.89839, observed  436.89830 (CI). 
 
2,2’-((1-(4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-2,5-dioxo-2,5-dihydro-1H-
pyrrole-3,4-diyl)bis(sulfanediyl))dibenzoic acid (16) 
 
 
 
Thiosalicyclic acid (19 mg, 0.122 mmol) in MeCN (1 ml) was added dropwise to a 
stirred solution of NHS ester 13 (28 mg, 0.064 mmol) and potassium acetate (63 mg, 
0.640 mmol) in MeCN (4 ml). After 10 min the solvent was removed in vacuo. The 
remaining solid was purified by column chromatography (gradient elution 30% petrol in 
EtOAc with 1% to 3% AcOH) and 16 was afforded as a bright yellow powder (26 mg, 
70%).  
 
m.p. 165 – 167 °C; 
1H NMR (500 MHz, MeOD) ʴ 7.82 (d, 2H, J = 7.6, Ar-H), 7.36 (m, 
2H, Ar-H), 7.22 (m, 2H, Ar-H), 7.12 (m, 2H, Ar-H), 3.61 (t, 2H, J = 7.2, NCH2), 2.82 
(s, 4H, COCH2CH2CO), 2.71 (t, 2H, J = 7.2, CH2CO), 2.00 (m, 2H, NCH2CH2); 
13C 
NMR (125 MHz, MeOD) ʴ 172.1 (C), 170.0 (C), 169.8 (C), 169.0 (C), 164.0 (C), 138.0 
(C), 133.3 (CH), 133.0 (CH), 132.3 (CH), 132.0 (CH), 128.2 (C), 39.2 (CH2), 29.0 
(CH2), 26.5 (CH2), 24.6 (CH2); IR (solid, cm
-1) 3350 (s, br), 2931 (w), 2471 (br), 2071 
(m), 1703 (m); MS (ES+) 608 ([M+H+Na]
+, 40), 607 ([M+Na]
+, 100), 470 (30), 297  
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(50),  288  (40),  256  (30);  Exact  Mass  calculated  for  C26H20N2O10S2Na    607.0457, 
observed  607.0485 (ES+). 
 
4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-butyric acid (18) 
 
 
 
To acid 12 (72 mg, 0.211 mmol) in MeOH (4 ml) was added NaHCO3 (106 mg, 1.266 
mmol).   Thiophenol (50 µl, 0.486 mmol) in MeOH (1 ml) was then added. After 1 h the 
solvent  was  removed  in  vacuo.  Purification  by  column  chromatography  (gradient 
elution from DCM to 10% MeOH in DCM) yielded 18 as a sticky yellow foam (83 mg, 
99%).  
 
1H NMR (500 MHz, MeOD) ʴ 7.30-7.21 (m, 6H, Ar-H), 7.19-7.13 (m, 4H, Ar-H), 3.55 
(t, 2H, J  = 6.9, NCH2CH2), 2.31 (t, 2H, J  = 7.1, CH2COOH), 1.87 (quin, 2H, J = 7.0, 
NCH2CH2); 
13C NMR (125 MHz, CDCl3) ʴ 176.5 (C), 168.3 (C), 137.2 (C), 132.2 
(CH), 130.0 (CH), 129.2 (CH), 39.3 (CH2), 32.2 (CH2), 25.0 (CH2); IR (oil, cm
-1) 3333 
(s, br), 2946 (w), 2483 (br), 2072 (w), 1703 (m), 1449 (m); MS (EI) 399 (M
+, 15), 218 
(25),  110  (100);  Exact  Mass  calculated  for  C20H17NO4S2  399.05935,  observed  
399.05964 (EI). 
 
2,5-dioxopyrrolidin-1-yl 4-(2,5-dioxo-3,4-bis(phenylthio)-2,5-dihydro-1H-pyrrol-1-
yl)butanoate (19) 
 
 
 
To a stirred solution of acid 18 (415 mg, 1.04 mmol) and N-hydroxysuccinimide (120 
mg, 1.04 mmol) in EtOAc (15 ml) at 0 °C was added N,N'-dicyclohexylcarbodiimide 
(214 mg, 1.04 mmol). The reaction mixture was allowed to warm to room temperature 
and  stirred  overnight.  The  formed  dicyclohexylurea  was  filtered  off  and  the  filtrate 
concentrated in vacuo. EtOAc (20 ml) was added and the solution washed with aqueous 
saturated NaHCO3 (20 ml), H2O (30 ml) and brine (30 ml). The organic layer was  
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separated and dried over MgSO4. Purification by column chromatography (40% EtOAc 
in petrol) yielded 19 as a bright yellow powder (420 mg, 81%).  
 
m.p. 41 – 43 °C; 
1H NMR (600 MHz, CDCl3) ʴ 7.28-7.24 (m, 6H, Ar-H), 7.19-7.08 (m, 
4H, Ar-H), 3.61 (t, 2H, J = 7.2, NCH2), 2.82 (s, 4H, COCH2CH2CO), 2.63 (t, 2H, J = 
7.2, CH2CO), 2.00 (quin, 2H, J = 7.2, NCH2CH2); 
13C NMR (125 MHz, CDCl3) ʴ 169.4 
(C), 167.9 (C), 166.8 (C), 135.6 (C), 131.6 (CH), 129.4 (C), 129.3 (CH), 128.3 (CH), 
37.7 (CH2), 28.5 (CH2), 25.4 (CH2), 23.6 (CH2); IR (solid, cm
-1) 2937 (w), 1738 (s), 
1705 (s); MS (EI): 496 (M
+, 100), 382 (25), 269 (35), 218 (50); Exact Mass calculated 
for C24H20O6N2S2 496.07573, observed  496.07547 (EI). 
 
4.4.1  Selectivity investigation using 1:1 of Linker 13 : Amine  
 
 
Benzylamine (3.76 µl, 0.034 mmol) was added to NHS ester 13 (15 mg, 0.034 mmol) 
stirring in DCM (3 ml). After 2 h the solvent was removed in vacuo. Purification by 
column chromatography (40% EtOAc in petrol) yielded amide 21 as a yellow solid (7.5 
mg, 52%) and diaddition product 22 as a yellow oil (4.5 mg, 29%). Acid 12 was also 
recovered as  a  yellow powder (2.2 mg, 19%) and the data matched that previously 
obtained.  
 
N-benzyl-4-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamide (21) 
 
m.p. 104 – 105 °C; 
1H NMR (500 MHz, CDCl3) ʴ 7.38-7.27 (m, 5H, Ar-H), 5.86 (s, 1H, 
NHCH2), 4.42 (d, 2H, J = 5.7, NHCH2), 3.69 (t, 2H, J = 7.2, NCH2), 2.22 (t, 2H, J =  
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7.2, CH2CO), 2.00 (quin, 2H, J = 7.2, NCH2CH2); 
13C NMR (125 MHz, CDCl3) ʴ 207.1 
(C), 164.0 (C), 138.2 (C), 129.7 (C), 128.9 (CH), 128.0 (CH), 127.7 (CH), 43.9 (CH2), 
39.2 (CH2), 31.0 (CH2), 25.7 (CH2); IR (solid, cm
-1) 2929 (m), 1727 (m); MS (EI) 432 
(
81,81M
+, 20), 430 (
81,79M
+, 40), 428 (
79,79M
+, 20), 324 (35), 268 (30), 149 (25), 106 
(100);  Exact  Mass  calculated  for  C15H14N2O3
79Br2  427.93656,  observed    427.93672 
(EI). 
 
N-benzyl-4-(3-(benzylamino)-4-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)butanamide (22) 
 
1H NMR (500 MHz, CDCl3) ʴ 7.40-7.25 (m, 10H, Ar-H), 6.16 (s, 1H, NHCH2), 5.63 (s, 
1H, NHCH2), 4.84 (d, 2H, J = 6.4, NHCH2), 4.43 (d, 2H, J = 5.7, NHCH2), 3.57 (t, 2H, 
J = 7.2, NCH2), 2.22 (t, 2H, J = 7.2, CH2CO), 2.00 (quin, 2H, J = 7.2, NCH2CH2); 
13C 
NMR (125 MHz, CDCl3) ʴ 207.2 (C), 164.0 (C), 138.2 (C), 136.9 (C), 131.0 (C), 129.2 
(CH), 128.8 (CH), 128.4 (CH), 128.0 (CH), 127.8 (CH), 127.6 (CH), 118.4 (C), 47.1 
(CH2), 43.7 (CH2), 38.0 (CH2), 29.8 (CH2), 25.2 (CH2); IR (solid, cm
-1) 2928 (m), 1719 
(m), 1657 (m); MS (ES+) 481 ([
81M+Na]
+, 20), 478 ([
79M+Na]
+, 100); Exact Mass 
calculated for C22H22N3O3
79BrNa 478.0742, observed  478.0753 (ES+). 
 
4.4.2  Selectivity investigation using 3:1 of Linker 13 : Amine  
 
 
Benzylamine (1.67 µl, 0.015 mmol) was added to NHS ester 13 (20 mg, 0.046 mmol) 
stirring in DCM (5 ml). After 3 h the solvent was removed in vacuo. Purification by 
column chromatography (40% EtOAc in petrol) yielded amide 21 as a yellow solid (4.5  
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mg, 70%) and diaddition product 22 as a yellow oil (1.9 mg, 28%). Data for compounds 
21 and 22 match that given above.  
 
4.4.3  Selectivity investigation using 3:1 of SMCC : Amine  
 
 
Benzylamine  (1.63  µl,  0.015  mmol)  was  added  to  succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) (15 mg, 0.045 mmol) stirring in 
DCM (5 ml). After 1 h the reaction was stopped and the solvent removed in vacuo. 
Purification  by  column  chromatography  (40%  EtOAc  in  petrol)  yielded  a  single 
product, amide 24 as a white solid (4.6 mg, 94%).   
 
N-benzyl-3-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)methyl)cyclohexanecarboxamide (24) 
 
m.p. 187 – 188 °C; 
1H NMR (600 MHz, CDCl3) ʴ 7.33-7.23 (m, 5H, Ar-H), 6.68 (s, 2H, 
CH=CH), 5.77 (s, 1H, NHCH2), 4.41 (m, 2H, NHCH2), 3.36 (d, 2H, J = 7.2, NCH2), 
2.01 (m, 1H,  COCH),  1.91 (m, 2H, CHCH2),  1.70 (m, 2H, CHCH2),  1.47 (m, 2H, 
CHCH2), 1.25 (m, 1H, NCH2CH), 1.01 (m, 2H, CHCH2); 
13C NMR (125 MHz, CDCl3) 
ʴ 175.4 (C), 171.3 (C), 138.5 (C), 134.1 (CH), 129.0 (CH), 127.8 (CH), 127.6 (CH), 
45.3 (CH2), 43.6 (CH2), 43.4 (CH), 36.5 (CH), 29.9 (CH2), 29.0 (CH2); IR (solid, cm
-1) 
3302 (s), 2929 (s), 1720 (s), 1621 (s), 1530 (m); MS (EI) 327 ([M+H]
+, 35), 326 (M
+, 
100); Exact Mass calculated for C19H22N2O3 326.16249, observed  326.16212 (EI). 
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4.4.4  Selectivity investigation using 3:1 of Linker 19 : Amine  
 
 
Benzylamine (1.47 µl, 0.013 mmol) was added to NHS ester 19 (20 mg, 0.040 mmol) 
stirring in DCM (3 ml). After 3 h the solvent was removed in vacuo. Purification by 
column  chromatography  (gradient  elution  from  CHCl3 to  CHCl3 with  0.5% MeOH) 
yielded amide 25 exclusively, as a yellow solid (6 mg, 91%). 
 
N-benzyl-4-(2,5-dioxo-3,4-bis(phenylthio)-2,5-dihydro-1H-pyrrol-1-yl)butanamide 
(25) 
 
m.p. 102 – 104 °C; 
1H NMR (500 MHz, CDCl3) ʴ 7.28-7.19 (m, 15H, Ar-H), 6.01 (bs, 
1H, NHCH2), 4.42 (d, 2H, J = 5.7, NHCH2), 3.57 (t, 2H, J = 6.8, NCH2), 2.16 (t, 2H, J 
= 7.1, CH2CO), 1.95 (quin, 2H, J = 6.8, NCH2CH2); 
13C NMR (125 MHz, CDCl3) ʴ 
171.1 (C), 167.3 (C), 138.3 (C), 136.7 (C), 132.0 (CH), 129.2 (CH), 129.1 (CH), 129.0 
(C), 128.8 (CH), 128.6 (CH), 127.6 (CH), 43.8 (CH2), 38.2 (CH2), 29.8 (CH2), 25.0 
(CH2); IR (solid, cm
-1) 3291 (m), 2930 (m), 1703 (s), 1647 (m); MS (EI): 488 (M
+, 
100),  250  (15);  Exact  Mass  calculated  for  C27H24O3N3S2  488.12229,  observed  
488.12188 (EI). 
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3,4-bis(phenylthio)-1H-pyrrole-2,5-dione (9)
168 
 
 
 
To dibromomaleimide (300 mg, 1.18 mmol) and  NaHCO3 (595 mg, 7.08 mmol) in 
MeOH (20 ml), thiophenol (277 µl, 2.71 mmol) in MeOH (2 ml) was slowly added. The 
reaction was stirred for 30 min at room temperature. The solvent was removed in vacuo 
and the residual material purified by column chromatography (gradient elution from 
10% EtOAc in petrol to 30% EtOAc in petrol) to afford 9 as bright yellow crystals (281 
mg, 76%).  
 
m.p. 104 - 105 °C (lit. m.p. 102 – 104 °C)
168; 
1H NMR (500 MHz, MeOD) ʴ 7.29-7.21 
(m, 6H, Ar-H), 7.16-7.11 (m, 4H, Ar-H); 
13C NMR (125 MHz, MeOD) ʴ 169.3 (C), 
137.6 (C), 132.4 (C), 130.7 (CH), 130.1 (CH), 129.1 (CH); IR (solid, cm
-1) 3275 (m), 
2924 (w), 1764 (m), 1715 (s); MS (EI): 315 ([M+2H]
+, 10), 314 ([M+H]
+, 20), 313 (M
+, 
100),  186  (15);  Exact  Mass  calculated  for  C16H11NO2S2  313.02257,  observed  
313.02274 (EI). 
 
Methyl 2,5-dioxo-3,4-bis(phenylthio)-2,5-dihydro-1H-pyrrole-1-carboxylate (27)
181 
 
 
 
N-Methyl morpholine (183 µl, 1.66 mmol) was added to a stirred solution of 9 (260 mg, 
0.831 mmol) and methyl chloroformate (161 µl, 2.08 mmol) in ethyl acetate (10 ml). 
The reaction mixture was left to stir for 30 min at room temperature. The mixture was 
then washed with water (2 x 20 ml), dried with MgSO4, filtered and concentrated in 
vacuo to yield 27 as a bright yellow powder (300 mg, 97%).  
 
m.p. 111 – 113 °C (lit. m.p. 110 – 112 °C)
181; 
1H NMR (500 MHz, CDCl3) ʴ 7.32-7.22 
(m, 10H, Ar-H), 3.90 (s, 3H, NCH3); 
13C NMR (125 MHz, CDCl3) ʴ 161.8 (C), 147.8 
(C), 137.2 (C), 132.4 (C), 129.5 (C), 129.3 (C), 129.1 (C), 54.4 (CH3); IR (solid, cm
-1) 
1805 (s), 1765 (s) 1720 (s), 1435 (m) 1322 (w); MS (ES+):372 (M
+, 60), 329 (55), 271  
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(35), 270 (50), 269 (100); Exact Mass calculated for C18H13NO4S2 372.0364, observed  
372.0377 (ES+). 
 
1-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-3,4-bis(phenylthio)-1H-pyrrole-2,5-
dione (28) 
 
 
 
11-Azido-3,6,9-trioxaundecan-1-amine  (43  µl,  0.22  mmol)  was  added  to  a  stirred 
solution of 27 (80 mg, 0.22 mmol) in DCM (5 ml), and left to stir for 1 h at room 
temperature. The solvent was then removed in vacuo and the reaction mixture purified 
by column chromatography (gradient elution from 30% petrol in EtOAc to EtOAc) to 
yield 28 as a bright orange oil (45 mg, 78%).  
 
1H NMR (600 MHz, CDCl3) ʴ 7.29-7.22 (m, 6H, Ar-H), 7.20-7.17 (m, 4H, Ar-H), 3.70 
(t,  2H,  J  =  5.4,  NCH2CH2O),  3.67-3.57  (m,  12H,  OCH2),  3.37  (t,  2H,  J  =  5.4, 
CH2CH2N3);  
13C NMR (125 MHz, CDCl3) ʴ 166.9 (C), 138.6 (C), 131.6 (CH), 129.3 
(CH), 128.9 (CH), 70.8 (CH2), 70.4 (CH2), 70.1 (CH2), 67.8 (CH2), 50.8 (CH2), 37.2 
(CH2); IR (oil, cm
-1) 2867 (w), 2098 (m), 1710 (s), 1580 (w), 1527 (w); MS (EI): 515 
([M+H]
+,  20),  514  (M
+,  65),  340  (100),  110  (80);  Exact  Mass  calculated  for 
C24H26N4O5S2 514.13391, observed  514.134269 (EI).  
 
1-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-3,4-dibromo-1H-pyrrole-2,5-dione 
(29)  
 
1-Azido-3,6,9-trioxaundecan-1-amine  (63  µl,  0.32  mmol)  was  added  to  a  stirred 
solution of carbamate dibromomaleimide 11 (100 mg, 0.32 mmol) in DCM (5 ml). The 
mixture  was  stirred  at  room  temperature  for  3  h.  After  this  time  the  solvent  was 
removed in vacuo and the mixture purified by column chromatography (30% EtOAc in 
petrol) to yield 29 as a pale yellow oil (113 mg, 78%).  
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1H NMR (500 MHz, CDCl3) ʴ 3.79 (t, 2H, J = 5.6, NCH2), 3.65-3.58 (m, 12H, 6 x 
OCH2), 3.36 (t, 2H, J = 5.6, CH2N3); 
13C NMR (125 MHz, CDCl3) ʴ 163.8 (C), 129.5 
(C), 70.7 (CH2), 70.1 (CH2), 67.6 (CH2), 50.8 (CH2), 39.0 (CH2); IR (oil, cm
-1) 3492 
(br), 2867 (m), 2097 (s), 1786 (s), 1720 (s); MS (EI): 476 ([
81,81M+NH4]
+, 50), 474 
([
81,79M+NH4]
+, 100),  472 ([
79,79M+NH4]
+, 50), 282 (10); Exact Mass calculated for 
[C12H16
81,79Br2N4O5+NH4] 473.9806, observed  473.9799 (EI).  
 
Exo- and endo-ethyl bicyclo[6.1.0]non-4-ene-9-carboxylate (31)
139 
 
 
To a solution of 1,5-cyclooctadiene (19.6 ml, 160 mmol) and Rh2(OAc)4 (190 mg, 0.86 
mmol) in DCM (10 ml) was added dropwise a solution of ethyl diazoactetate (2.10 ml, 
20  mmol)  in  DCM  (10  ml)  over  3  h.  The  solution  was  stirred  for  40  h  at  room 
temperature. The solvent was then removed in vacuo and the excess cyclooctadiene 
removed  by  a  short  plug  of  silica  with  petrol.  Separation  of  the  diastereomers  was 
achieved by column chromatography (gradient elution from 1% Et2O in petrol to 5% 
Et2O in petrol) to yield exo-31 (1.13 g, 29%) and endo-31 (2.10 g, 54%) as colourless 
oils.  
 
Exo-31 
 
1H NMR (500 MHz, CDCl3) ʴ 5.64 (m, 2H, H-1), 4.13 (q, 2H, J = 7.1, OCH2CH3), 2.28 
(m, 2H, HH-2), 2.18 (m, 2H, HH-2), 2.10 (m, 2H, HH-3), 1.56 (m, 2H, HH-3), 1.48 (m, 
2H, H-4), 1.25 (t, 3H, J = 7.1, CH2CH3), 1.19 (t, 1H, J = 4.7, H-5); 
13C NMR (125 
MHz, CDCl3) ʴ 174.5 (C), 130.0 (C), 60.3 (CH2), 28.3 (CH2), 28.0 (CH), 27.8 (CH), 
26.7 (CH2), 14.4 (CH3); IR (oil, cm
-1) 2935 (w), 1719 (s); MS (EI): 194 (M
+, 15), 121 
(95),  79  (90),  67  (100);  Exact  Mass  calculated  for  C12H18O2  194.13013,  observed  
194.129448 (EI).  
 
 
Endo-31 
 
1H NMR (500 MHz, CDCl3) ʴ 5.58 (m, 2H, H-1), 4.11 (q, 2H, J = 7.1, OCH2CH3), 2.46 
(m, 2H, HH-2), 2.16 (m, 2H, HH-2), 2.05 (m, 2H, HH-3), 1.79 (m, 2H, HH-3), 1.68 (t,  
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1H, J = 8.7, H-5), 1.37 (m, 2H, H-4), 1.25 (t, 3H, J = 7.1, CH2CH3); 
13C NMR (125 
MHz, CDCl3) ʴ 172.3 (C), 130.0 (C), 60.3 (CH2), 27.0 (CH2), 24.2 (CH), 22.7 (CH), 
21.2 (CH2), 14.4 (CH3).  
 
Exo-bicyclo[6.1.0]non-4-yn-9-ylmethanol (32)
139 
 
 
 
To a suspension of LiAlH4 (78 mg, 2.06 mmol) in Et2O (8 ml) was added dropwise at 0 
°C a solution of exo-31 (400 mg, 2.06 mmol) in Et2O (8 ml). The suspension was stirred 
at room temperature for 15 min, and then cooled down to 0 °C. Water was carefully 
added until the grey suspension turned white. The mixture was then washed with Et2O 
(150 ml) and dried with Na2SO4. The filtrate was concentrated in vacuo.  
 
Without further purification the alcohol was  dissolved in  DCM (15 ml). At 0 °C a 
solution of bromine (146 µl, 2.83 mmol) in DCM (2 ml) was added dropwise. The 
reaction mixture was stirred for 15 min at room temperature and then quenched with 
10% Na2S2O3 solution (5 ml), extracted with DCM (2 x 20 ml) and dried with Na2SO4. 
The  organic  layers  were  concentrated  in  vacuo  to  afford  the  dibromide  (639  mg, 
quantitative).  
 
Without further purification the dibromide (570 mg, 1.83 mmol) was dissolved in dry 
THF (20 ml). A solution of KOtBu (7.3 ml, 1M in THF) was added dropwise at 0°C. 
The solution was heated at reflux for 3 h. After cooling down to room temperature the 
mixture was quenched with saturated NH4Cl solution (20 ml) and extracted with DCM 
(3 x 20 ml). The organic layers were combined, dried with Na2SO4 and concentrated in 
vacuo. The residue was purified by column chromatography (gradient elution from 10% 
EtOAc in petrol to 80% EtOAc in petrol) to yield exo-32 as a white solid (130 mg, 
47%).  
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m.p. 63 – 65 °C; 
1H NMR (500 MHz, CDCl3) ʴ 3.50 (d, 2H, J = 6.4, H2-6), 2.36 (m, 
2H, HH-2), 2.22 (m, 2H, HH-2), 2.11 (m, 2H, HH-3), 1.89 (s, 1H, OH), 1.34 (m, 2H, 
HH-3), 0.66 (m, 3H, H-4, H-5); 
13C NMR (125 MHz, CDCl3) ʴ 98.9 (C), 66.4 (CH2), 
29.7 (CH2), 27.1 (CH), 22.6 (CH), 21.8 (CH2); IR (solid, cm
-1) 3323 (w, br), 2994 (m), 
2915 (m); MS: Molecular ion not found. 
 
Endo-bicyclo[6.1.0]non-4-yn-9-ylmethanol (32)
139 
 
 
 
The same procedure used to generate exo-32 was used for endo-32, yielding endo-32 as 
a white solid (110 mg, 58%).  
 
m.p. 63 – 65 °C; 
1H NMR (500 MHz, CDCl3) ʴ 3.69 (d, 2H, J = 7.8, H2-6), 2.21 (m, 
6H, HH-2, HH-3), 1.56 (m, 3H, HH-3, OH), 1.31 (m, 1H, H-5), 0.92 (m, 2H, H-4); 
13C 
NMR (125 MHz, CDCl3) ʴ 99.0 (C), 60.2 (CH2), 29.0 (CH), 21.6 (CH2), 21.4 (CH), 
20.0 (CH2); IR (solid, cm
-1) 3323 (w, br), 2994 (m), 2915 (m); MS: Molecular ion not 
found. 
 
Exo-bicyclo[6.1.0]non-4-yn-9-ylmethyl(4-nitrophenyl)carbonate (33)
139 
 
 
To a solution of exo-32 (100 mg, 0.67 mmol) in DCM (15 ml) was added pyridine (135 
µl, 1.66 mmol) and 4-nitrophenyl chloroformate (168 mg, 0.83 mmol). The mixture was 
stirred  for  30  min  at  room  temperature  and  then  quenched  with  saturated  NH4Cl 
solution  (10  ml)  and  extracted  with  DCM  (2  x  20  ml).  The  organic  layers  were 
combined, dried with Na2SO4 and concentrated in vacuo. The residue was purified by  
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column chromatography (10% EtOAc in petrol) to afford exo-33 as a white solid (140 
mg, 67%).  
 
m.p. 69 - 72 °C; 
1H NMR (500 MHz, CDCl3) ʴ 8.23 (d, 2H, J = 8.6, Ar-H), 7.37 (d, 2H, 
J = 8.6, Ar-H), 4.18 (d, 2H, J = 6.9, H2-6), 2.40 (m, 2H, HH-2),  2.24 (m, 2H, HH-2), 
2.13 (m, 2H, HH-3), 1.22 (m, 2H, HH-3), 0.82 (m, 3H, H-4, H-5); 
13C NMR (125 MHz, 
CDCl3) ʴ 155.6 (C), 152.6 (C), 145.2 (C), 125.3 (CH), 122.0 (CH), 98.7 (C), 74.0 
(CH2), 33.0 (CH), 23.6 (CH2), 22.8 (CH), 21.4 (CH2); IR (solid, cm
-1) 2923 (w), 1747 
(m), 1617 (w), 1595 (w), 1518 (m); MS (CI): 316 ([M+H]
+, 10), 272 (15), 214 (55), 140 
(60), 133 (100), 91 (20), 85 (25); Exact Mass calculated for C17H17NO5 316.11849, 
observed  316.11855 (CI).  
 
Endo-bicyclo[6.1.0]non-4-yn-9-ylmethyl(4-nitrophenyl)carbonate (33)
139 
 
 
The same procedure used to generate exo-33 was used for endo-33, yielding endo-33 as 
a white solid (100 mg, 72%).  
 
1H NMR (500 MHz, CDCl3) ʴ 8.26 (d, 2H, J = 8.2, Ar-H), 7.39 (d, 2H, J = 8.2, Ar-H), 
4.39 (d, 2H, J = 8.3, H2-6), 2.23 (m, 6H, HH-2, HH-3,), 1.58 (m, 2H, HH-3), 1.50 (m, 
1H, H-5), 1.10 (m, 2H, H-4); 
13C NMR (125 MHz, CDCl3) ʴ 155.7 (C), 152.6 (C), 
145.4 (C), 125.4 (CH), 121.8 (CH), 98.8 (C), 68.1 (CH2), 29.1 (CH), 21.4 (CH2), 20.6 
(CH2), 17.3 (CH); IR (solid, cm
-1) 2923 (w), 1747 (m), 1617 (w), 1595 (w), 1518 (m); 
MS (CI): 316 ([M+H]
+, 10), 272 (15), 214 (55), 140 (60), 133 (100), 91 (20), 85 (25); 
Exact Mass calculated for C17H17NO5 316.11849, observed  316.11855 (CI).  
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tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (38) 
 
 
 
4,7,10-trioxa-1,3-tridecanediamine (6.7 ml, 30.3 mmol) was dissolved in 1,4-dioxane 
(12 ml) and Boc2O (1.10 g, 5.86 mmol) in 1,4-dioxane (7.5 ml) was added dropwise at 
room temperature over 90 min. The reaction mixture was then stirred for a further 90 
min. The solvent was removed in vacuo and the resulting yellowish oil was dissolved in 
water, extracted with DCM (4 x 25 ml) and the combined organic phases dried with 
MgSO4. The solvent was removed in vacuo to yield 38 as a yellow oil (1.65 g, 93%).  
 
1H NMR (500 MHz, CDCl3) ʴ 5.11 (s, 1H, NH), 3.64-3.53 (m, 12H, OCH2), 3.23 (m, 
2H, NHCH2), 2.79 (t, 2H, J = 6.7, NH2CH2), 1.75 (m, 4H, OCH2CH2CH2O), 1.43 (s, 
9H, C(CH3)3); 
13C NMR (125 MHz, CDCl3) ʴ 155.8 (C), 78.40 (C), 70.32 (CH2), 70.28 
(CH2), 69.93 (CH2), 69.90 (CH2), 69.15 (CH2), 69.10 (CH2), 39.31 (CH2), 38.14 (CH2), 
33.05 (CH2), 29.36 (CH2), 28.17 (CH3); IR (oil, cm
-1) 3360 (w, br), 2930 (m), 2870 (m), 
1704 (s); MS (EI): 320 (M
+, 100), 247 (80), 177 (60), 164 (40), 148 (50), 102 (40), 89 
(50),  75  (35),  56  (30),  43  (50);  Exact  Mass  calculated  for  C15H32N2O5  320.23112, 
observed  320.24556 (EI).  
 
 
tert-butyl(3-(2-(2-(3-(2,5-dioxo-3,4-bis(phenylthio)-2,5-dihydro-1H-pyrrol-1-
yl)propoxy)ethoxy)ethoxy)propyl)carbamate (39) 
 
 
 
 
Monoprotected diamine 38 (50 mg, 0.164 mmol) and triethylamine (23 µl, 0.164 mmol) 
were added to a stirred solution of dithiophenol carbamate maleimide 27 (67 mg, 0.181 
mmol) in chloroform (5 ml). After 30 min silica (100 mg) was added and the reaction 
mixture was stirred for a further 4 h. After filtration, the solvent was removed in vacuo 
and the resulting residue was purified by column chromatography (gradient elution from 
30% EtOAc in petrol to 50% EtOAc in petrol) to yield 39 as an orange oil (71 mg, 
70%).  
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1H NMR (500 MHz, CDCl3) ʴ 7.29-7.23 (m, 6H, Ar-H), 7.21-7.19 (m, 4H, Ar-H), 3.63-
3.56 (m, 8H, OCH2), 3.53 (m, 4H, OCH2), 3.45 (t, 2H, J = 6.0, NHCH2CH2CH2O), 3.20 
(m, 2H, NH2CH2), 1.85 (pent., 2H, J = 6.2, OCH2CH2CH2O), 1.75 (pent., 2H, J = 6.2, 
OCH2CH2CH2O), 1.43 (s, 9H, C(CH3)3); 
13C NMR (125 MHz, CDCl3) ʴ 166.9 (C), 
156.1 (C), 135.8 (C), 132.0 (C), 129.0 (C), 128.4 (C), 78.40 (C), 70.32 (CH2), 70.28 
(CH2), 69.93 (CH2), 69.90 (CH2), 69.15 (CH2), 69.10 (CH2), 39.31 (CH2), 38.14 (CH2), 
33.05 (CH2), 29.36 (CH2), 28.17 (CH3); IR (oil, cm
-1) 3348 (w, br), 2927 (m), 2868 (m), 
1704 (s), 1517 (w), 1476 (w). 1441 (w); MS (EI): 617 ([M+H]
+, 25), 616 (M
+, 80), 442 
(60),  160  (40);  Exact  Mass  calculated  for  C31H40N2O7S2  616.78850,  observed  
616.22809 (EI).  
 
Endo-bicyclo[6.1.0]non-4-yn-9-ylmethyl (2-(2-(2-
aminoethoxy)ethoxy)ethyl)carbamate (41)
139 
 
 
To a solution of activated para-nitrophenol alkyne endo-33 (14 mg, 0.044 mmol) in 
DMF  (1  ml)  was  added  1,8-diamino-3,6-dioxaoctane  (38  µl,  0.226  mmol)  and 
triethylamine  (19  µl,  0.133  mmol).  The  reaction  mixture  was  stirred  at  room 
temperature for 15 min. The mixture was concentrated in vacuo, taken up in DCM (20 
ml) and extracted with 1 M NaOH (2 x 2 ml), followed by water (2 ml). The combined 
aqueous phases were extracted once more with DCM (10 ml) and the combined organic 
layers were dried with MgSO4, filtered and concentrated in vacuo. The product 41 was 
isolated without further purification as a slightly yellow oil (14 mg, 99%).  
 
1H NMR (600 MHz, CDCl3) ʴ 5.37 (s, 1H, NH), 4.15 (m, 2H, H2-6), 3.62-3.52 (m, 8H, 
4 x OCH2), 3.37 (m, 2H, NHCH2), 2.89 (m, 2H, CH2NH2), 2.30-2.19 (m, 6H, HH-2, 
HH-3), 1.98 (s, 2H, NH2), 1.58 (m, 2H, HH-3), 1.35 (m, 1H, H-5), 0.94 (m, 2H, H-4); 
13C NMR (150 MHz, CDCl3) ʴ 156.9 (C), 98.9 (C), 73.2 (CH2), 70.4 (CH2), 70.3 (CH2), 
70.2 (CH2), 62.8 (CH2), 41.7 (CH2), 40.9 (CH2), 29.2 (CH2), 21.5 (CH2), 20.2 (CH), 
17.9 (CH); IR (oil, cm
-1) 2915 (m), 1707 (m); MS (EI): 325 ([M+H]
+, 70), 199 (30); 
Exact Mass calculated for C17H29N2O4 325.2122 observed  325.2124 (EI).   
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Endo-bicyclo[6.1.0]non-4-yn-9-ylmethyl (2-(2-(2-(4-(2,5-dioxo-3,4-bis(phenylthio)-
2,5-dihydro-1H-pyrrol-1-yl)butanamido)ethoxy)ethoxy)ethyl)carbamate (42) 
 
 
Synthesis of 42 via NHS ester linker  
 
To a solution of monoamine strained alkyne 41 (14 mg, 0.043 mmol) in DMF (0.5 ml) 
was added NHS ester 19 (21 mg, 0.043 mmol) in DMF (0.5 ml). The mixture was left to 
stir overnight at room temperature. The solvent was removed in vacuo and the residue 
purified by column chromatography (gradient elution DCM to DCM with 10% MeOH) 
to yield 42 as a dark yellow oil (22 mg, 73%).  
 
Synthesis of 42 via HBTU coupling 
 
Dithiophenol maleimide carboxylic acid 18 (62 mg, 0.154 mmol), HOBt (10 mg, 0.077 
mmol) and HBTU (58  mg, 0.154 mmol) were  stirred in  DMF  (4 ml)  under argon. 
DIPEA (40 µl, 0.231 mmol) in DMF (1 ml) was then added, and the reaction stirred at 
room temperature for 15 min. Monoamine strained alkyne 41 (50 mg, 0.154 mmol) in 
DMF (1 ml) was then added. The reaction mixture was left to stir overnight and then 
DMF  removed  in  vacuo.  The  mixture  was  redissolved  in  DCM  and  washed  with 
saturated LiCl (10 ml), 15% K2CO3 (10 ml), 15% citric acid (10 ml) and water (10 ml). 
The organic layer was then dried with MgSO4. Purification by column chromatography 
(10% DCM in EtOAc to EtOAc) yielded 42 as a dark yellow oil (87 mg, 80%).  
 
1H NMR (600 MHz, CDCl3) ʴ 7.29-7.23 (m, 6H, Ar-H), 7.18 (m, 4H, Ar-H), 6.16 (s, 
1H, NH-8), 5.21 (s, 1H, NH-7), 4.14 (m, 2H, H2-6), 3.60-3.53 (m, 10H, 4 x OCH2, H2-
11), 3.45 (m, 2H, CH2NH-7), 3.38 (m, 2H, CH2NH-8), 2.30-2.15 (m, 8H, HH-2, HH-3, 
H2-9), 1.92 (pent., 2H, J = 7.2 ,H2-10), 1.56 (m, 2H, HH-3), 1.33 (m, 1H, H-5), 0.95 (m, 
2H, H-4); 
13C NMR (150 MHz, CDCl3) ʴ 172.1 (C), 167.3 (C), 156.9 (C), 135.6 (C), 
132.4 (C), 131.9 (CH), 129.1 (CH), 128.9 (CH), 98.9 (C), 70.3 (CH2), 69.9 (CH2), 62.9 
(CH2), 40.9 (CH2), 39.4 (CH2), 38.9 (CH2), 38.3 (CH2), 32.0 (CH2), 29.1 (CH2), 27.7 
(CH2), 24.8 (CH2), 21.6 (CH2), 20.2 (CH), 17.9 (CH); IR (oil, cm
-1) 2927 (s), 1701 (s),  
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1553  (m);  MS  (EI):  706  ([M+H]
+,  85),  616  (20),  556  (15),  530  (75);  Exact  Mass 
calculated for [C34H43N3O7S2+H] 706.2615 observed 706.2615 (EI).  
 
Endo-bicyclo[6.1.0]non-4-yn-9-ylmethyl (2-(2-(2-(4-(3,4-dibromo-2,5-dioxo-2,5-
dihydro-1H-pyrrol-1-yl)butanamido)ethoxy)ethoxy)ethyl)carbamate (43) 
 
 
 
To a solution of monoamine strained alkyne 41 (25 mg, 0.077 mmol) in DMF (1 ml) 
was added dibromomaleimide-NHS ester 13 (51 mg, 0.116 mmol) in DMF (1 ml). The 
mixture was left to stir overnight. The solvent was removed in vacuo and purified by 
column chromatography (gradient elution from DCM to DCM with 10% MeOH) to 
yield 43 as a yellow oil (20 mg, 41%).  
 
1H NMR (600 MHz, CDCl3) ʴ 6.13 (s, 1H, NH-8), 5.19 (s, 1H, NH-7), 4.14 (m, 2H, H2-
6),  3.67-3.55  (m,  10H,  4  x  OCH2,  H2-11),  3.44  (m,  2H,  CH2NH-7),  3.39  (m,  2H, 
CH2NH-8), 2.31-2.20 (m, 8H, HH-2, HH-3, H2-9), 1.97 (pent., 2H, J = 7.2 ,H2-10), 1.58 
(m, 2H, HH-3), 1.34 (m, 1H, H-5), 0.94 (m, 2H, H-4); 
13C NMR (150 MHz, CDCl3) ʴ 
171.6 (C), 164.2 (C), 156.8 (C), 129.5 (C), 98.9 (C), 70.4 (CH2), 70.2 (CH2), 70.0 
(CH2), 63.0 (CH2), 40.9 (CH2), 39.2 (CH2), 33.5 (CH2), 29.8 (CH2), 29.2 (CH2), 24.6 
(CH2), 21.6 (CH2), 20.2 (CH), 17.9 (CH); IR (oil, cm
-1) 3433 (w, br), 2955 (m), 2912 
(m), 1721 (m), 1662 (m); MS (EI): 650 ([
81,81M+H]
+, 50), 648 ([
81,79M+H]
+, 100), 646 
([
79,79M+H]
+,  50),  493  (20),  472  (50),  304  (40),  234  (50),  199  (60);  Exact  Mass 
calculated for [C25H33
81,79Br2N3O7+H] 648.0740 observed  648.0738 (EI).  
 
But-3-yn-1-yl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (45) 
 
 
 
A mixture of 4,7,10-trioxa-1,3-tridecanediamine (946 µl, 4.40 mmol) and triethylamine 
(135 µl, 0.97 mmol) was cooled to -15 °C. 3-Butynl-1-yl chloroformate (50 µl, 0.44 
mmol) in DMF (5 ml) was then added dropwise over 1 h. The reaction was then stirred  
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at room temperature for 30 min. The solvent was removed in vacuo and the resulting oil 
purified by column chromatography (10% MeOH in DCM). The desired product 45 was 
obtained as a brown oil (120 mg, 86%).  
 
1H NMR (600 MHz, MeOD) ʴ 4.10 (t, 2H, J = 6.0, H2-3), 3.64 (m, 8H, H2-7, H2-8, H2-
9, H2-10), 3.60 (m, 2H, H2-4), 3.52 (t, 2H, J = 6.0, H2-11), 3.19 (t, 2H, J = 6.0, H2-6), 
3.00 (t, 2H, J = 6.0, H2-13), 2.49 (td, 2H, J = 7.2, J = 3.0, H2-2), 2.31 (m, 1H, H-1), 
1.87 (pent., 2H, J = 6.0, H2-12), 1.75 (pent., 2H, J = 6.0, H2-5); 
13C NMR (150 MHz, 
MeOD) ʴ 158.7 (C), 81.2 (C), 71.4 (CH2), 71.2 (CH2), 71.1 (CH2), 71.0 (CH), 63.8 
(CH2), 40.2 (CH2), 39.0 (CH2), 30.9 (CH2), 29.5 (CH2), 20.0 (CH2); IR (oil, cm
-1) 3331 
(s, br), 1631 (m); MS (EI): 317 ([M+H]
+, 100), 247 (10), 154 (5); Exact Mass calculated 
for [C15H28N2O5+H] 317.2071 observed  317.2073 (EI).  
 
But-3-yn-1-yl (3-(2-(2-(3-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propoxy)ethoxy)ethoxy)propyl)carbamate (46) 
 
 
To a stirred solution of carbamate dibromomaleimide 11 (30 mg, 0.095 mmol) in DCM 
(3 ml) was  added monoamine linear alkyne  45 (30 mg, 0.095 mmol). The reaction 
mixture was stirred at room temperature under argon for 3 h. The solvent was removed 
in vacuo and the mixture purified by column chromatography (DCM) to yield 46 as a 
yellow oil (39 mg, 74%).  
 
1H NMR (600 MHz, CDCl3) ʴ 5.30 (s, 1H, NH), 4.13 (t, 2H, J = 6.0, H2-3), 3.66-3.52 
(m, 12H, H2-6, H2-7, H2-8, H2-9, H2-10, H2-11), 3.47 (m, 2H, H2-13), 3.31 (m, 2H, H2-
4), 2.47 (m, 2H, H2-2), 1.99 (m, 1H, H-1), 1.85 (pent., 2H, J = 6.0, H2-12), 1.77 (pent., 
2H, J = 6.0, H2-5); 
13C NMR (150 MHz, CDCl3) ʴ 166.3 (C), 157.2 (C), 129.7 (C), 81.0 
(C), 70.5 (CH2), 70.4 (CH2),  70.3 (CH2),  70.0 (CH2),  67.9 (CH2),  62.6 (CH2),  60.4 
(CH),  39.1 (CH2),  36.6 (CH2),  29.2 (CH2),  27.9 (CH2),  19.6 (CH2); IR (oil, cm
-1) 
3294 (s, br), 2948 (w), 1706 (m); MS (EI): 557 ([
81,81M+H]
+, 45), 555 ([
81,79M+H]
+, 
100),  553  ([
79,79M+H]
+,  45),  477  (35),  324  (20);  Exact  Mass  calculated  for 
[C19H26
81,79Br2N2O7+H] 555.0106 observed  555.0152 (EI).  
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But-3-yn-1-yl (3-(2-(2-(3-(2,5-dioxo-3,4-bis(phenylthio)-2,5-dihydro-1H-pyrrol-1-
yl)propoxy)ethoxy)ethoxy)propyl)carbamate (47) 
 
 
 
To a stirred solution of carbamate dithiophenol maleimide 27 (53 mg, 0.142 mmol) in 
DCM (5 ml) was added monoamine linear alkyne 45 (30 mg, 0.095 mmol). The reaction 
mixture  was  stirred  at  room  temperature  under  argon  for  45  min.  The  solvent  was 
removed in vacuo and the mixture purified by column chromatography (DCM) to yield 
47 as a yellow oil (45 mg, 77%).  
 
1H NMR (600 MHz, CDCl3) ʴ 7.30-7.18 (m, 10H, Ar-H), 5.35 (s, 1H, NH), 4.14 (t, 2H, 
J = 6.0, H2-3), 3.64-3.53 (m, 12H, H2-6, H2-7, H2-8, H2-9, H2-10, H2-11), 3.45 (m, 2H, 
H2-13), 3.29 (m, 2H, H2-4), 2.49 (m, 2H, H2-2), 1.99 (m, 1H, H-1), 1.86 (pent., 2H, J = 
6.0, H2-12), 1.76 (pent., 2H, J = 6.0, H2-5); 
13C NMR (150 MHz, CDCl3) ʴ 167.0 (C), 
156.3 (C), 135.7 (C), 131.9 (C), 129.5 (CH), 129.0 (CH), 128.5 (CH), 80.7 (C), 70.7 
(CH2), 70.4 (CH2),  70.3 (CH2),  69.8 (CH2),  68.8 (CH2),  62.5 (CH2),  60.5 (CH),  39.3 
(CH2),  36.6 (CH2),  29.4 (CH2),  28.6 (CH2),  19.6 (CH2); IR (oil, cm
-1) 3293 (s, br), 
2950 (w), 1708 (m), 1552 (m); MS (EI): 613 ([M+H]
+, 100), 536 (30), 354 (40), 154 
(30); Exact Mass calculated for [C31H36N2O7S2+H] 613.2037 observed  613.2027 (EI).  
 
N,N-PEG2-bis-3,4-dibromomaleimide (BDBM(PEG)2)
181 
 
 
 
2,2’-(Ethylenedioxy)bis(ethylamine)  (0.2  ml,  1.38  mmol)  was  added  to  a  stirred 
solution of N-(methoxycarbonyl)-3,4-dibromomaleimide (1.08 g, 3.45 mmol) in DCM 
(8 ml). After 20 min EtOAc (80 ml) was added and the organic layer extracted with 
saturated NH4Cl solution (2 x 40 ml) and H2O (3 x 40 ml). The organic layer was dried 
with  MgSO4,  filtered  and  concentrated  in  vacuo.  Purification  by  column 
chromatography (gradient elution from 10% EtOAc in petrol to 30% EtOAc in petrol) 
yielded BDBM(PEG)2 as a pale yellow solid (600 mg, 70%). 
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m.p. 116 – 117 ºC; 
1H NMR (500 MHz, CDCl3) ʴ 3.82 (t, 4H, J = 5.6 Hz, NCH2), 3.65 
(t,  4H,  J  =  5.6  Hz,  NCH2CH2O),  3.58  (s,  4H,  OCH2CH2O); 
13C  NMR  (125  MHz, 
CDCl3) ʴ 164.2 (C), 129.8 (C), 70.4 (CH2), 68.0 (CH2), 39.3 (CH2); IR (solid, cm
-1) 
2913 (s), 2882 (s) 1785 (s), 1720 (s), 1597 (s); MS (ES+) 651 ([
81,81,81,81M+Na]
+, 20), 
649 ([
81,81,81,79M+Na]
+, 70), 647 ([
81,81,79,79M+Na]
+, 100), 645 ([
81,79,79,79M+Na]
+, 70),  
643 ([
79,79,79,79M+Na]
+, 20); Exact Mass calculated for C14H12N2O6Na
79Br4 642.7327, 
observed  642.7355 (ES+). 
 
N,N-PEG19-bis-3,4-dibromomaleimide (BDBM(PEG)19) 
 
 
O,O′-Bis(2-aminoethyl)octadecaethylene  glycol  (50 mg, 0.06 mmol) was  added to  a 
stirred solution of N-(methoxycarbonyl)-3,4-dibromomaleimide (44 mg, 0.14 mmol) in 
DCM (2 ml). The reaction mixture was left at room temperature overnight, and then the 
solvent removed in vacuo. Purification by column chromatography (gradient elution 
from DCM to 5% MeOH in DCM) afforded BDBM(PEG)19 as a pale yellow oil (53 
mg, 65%).  
 
1H NMR (600 MHz, CDCl3) ʴ 3.81 (t, 4H, J = 6.0, NCH2), 3.67-3.59 (m, 76H, 38 x 
CH2); 
13C NMR (150 MHz, CDCl3) ʴ 164.0 (C), 129.6 (C), 70.7 (CH2), 70.2 (CH2), 
67.7  (CH2),  39.0  (CH2);  IR  (oil,  cm
-1)  2865  (s),  1722  (s);  MS  (ES+)  1394 
([
81,81,81,81M+NH4]
+, 20), 1392 ([
81,81,81,79M+NH4]
+, 70), 1390 ([
81,81,79,79M+NH4]
+, 100), 
1388 ([
81,79,79,79M+NH4]
+, 70),  1386 ([
79,79,79,79M+NH4]
+, 20), 1346 (40), 1300 (10); 
Exact Mass calculated for C48H80
81,81,79,79Br4N2O23NH4 1390.2192, observed 1390.2181 
(ES+).  
 
3,4-dibromo-1-(prop-2-yn-1-yl)-1H-pyrrole-2,5-dione (48)
181 
 
 
Propargylamine  (13  µl,  0.193  mmol)  was  added  to  a  stirred  solution  of 
dibromomaleimide carbamate 11 (50 mg, 0.161 mmol) in DCM (2 ml). After 20 min,  
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EtOAc (10 ml) was added and the organic layer washed with saturated NH4Cl (10 ml) 
and water (10 ml), dried with MgSO4, filtered and concentrated in vacuo to yield 48 as a 
pale yellow solid (39 mg, 83%).  
 
m.p. 118 - 120 °C; 
1H NMR (500 MHz, CDCl3) ʴ 4.38 (d, 2H, J = 2.5, CH2), 2.27 (1H, 
t, J = 2.5, CH); 
13C NMR (125 MHz, CDCl3) ʴ 162.7 (C), 129.9 (C), 76.1 (C), 72.6 (C), 
28.7 (CH2); IR (solid, cm
-1) 3020 (w), 2925 (m), 1735 (m); MS (EI): 296 ([
81,81M+H]
+, 
50),  294  ([
81,79M+H]
+,  100),  292  ([
79,79M+H]
+,  50);  Exact  Mass  calculated  for 
[C7H3
79Br2NO2+H] 291.8603 observed  291.8606 (EI).  
 
N
1-(5-(4-(2,5-dioxo-3,4-bis(phenylthio)-2,5-dihydro-1H-pyrrol-1-
yl)butanamido)pentyl)-N
1-hydroxy-N
4-(5-(N-hydroxy-4-((5-(N-
hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide (51) 
 
 
Dithiophenolmaleimide-NHS ester  19  (42 mg,  0.085 mmol), deferoxamine mesylate 
salt (55 mg, 0.085 mmol) and DIPEA (17 µl, 0.100 mmol) were dissolved in DMF (2.0 
ml) and water (0.2 ml). The reaction mixture was stirred for 1 h at room temperature. 
The reaction was then quenched with water (8 ml), sealed and incubated in the freezer 
overnight. After this time, an orange/yellow solid had precipitated of solution. The solid 
was obtained by vacuum filtration and washed with water. The solid was the washed 
with  DCM  to  remove  dithiophenol  carboxylic  acid  maleimide  18,  to  yield  51  as  a 
yellow solid (45 mg, 56%).  
 
m.p. 156 - 160 °C; At 60 °C: 
1H NMR (400 MHz, MeOD) ʴ 7.32-7.23 (m, 10H, Ar-H), 
4.14 (s, 2H, H2-1), 3.61 (t, 4H, J = 8.0, H2-15), 3.55 (t, 2H, J = 4.0, H2-8), 3.19 (m, 6H, 
H2-4, H2-11), 2.76 (m, 4H, H2-9), 2.48 (t, 4H, J = 8.0, H2-10), 2.20 (t, 2H, J = 4.0, H2-
3), 2.10 (s, 3H, H3-16), 1.90 (pent., 2H, J = 8.0, H2-2), 1.66-1.35 (m, 18H, H2-5, H2-6, 
H2-7, H2-12, H2-13, H2-14); 
13C NMR (125 MHz, MeOD) ʴ 174.8 (C), 168.4 (C), 137.4 
(C), 132.7 (CH), 130.8 (C), 130.1 (CH), 129.3 (CH), 40.3 (CH2), 39.4 (CH2), 34.4 
(CH2), 31.7 (CH2), 30.0 (CH2), 29.0 (CH2), 27.3 (CH2), 25.6 (CH2), 24.9 (CH2), 19.8 
(CH3); IR (solid, cm
-1) 3301 (w, br), 2928 (m), 1702 (m), 1617 (m), 1563 (m); MS (EI): 
942 ([M+H]
+, (10)), 855 (20), 507 (35), 434 (100), 304 (90), 242 (50); Exact Mass 
calculated for [C45H63N7O11S2+H] 942.4100 observed  942.4107 (EI).   
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4.5  Application of disulfide to lysine linker 
 
4.5.1  In situ bridging of anti-CEA ds-scFv  
Anti-CEA ds-scFv was diluted in PBS with 10% DMF to a concentration of 70 µM 
(1.87 mg/ml). Dithiophenolmaleimide 9 was added (5 equiv relative to scFv, 28 mM 
stock in DMF) followed by benzeneselenol (25 equiv relative to scFv, 70 mM stock in 
DMF) and the mixture incubated for 20 min at room temperature. The formation of 
bridged scFv was monitored by LCMS (expected 26,831, observed 26,831).  
 
4.5.2  Incubation of CPG2 with dibromomaleimide or dithiophenolmaleimide 
CPG2 was diluted in PBS with 10% DMF to a concentration of 11.4 µM (0.5 mg/ml). 
Dibromomaleimide 8 or dithiophenolmaleimide 9 (20 and 50 equiv relative to CPG2, 
4.6 mM stock in DMF) were added to aliquots of CPG2 and the mixture left for 1 h at 
room temperature. The reaction was monitored by LCMS and no change is mass was 
observed (unmodified CPG2 42,403).  
 
4.5.3  Conjugation of dithiophenolmaleimide-NHS ester linker to CPG2 
CPG2 was diluted in PBS with 10% DMF to a concentration of 11.4 µM (0.5 mg/ml). 
Dithiophenolmaleimide-NHS ester linker 19 was added (2 equiv relative to CPG2, 4.6 
mM stock in DMF) and the mixture incubated for 1 h at room temperature. Glycine 
(150 equiv  relative to CPG2, 44 mM  stock in PBS) was  then added to  quench the 
reaction. The formation of singly-modified CPG2 monomer was monitored by LCMS 
(expected  42,785,  observed  42,772).  Excess  linker  was  removed  using  a  desalting 
column (PD-10, GE Healthcare) and the modified CPG2 buffer exchanged into 50 mM 
phosphate, pH 6.8, 1 mM EDTA buffer for subsequent conjugation.  
 
4.5.4  General method for the conjugation of modified CPG2 to anti-CEA ds-scFv 
via the stepwise protocol 
Anti-CEA ds-scFv in PBS (122 µM, 3.26 mg/ml) was reduced with DTT (20 equiv 
relative to scFv, 122 mM stock in PBS) for 1 h at room temperature. DTT was then 
removed by centrifugal ultrafiltration (GE Healthcare, Vivaspin 500, 10 kDa cut-off) 
and  buffer  exchanged  into  50  mM  phosphate,  pH  6.8,  1  mM  EDTA  buffer.  After 
concentration, the reduced scFv was added to modified CPG2 at the desired molar ratio 
and the mixture incubated at room temperature. A variety of reaction time scales were 
investigated. For specific examples please see Section 2.1.6.   
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4.5.5  General method for the conjugation of modified CPG2 to anti-CEA ds-scFv 
via the in situ portionwise protocol 
Anti-CEA ds-scFv in PBS with 10% DMF was prepared to the desired concentration. 
Modified CPG2 in PBS was also concentrated and prepared with 10% DMF. The ds-
scFv was added to the modified CPG2 at the desired molar ratio. Benzeneselenol (15 
equiv relative to scFv, 1000x stock in DMF) was immediately added.  After this initial 
addition, benzeneselenol (15 equiv relative to scFv, 1000x stock in DMF) was then 
added  every  20  min  for  1  h.  Reactions  were  carried  out  at  room  temperature  and 
samples were taken after 90 min and analysed by SDS-PAGE.  For specific examples of 
concentrations and molar ratios attempted please see Section 2.1.6. 
 
4.5.6  Bradford assay for determining concentration of modified CPG2 
The Coomassie (Bradford) protein assay kit from Thermo scientific was used. On every 
use a standard curve was determined using unmodified CPG2.  
 
4.5.7  General method for the conjugation of modified CPG2 to anti-CEA ds-scFv 
via the in situ protocol using selenocystamine dihydrochloride and TCEP 
Anti-CEA  ds-scFv  and  modified  CPG2  were  prepared  in  PBS  to  the  desired 
concentration. The ds-scFv was added to modified CPG2 at the desired molar ratio and 
Selenocystamine  dihydrochloride  (25  equiv  relative  to  scFv,  1000x  stock  in  PBS) 
immediately  added,  followed by  TCEP (100 equiv relative to  scFv, 1000x stock in 
PBS).  The reaction mixture was left at room temperature and a variety of reaction time 
scales investigated. For specific examples please see Section 2.1.6. 
 
4.5.8  Western blot for ds-scFv and CPG2 
The membrane was blocked with a 5% solution of Marvel milk powder in PBS (Premier 
Foods) for 1 h at room temperature and subsequently washed three times with PBS-T 
and PBS. For ds-scFv detection the membrane was incubated with anti-tetra-His mouse 
IgG1-HRP (Quiagen, 1 : 1,000 in 1% Marvel solution) for 1 h. For CPG2 detection the 
membrane  was  incubated  with  the  primary  antibody  (anti-CPG2,  1  :  1,000  in  1% 
Marvel solution) for 1 h. The membrane was washed three times with PBS-T and PBS 
and then incubated with  the secondary antibody (anti-rabbit,  1 :  500  in 1% Marvel 
solution) for 1 h. Both membranes were then washed three times with PBS-T and PBS, 
and 3,3’-diamino-benzidine (DAB, 10 mg in 40 ml distilled water with 20 µl H2O2)  
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added. Once bands were visible the membrane was washed with distilled water and air 
dried.  
4.6  Application of substituted maleimide reagents with a bioorthogonal 
handle 
 
4.6.1  General method for anti-CEA ds-scFv bridging with dithiophenolmaleimide 
linkers via the in situ protocol 
Anti-CEA ds-scFv was diluted in PBS with 10% DMF to a concentration of 70 µM 
(1.87 mg/ml).  The dithiophenolmaleimide linker was added (5 equiv relative to scFv, 
28 mM stock in DMF) followed by benzeneselenol (25 equiv relative to scFv, 70 mM 
stock  in  DMF)  and  the  mixture  incubated  for  20  min  at  room  temperature.  The 
formation of bridged scFv was monitored by LCMS. Note: DMSO is not compatible 
with benzeneselenol.  
 
4.6.2  General method for anti-CEA ds-scFv bridging with dibromomaleimide 
linkers via the sequential protocol 
Anti-CEA ds-scFv was diluted in PBS to a concentration of 70 µM (1.87 mg/ml) and 
reduced with DTT (10 equiv relative to scFv, 70 mM stock in PBS). After 15 min, the 
dibromomaleimide linker was added (15 equiv relative to scFv, 28 mM stock in DMF) 
and the mixture incubated for a further 15 min at room temperature. The formation of 
bridged scFv was monitored by LCMS.  
 
4.6.3  Trastuzumab (Herceptin) Fab Fragment Preparation 
The pH of trastuzumab (0.5 ml, 6.41 mg/ml) and immobilised pepsin (0.15 ml) was 
lowered  via  washing  with  20  mM  sodium  acetate  buffer,  pH  3.1  four  times. 
Trastuzumab was then added to the pepsin and the mixture was incubated for 7 h at 37 
ºC whilst shaking (1100 rpm). The resin was then separated from the digest using a 
filter column and washed with digest buffer (50 mM phosphate, 150 mM NaCl, 1 mM 
EDTA, pH 6.8) three times. The digest was combined with the washes and the volume 
adjusted to 0.5 ml.  
 
Next immobilised papain (0.5 ml, 0.25 mg/ml) was activated with 20 mM DTT (in 
digest buffer: 50 mM phosphate, 150 mM NaCl, 1 mM EDTA, pH 6.8) whilst shaking 
(1100 rpm) for 2 h at 37 ºC. The resin was washed with digest buffer (without DTT) 
four times and the 0.5 mL of Herceptin-F(ab’)2 added. The mixture was incubated for  
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16 h at 37 ºC whilst shaking (1100 rpm) in the dark. Then the resin was separated from 
the digest using a filter column, and washed with Borate buffer (25 mM sodium borate, 
25 mM NaCl, 1 mM EDTA, pH 8.0) three times. The digest was combined with the 
washes and the buffer was exchanged completely for  Borate buffer and the volume 
adjusted to 0.4 ml. The digest was analysed by SDS-PAGE and LCMS. Generally, the 
digest was purified by size exclusion (500 ml Superdex 75 column, GE Healthcare). 
 
4.6.4  General method for Herceptin Fab bridging with dibromo- and 
dithiophenol-maleimide linkers via the sequential protocol 
Herceptin Fab was diluted in Borate buffer (25 mM sodium borate, 25 mM NaCl, 1 mM 
EDTA, pH 8.0) to a concentration of 21 µM (1.0 mg/ml) and reduced with TCEP (5 
equiv relative to Fab, 10.5 mM stock in Borate buffer). After 1 h, the disubstituted 
maleimide linker was added (8 equiv relative to Fab, 10.5 mM stock in DMF) and the 
mixture incubated for a further 30 min at room temperature. The formation of bridged 
Fab was monitored by LCMS and SDS-PAGE.  
 
4.6.5  General method for Herceptin Fab bridging with dithiophenolmaleimide 
linkers via the in situ protocol 
Herceptin Fab was diluted in Borate buffer (25 mM sodium borate, 25 mM NaCl, 1 mM 
EDTA, pH 8.0) to a concentration of 21 µM (1.0 mg/ml) and dithiophenolmaleimide 
linker added (3 equiv relative to Fab, 5.25 mM stock in DMF). TCEP (5 equiv relative 
to Fab, 10.5 mM stock in Borate buffer) was then added and the mixture incubated at 
room temperature for 30 min. The formation of bridged Fab was monitored by LCMS 
and SDS-PAGE.  
 
4.6.6  General method for SPAAC conjugation between azide or strained alkyne 
modified scFv or Fab and other functional molecule 
After purification from free linker using a desalting column (PD-10, GE Healthcare), 
the concentration of the azide or strained alkyne functionalised antibody fragment was 
adjusted to 100 µM in PBS. The azide or strained alkyne other functional molecule e.g. 
azide-fluorophore, was then added (20 equiv relative to antibody fragment, 100 mM 
stock in DMF, DMSO or water as appropriate). The reaction mixture was incubated for 
1 h at room temperature with moderate shaking (300 rpm). Results were analysed by 
LCMS and SDS-PAGE. Note for antibody fragment concentrations less than 100 µM, 
the equivalents of other functional molecule should be increased accordingly.   
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4.6.7  General method for generation of scFv or Fab homodimer via SPAAC  
After purification from free linker using a desalting column (PD-10, GE Healthcare), 
the azide and strained alkyne functionalised antibody fragment were diluted in PBS to 
the desired concentration. The two functionalised antibody fragments were then mixed 
at the desired molar ratio and incubated with moderate shaking (300 rpm).  37 °C, room 
temperature and 4 °C were investigated, in addition to a variety of time scales. The 
results were analysed SDS-PAGE. For specific examples please see Section 2.2.6.  
 
4.6.8  Stock solutions for CuAAC conjugation
188 
  CuSO4, 20 mM stock in distilled water 
  THPTA ligand*, 50 mM stock in distilled water 
  Sodium ascorbate, 50 mM stock in distilled water 
  Aminoguanidine hydrochloride, 50 mM stock in distilled water 
*THPTA  ligand  was  kindly  provided  by  Antoine  Maruani,  UCL  Chemistry  and 
synthesised according to the published procedure (188).  
 
4.6.9  Final concentrations for CuAAC conjugation
188 
  CuSO4: 200 µM (was adjusted to 500 µM for ds-scFv due to His-tag) 
  THPTA ligand: 1 mM (ligand to copper ratio is 5:1) 
  Sodium ascorbate: 5 mM  
  Aminoguanidine hydrochloride: 5 mM 
 
4.6.10 General procedure for 10 µl CuAAC conjugation between azide or linear 
alkyne functionalised antibody fragment and other functional molecule 
The CuSO4 and THPTA stocks were pre-mixed (5 µl CuSO4, 10 µl THPTA and 85 µl 
PBS)  and  a  blue  colour  was  observed.  The  azide  or  linear  alkyne  functionalised 
antibody fragment was concentrated to 167 µM in PBS (6 µl required for 10 µl reaction, 
therefore yielding final concentration of approximately 100 µM). The azide or linear 
alkyne other functional molecule was added (20 equiv relative to antibody fragment, 
100 mM stock in DMF, DMSO or water as appropriate). The pre-mixed CuSO4:THPTA 
was added (2 µl) and the reaction mixed. Then, aminoguanidine hydrochloride (1 µl) 
and finally sodium ascorbate (1 µl) were added. The mixture was incubated at room 
temperature with mild shaking for 1 h. The results were analysed by LCMS or SDS-
PAGE.   
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4.6.11 General procedure to generate Fab homodimer via CuAAC 
The  azide  and  linear  alkyne  functionalised  Fab  fragments  were  concentrated  to  the 
desired concentration in PBS, and mixed in the desired molar ratio. Following which the 
same stocks and final concentrations were used as described in Section 4.6.8 and 4.6.9 
to generate Fab homodimer. A variety of time scales were investigated and the results 
were analysed by SDS-PAGE. For specific examples please see Section 2.2.7.  
4.7  Application of disulfide to disulfide linkers 
 
4.7.1  Disulfide bridging of scFv with linker BDBM(PEG)2 to generate scFv-scFv 
homodimer 
Anti-CEA  ds-scFv  in  PBS  (1  mg/ml,  37.2  µM)  was  reduced  with  DTT  (20  equiv 
relative to scFv, 37.2 mM stock in PBS) for 1 h at room temperature. DTT was then 
removed using a desalting column (PD-10, GE Healthcare) and the reduced scFv buffer 
exchanged into conjugation buffer (20 mM phosphate buffer, 5 mM EDTA, pH 7.4). 
The scFv was concentrated to approximately 1 mg/ml and linker BDBM(PEG)2 added 
(0.42 equiv relative to scFv, 3.72 mM stock in DMF). After 1 h at room temperature or 
overnight at 4 °C, the reaction was purified by size exclusion (500 ml Superdex 75 
column, GE Healthcare).  
 
4.7.2  Disulfide bridging of scFv with linker BDBM(PEG)19 to generate scFv-scFv 
homodimer 
Anti-CEA  ds-scFv  in  PBS  (1  mg/ml,  37.2  µM)  was  reduced  with  DTT  (20  equiv 
relative to scFv, 37.2 mM stock in PBS) for 1 h at room temperature. DTT was then 
removed using a desalting column (PD-10, GE Healthcare) and the reduced scFv buffer 
exchanged into conjugation buffer (20 mM phosphate buffer, 5 mM EDTA, pH 7.4). 
The scFv was concentrated to approximately 1 mg/ml and linker BDBM(PEG)19 added 
(0.42 equiv relative to scFv, 3.72 mM stock in water). After 1 h at room temperature or 
overnight at 4 °C, the reaction was purified by size exclusion (500 ml Superdex 75 
column, GE Healthcare).  
 
4.7.3  Disulfide bridging of scFv with linker BDBM(PEG)19 to generate a scFv-
scFv heterodimer 
Anti-CEA  ds-scFv  in  PBS  (1  mg/ml,  37.2  µM)  was  reduced  with  DTT  (20  equiv 
relative to scFv, 37.2 mM in PBS) for 1 h at room temperature. DTT was then removed 
using  a  desalting  column  (PD-10,  GE  Healthcare)  and  the  reduced  scFv  buffer  
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exchanged into conjugation buffer (20 mM phosphate buffer, 5 mM EDTA, pH 7.4). 
The scFv was concentrated to approximately 1 mg/ml and linker BDBM(PEG)19 added 
(30 equiv relative to scFv, 37.2 mM in water). After 10 mins excess linker was removed 
by buffer exchange (repeat 3 times, Amicon® Ultra-4 Centrifugal Filter Units, 10 kDa 
cut-off) into conjugation buffer, and the bridged scFv concentrated to approximately 1 
mg/ml.  Meanwhile,  the  second  ds-scFv  fragment  was  reduced  and  purified  into 
conjugation  buffer  (20  mM  phosphate  buffer,  5  mM  EDTA,  pH  7.4)  as  described 
earlier. The reduced scFv concentration was adjusted to 37.2 µM, and bridged scFv 
(37.2 µM) mixed with the reduced scFv in a 3 : 1 ratio by volume respectively. After 1 
h at room temperature or overnight at 4 °C, the reaction was purified by size exclusion 
(500 ml Superdex 75 column, GE Healthcare).  
 
4.7.4  Disulfide bridging of scFv and Fab with linker BDBM(PEG)19 to generate 
scFv-Fab heterodimer 
Anti-CEA  ds-scFv  in  PBS  (1  mg/ml,  37.2  µM)  was  reduced  with  DTT  (20  equiv 
relative to scFv, 37.2 mM in PBS) for 1 h at room temperature. DTT was then removed 
using  a  desalting  column  (PD-10,  GE  Healthcare)  and  the  reduced  scFv  buffer 
exchanged into conjugation buffer (20 mM phosphate buffer, 5 mM EDTA, pH 7.4). 
The scFv was concentrated to approximately 1 mg/ml and linker BDBM(PEG)19 added 
(30 equiv relative to scFv, 37.2 mM in water). After 10 mins excess linker was removed 
by buffer exchange (repeat 3 times, Amicon® Ultra-4 Centrifugal Filter Units, 10 kDa 
cut-off) into conjugation buffer, and the bridged scFv concentrated to approximately 1 
mg/ml. Meanwhile, Herceptin Fab in Borate buffer (1 mg/ml, 25 mM sodium borate, 25 
mM NaCl, 1 mM EDTA, pH 8.0) was reduced with TCEP (10 equiv relative to Fab, 
37.2 mM in Borate buffer) for 1 h at room temperature. TCEP was then removed using 
a desalting column (PD-10, GE Healthcare) and the reduced Fab buffer exchanged into 
conjugation buffer (20 mM phosphate buffer, 5 mM EDTA, pH 7.4). The reduced Fab 
concentration was adjusted to 37.2 µM, and bridged scFv (37.2 µM) mixed with the 
reduced Fab in a 2 : 1 ratio by volume respectively. After 1 h at room temperature or 
overnight at 4 °C, the reaction was purified by size exclusion (500 ml Superdex 75 
column, GE Healthcare).  
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4.7.5  Disulfide bridging of Fab with linker BDBM(PEG)19 to generate Fab-Fab 
homodimer 
Herceptin Fab in Borate buffer (1 mg/ml, 25 mM sodium borate, 25 mM NaCl, 1 mM 
EDTA, pH 8.0) was reduced with TCEP (10 equiv relative to Fab, 21 mM in Borate 
buffer) for 1 h at room temperature. TCEP was then removed using a desalting column 
(PD-10, GE Healthcare) and the reduced Fab buffer exchanged into conjugation buffer 
(20  mM  phosphate  buffer,  5  mM  EDTA,  pH  7.4).  The  Fab  was  concentrated  to 
approximately 1 mg/ml and linker BDBM(PEG)19 added (0.42 equiv relative to Fab, 
2.10  mM  stock in  water). After 1 h  at  room temperature or overnight at  4 °C, the 
reaction was purified by size exclusion (500 ml Superdex 75 column, GE Healthcare).  
 
4.7.6  Protocol for CEA ELISA 
ELISA plates were coated with full length human CEA diluted to a final concentration 
of 1 μg/ ml in PBS and incubated for 1 h at room temperature. After washing with PBS, 
the plates were blocked for 1 h at room temperature with a 5% solution of Marvel milk 
powder in PBS (Premier Foods). Plates were washed three times with PBS, and the 
serially diluted test samples (60 nM, 20 nM, 6.6 nM, 2.2 nM, 0.74 nM, 0.24 nM) of ds-
scFv, Fab, scFv-scFv and scFv-Fab were added in PBS. The assay was incubated at 
room temperature for 1 h, washed three times with PBS-T and PBS, and the primary 
antibody (anti-tetra-His mouse IgG1, Quiagen, 1 : 1,000 in 1% Marvel solution) added. 
After 1 h the ELISA plates were washed again and the secondary antibody (ECL anti-
mouse sheep IgG1 HRP linked, GE Healthcare, 1 : 1,000 in 1% Marvel solution) added 
and incubated for 1 h at room temperature. The plates were washed and 100 μL of 0.5 
mg/mL  o-phenylenediamine  hydrochloride  (Sigma-Aldrich)  in  a  phosphate-citrate 
buffer with sodium perborate were added as substrate. Once colour was observed, the 
reaction  was  stopped  by  acidifying  with  50  μL  of  4  M  HCl.  Absorbance  was 
immediately measured at 490 nm. Controls were included in every ELISA, in which 
PBS  had  been  added  to  some  of  the  wells  instead  of  CEA  or  instead  of  antibody 
fragment. Each sample was tested in triplicate, and errors are shown as the standard 
deviation of the average. 
 
4.7.7  Protocol for HER2 ELISA 
ELISA plates were coated with HER2 diluted to a final concentration of 0.25 μg/mL in 
PBS and incubated for 1 h at room temperature. After washing with PBS, the plates  
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were blocked for 1 h at room temperature with a 5% solution of Marvel milk powder in 
PBS (Premier Foods). Plates were washed three times with PBS, and the serially diluted 
test samples (60 nM, 20 nM, 6.6 nM, 2.2 nM, 0.74 nM, 0.24 nM) of ds-scFv, Fab, scFv-
scFv and scFv-Fab were added in PBS. The assay was incubated at room temperature 
for 1 h, washed three times with PBS-T and PBS, and anti-human IgG, Fab-specific-
HRP antibody (Sigma-Aldrich, 1 : 5,000 in 1% Marvel solution) was added. After 1 h 
the  plates  were  washed  again  and  100  μL  of  0.5  mg/mL  o-phenylenediamine 
hydrochloride  (Sigma-Aldrich)  in  a  phosphate-citrate  buffer  with  sodium  perborate 
were  added  as  substrate.  Once  colour  was  observed,  the  reaction  was  stopped  by 
acidifying with 50 μL of 4 M HCl. Absorbance was immediately measured at 490 nm. 
Controls were included in every ELISA, in which PBS had been added to some of the 
wells  instead of HER2 or instead of antibody  fragment. Each sample  was  tested in 
triplicate, and errors are shown as the standard deviation of the average. 
 
4.7.8  Protocol for Sandwich ELISA 
ELISA plates were coated with CEA diluted to a final concentration of 1 μg/ ml in PBS 
and incubated for 1 h at room temperature. After washing with PBS, the plates were 
blocked for 1 h at room temperature with a 5% solution of Marvel milk powder in PBS 
(Premier Foods). Plates were washed three times with PBS, and the serially diluted test 
samples (60 nM, 20 nM, 6.6 nM, 2.2 nM, 0.74 nM, 0.24 nM) of ds-scFv, Fab, scFv-
scFv and scFv-Fab were added in PBS. The assay was incubated at room temperature 
for 1 h, washed three times with PBS-T and PBS, and HER2-Biotin (1 : 500 in 1% 
Marvel solution) was added. After 1 h the plates were washed again and Extravidin-
Peroxidase (Sigma Aldrich, 1 : 2,000 in 1% Marvel solution) added. The plates were 
washed and 100 μL of 0.5 mg/mL o-phenylenediamine hydrochloride (Sigma-Aldrich) 
in  a  phosphate-citrate  buffer  with  sodium  perborate  were  added  as  substrate.  Once 
colour was observed, the reaction was stopped by acidifying with 50 μL of 4 M HCl. 
Absorbance was immediately measured at 490 nm. Controls were included in every 
ELISA.  Each  sample  was  tested  in  triplicate,  and  errors  are  shown  as  the  standard 
deviation of the average. 
 
4.7.9  Cell Lines 
The breast cancer cell lines BT474 and MDA-MB-468 were purchased from ATCC. 
The A375CEA was generated by stable transfection of the A375 melanoma cell line  
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(ATCC); in brief, A375 cells were transfected with pIRES-puro-CEA (kind gift of Dr. 
David Gilham) and stable clones selected using 1µg/ml of puromycin (Sigma) over a 
period of two weeks. A375CEA and MDA-MB-468 cell lines were maintained at 37˚C, 
5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) containing 2mM L-
glutamine and complemented with 10% foetal calf serum (Labtech International, UK). 
BT474  cells  were  maintained  in  Hybricare  X-46  (ATCC),  supplemented  with  10% 
foetal calf serum.  
 
4.7.10 Flow cytometry analysis 
Cell lines were prepared by removal of media and incubation with 10 ml of 0.2% EDTA 
for 10 min. The cells were then transferred to centrifuge tubes and pelleted (4 °C, 4 min, 
1000 rpm). The EDTA solution was removed and 5 ml of fresh media added. Cells were 
counted and diluted to 1 million per ml, and 1 ml used for each condition to be tested. 
After washing with cold PBS, 200 µl of sample at 10 µg/ml was added and incubated 
for 1 h at 4 °C. Cells were washed with cold PBS twice, and incubated with 200 µl of 
detection antibody for 1 h at 4 °C. For scFv detection AlexaFluor488-conjugated Mouse 
anti-his tag (R&D Systems) was used and for Fab AlexaFluor488-conjugated Goat anti-
human IgG (Molecular Probes). After further washing with cold PBS, the cells were 
suspended  in  500  µl  of  cold  PBS.  Samples  were  analysed  on  a  CyAn  ADP  High-
Performance Flow Cytometer (Becton Dickinson); cells were gated according to size 
scattering, forward scattering and pulse width so only single cells were analysed. A total 
of 10,000 cell events were recorded per sample and data was analysed using FlowJo 
software (Tree Star Inc.).  
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4.7.10.1 FACS controls 
 
CEA-positive cell line A375CEA controls 
  
HER2-positive cell line BT474 controls 
 
 
 
 
 
 
 
 
 
Untreated 
anti-His 
anti-Human 
scFv + anti-Human 
Fab + anti-His 
Untreated 
anti-His 
anti-Human 
scFv + anti-Human 
Fab + anti-His  
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CEA-negative and HER2-negative cell line MDA-MD-468 
  
  
  
Untreated 
scFv + anti-His 
Fab + anti-Human 
Untreated 
scFv-scFv + anti-His 
scFv-scFv + anti-Human 
Untreated 
scFv-Fab + anti-His 
scFv-Fab + anti-Human  
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4.8  Modification of scFv-Fc  
 
4.8.1  scFv-Fc reduction study 
Aliquots of scFv-Fc in Borate buffer (0.5 mg/ml, 25 mM sodium borate, 25 mM NaCl, 
1 mM EDTA, pH 8.0) were reduced with TCEP (3, 5, 8, 12, 20 and 50 equiv relative to 
scFv-Fc, 0.5 mM in Borate buffer) and DTT (3, 5, 8, 12, 20 and 50 equiv relative to 
scFv-Fc, 0.5 mM stocks in Borate buffer) for 2 h at 37 °C. The samples were analysed 
by SDS-PAGE.   
 
4.8.2  scFv-Fc bridging study 
scFv-Fc in  Borate buffer (0.5  mg/ml,  25 mM  sodium  borate, 25 mM  NaCl,  1 mM 
EDTA, pH 8.0) was reduced with DTT (20 equiv relative to scFv-Fc, 0.5 mM in Borate 
buffer) for 2 h at 37 °C. DTT was then removed using a desalting column (PD-10, GE 
Healthcare) and the reduced scFv-Fc buffer exchanged into conjugation buffer (20 mM 
phosphate buffer, 5 mM EDTA, pH 7.4). The scFv-Fc was then prepared with 10% 
DMF  to  a  concentration  of  0.5  mg/ml  and  dithiophenolmaleimide  9  or 
dibromomaleimide 8 (2, 3, 4, 5, 8, 12 and 16 equiv relative to scFv-Fc, 0.5 mM in 
DMF) added.  Samples were incubated for 1 h over ice and analysed by SDS-PAGE.  
 
4.8.3  scFv-Fc modification with N-alkyne dibromomaleimide  
scFv-Fc in  Borate buffer (1.0  mg/ml,  25 mM  sodium  borate, 25 mM  NaCl,  1 mM 
EDTA, pH 8.0) was reduced with DTT (20 equiv relative to scFv-Fc, 1 mM in Borate 
buffer) for 2 h at 37 °C. DTT was then removed using a desalting column (PD-10, GE 
Healthcare) and the reduced scFv-Fc buffer exchanged into conjugation buffer (20 mM 
Untreated 
anti-His 
anti-Human 
scFv + anti-Human 
Fab + anti-His  
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phosphate buffer, 5 mM EDTA, pH 7.4). The scFv-Fc was then prepared with 10% 
DMF to a concentration of 1.0 mg/ml and N-alkyne dibromomaleimide 48 (20 equiv 
relative to scFv-Fc, 1 mM in DMF) added.  Samples were incubated for 1 h over ice and 
analysed by SDS-PAGE.  
 
4.8.4  CuAAC between alkyne functionalised scFv-Fc and azide Atto-565 
The CuSO4 and THPTA stocks were pre-mixed (5 µl CuSO4, 10 µl THPTA and 85 µl 
PBS) and a blue colour was observed. Alkyne functionalised scFv-Fc was concentrated 
to 167 µM in PBS (30 µl). The azide Atto-565 (20 equiv relative to scFv-Fc, 50 mM 
stock  in  DMF).  The  pre-mixed  CuSO4:THPTA  was  added  (10  µl)  and  the  reaction 
mixed. Then, aminoguanidine hydrochloride (5 µl) and finally sodium ascorbate (5 µl) 
were added. The mixture was incubated at room temperature with mild shaking for 1 h. 
The results were analysed by SDS-PAGE and UV-Vis.  
4.9  Modification of anti-PSMA ds-scFv with dithiophenolmaleimide-
DFO  
 
Anti-PSMA ds-scFv in PBS (1 mg/ml, 37.2 µM) was reduced with DTT (20 equiv 
relative to scFv, 37.2 mM in PBS) for 1 h at room temperature. DTT was then removed 
using  a  desalting  column  (PD-10,  GE  Healthcare)  and  the  reduced  scFv  buffer 
exchanged into conjugation buffer (20 mM phosphate buffer, 5 mM EDTA, pH 7.4). 
The scFv was concentrated to approximately 1 mg/ml and dithiophenolmaleimide-DFO 
51 added (20% by volume relative to scFv in PBS, 2 mM stock in DMSO). After 2 h at 
37 °C with moderate shaking (400 rpm), the reaction was purified by size exclusion 
(500 ml Superdex 75 column, GE Healthcare) and results analysed by LCMS and SDS-
PAGE.  
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